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PREFACE
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Taxpayers in the United States have invested heavily in public-sector research in agri-
cultural biotechnology to provide more-sustainable and productive crops and safe and 
nutritious foods. Since the mid-1980s, scientists at the USDA and in university and small 
private laboratories have developed a broad range of genetically engineered (gE) varieties 
of specialty crops with useful traits including enhanced tolerances of biotic and abiotic 
stresses and improved nutrition1. Almost a thousand different gE lines of small-market 
and specialty crops1 were among the almost 17,000 regulated field trials approved by 
USDA since 19872. 
 In spite of this large public investment—as well as early technical successes and promis-
ing results in field trials—only a few gE specialty crops developed in public institutions 
have been released to date:
• Virus-resistant papaya
• A now defunct flax intended to be used for bioremediation
• Virus-resistant plum
These are very sparse returns considering substantial public investment over a quarter 
century. In fact, the majority of scientists at public institutions do not even consider fur-
ther development of gE crops for commercial utility, even for traits that could advance 
agricultural systems, improve human health and help feed the increasing global population. 
On the other hand, there are signs that this trend is changing. Several transgenic events 
in specialty crops, are now moving towards commercialization as a result of collaborative 
efforts involving universities, industry, and regulatory agencies.
 Furthermore, the Farm Bill—passed in February 2014—has restored the Specialty 
Crop Research Initiative funding, to about $80 million per year3. We are pleased with 
this reemphasis of the fundamental importance of research in specialty crops, consistent 
with the focus of NABC’s twenty-fifth annual conference.
 NABC 25—held at Texas A&M University, College Station, June 4–6, 2013—brought 
together academic researchers, industry leaders, and government officials to discuss the 
roles of genomic sciences, regulatory policy and related topics in an attempt to catalyze 
increased agricultural progress, especially as it relates to specialty crops.
1Miller J Bradford K (2010) The regulatory bottleneck for biotech specialty crops. Nature Biotechnology 
28(10) 1012–1014.
2Anonymous (2014) Information Systems for Biotechnology: A National Resource in Agbiotech Informa-
tion–USDA Field Tests of gM Crops. http://gophisb.biochem.vt.edu/search-release-data.aspx
3http://www.thepacker.com/fruit-vegetable-news/Senate-passes-farm-bill-243553121.html#sthash.I9Xbcib1.
dpuf.
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 To foster discussion, NABC 25 was organized under five topics:
• Opportunities and Challenges for Specialty Crops
• genetic Engineering and Specialty-Crop Improvement
• Case Studies
• The Regulatory Process and Technology Access
• Perspectives from Relevant groups
 The final session on the morning of the third day focused on “Next Steps.” Speakers 
Tony Shelton (Cornell), Thomas Redick (global Environmental Ethics Counsel) and 
Neal Carter (Okanagan Specialty Fruits) formed a panel along with conference host Bill 
McCutchen (Texas A&M). The discussion, which involved audience contributions, was 
moderated by Steve Pueppke (Michigan State). Salient points emerging from the “Next 
Steps” exchanges are included in a “conference overview” chapter.
 A poster session was held on the evening of the first day. Prizes totaling $5,000 were 
awarded to the five best poster presentations ($1,500–$500).
 Participants in the Student Voice at NABC program4 attended the keynote and plenary 
sessions and met as a group on the second evening to discuss issues that emerged from 
the conference subject matter.
 This volume contains the conference overview, manuscripts generated from transcripts 
of the verbal presentations by the speakers (see Contents on pages ix–x for the full speaker 
list), transcripts of Q&A sessions, which included audience participation, the Student 
Voice report, and abstracts from the posters.
 NABC’s twenty-sixth conference—New DNA-Editing Approaches: Methods, Applica-
tions and Policy for Agriculture—will be held October 8–9, 2014, in Ithaca, NY, hosted 
by Cornell University and the Boyce Thompson Institute.
Allan Eaglesham      Ralph W.F. Hardy
Executive Director      President
NABC       NABC
Figures are printed in grayscale, hence information may have been lost from graphics
lifted from colored PowerPoint slides. Color versions of the figures are available at 
http://nabc.cals.cornell.edu/Publications/Reports/pubs_reports_25.htm.
4The Student Voice at NABC program provides grants of up to $750 to graduate students at NABC-member 
institutions (one student per institution) to offset travel and lodging expenses. Also, registration fees are 
waived for grant winners. Information on the Student Voice at NABC 26 will be available at http://nabc.cals.
cornell.edu/StudentVoice.htm.
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Part I– ConferenCe overvIew
Biotechnology and North American Specialty Crops: 3
Linking Research, Regulation, and Stakeholders
Allan Eaglesham and Ralph W.F. Hardy
 Biotechnology and North American Specialty Crops
3Specialty crops—fruits, vegetable, nuts (also turf and ornamentals)—are an important 
part of the human diet. In 007, such crops represented approximately 40 percent of the 
$40 billion in total agricultural receipts, despite being cultivated on just 4 percent of the 
total cropped area (Miller and Bradford, 00; Alston and Pardey, 008; USDA-NASS, 
009). Only six genetically engineered (GE) specialty crops are commercially available 
in the United States, whereas, in contrast, GE commodity crops—corn, soybean, cot-
ton, canola, sugar beet—now dominate the markets in countries where they have been 
released. Possible reasons for this disparity are lack of research on specialty crops and/or 
a dearth of beneficial traits for crop improvement through genetic engineering. Alterna-
tively, progression through the regulatory process may have failed (Miller and Bradford, 
00). To assess the R&D pipeline for GE specialty crops, Miller and Bradford (00) 
conducted an extensive search for journal articles (January 003–October 008, 33 
articles) describing work in specialty crops using recombinant DNA methods. Their data 
demonstrated a broad global research pipeline for GE specialty crops focused on traits 
potentially beneficial to producers and consumers. However, qualitative data revealed 
that although laboratory and field trials had been conducted on GE specialty crops in 
many countries, none had progressed to commercial production outside of the United 
States1. Interviews with representatives of specialty crop-seed companies and nurseries 
provided extensive anecdotal evidence that potentially marketable GE products had been 
created and tested, but cost and uncertainty of the regulatory process had made further 
development uneconomical and precluded appraisal of market acceptance (Miller and 
Bradford, 00).
Overview of NABC 25
Biotechnology and North American Specialty Crops:
Linking Research, Regulation, and Stakeholders
Allan Eaglesham and Ralph W.F. Hardy
North American Agricultural Biotechnology Council (NABC)
Ithaca, New York
aeaglesh@twcny.rr.com
1With the possible exception of virus-resistant tomato and pepper in China.
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A survey of NABC-member institutions in early 03 confirmed the existence of 
 several GE specialty crops, as did the above-described earlier worldwide study. Additional 
costs—beyond those required for varieties developed by “traditional” breeding—per inser-
tion event associated with receiving regulatory approval have been assessed at $ million 
to $5 million (Kalaitzandonakes et al., 007).
Although research on GE specialty crops continues to explore a range of beneficial 
applications their commercialization may depend upon a reexamination of the balance 
between potential risks versus benefits to society and adjustment in regulatory require-
ments (Miller and Bradford, 00).
Advances in molecular genetics and genomics are providing new ways to help food 
production keep pace with global population growth. “Omics” technologies are becom-
ing more rapid and more efficient, even as costs decrease. In spite of these advances—as 
discussed above—a majority of scientists at public US research institutions do not attempt 
to commercialize their GE crops even for traits that could help to feed hungry mouths 
and otherwise enhance human health.
NABC 5 was hosted by Texas A&M University, June 4–6, 03. The conference—at 
the George Bush Presidential Library in College Station—brought together government 
officials, academic researchers and industry leaders, with the objective of encouraging 
the improvement and subsequent commercialization of specialty crops. Recent meet-
ings with a similar theme include those convened by the American Association for the 
 Advancement of Science (AAAS), Whither “Orphan” GM Specialty and Small Market 
Crops?, February 8, 0, in Washington, DC, and by the Specialty Crop Regulatory 
Assistance (SCRA) initiative, Nuts and Bolts of US Regulatory Dossiers for Genetically 
 Engineered Crops, December 6–8, 0, in Riverdale, MD. A unique aspect of NABC 5 
was the objective to formulate strategies to encourage progression to commercialization 
of GE specialty crops by public-sector researchers.
The presentations at NABC 5 were grouped in five areas:
• Opportunities and Challenges for Specialty Crops
• Genetic Engineering and Specialty-Crop Improvement
• Case Studies
• The Regulatory Process and Technology Access
• Perspectives from Relevant Groups
There follows a selection of “Major Issues” that emerged from the presentations and from 
the Q&A sessions, and “Opportunities and Challenges for Specialty Crops,” i.e. a more 
comprehensive listing of considerations underpinning the state-of-the-art as it relates to 
GE specialty crops, the paucity of commercialization of GE specialty crops and how this 
situation may be improved. Also presented are issues that speakers and audience mem-
bers stressed as important under the rubrics of “Genetic Engineering and Specialty-Crop 
Improvement,” “Case Studies,” and “The Regulatory Process and Technology Access.”
In short, this chapter provides a relatively brief summary of the conference 
 proceedings.
5Major Issues
The Dearth of GE Specialty Crops Commercially Available in the United States
• Virus-resistant papaya.
• Virus-resistant squash.
• Insect resistant sweet corn.
• Virus-resistant plum.
• Herbicide-tolerant sugar beet.
• Violet carnation.
Only a Few GE Specialty Crops Are Within the US Regulatory Process 2
• Innate™ potato with reduced black-spot bruising and reduced asparagine content.
• Orange resistant to citrus-greening bacterial disease.
• Non-browning Arctic apple.
Barriers to Commercialization of GE Specialty Crops
• Current, time-consuming, costly, federal regulatory strictures.
• Uncertainty over the cost of achieving commercialization.
 — One report indicated that the cost of discovery, development and authoriza-
tion of a new GE trait introduced to a commodity crop by a large company 
between 008 and 0 was $36 million, of which achieving deregulation 
cost 6 percent ($35. million) (Crop Life, 0).
• Lack of access to essential technologies.
• Lack of interest on the part of major companies.
• Declining entrepreneurial spirit on the part of public-sector scientists.
• Declining funding for public-sector research.
• Need to invigorate public interest in new specialty crops advantageous to 
 producers, to processors and to consumers.
Key Recommendations for Achieving Timely Deregulation and Market Acceptance
• Communicate with the appropriate federal agency/agencies early and often.
• Invest in the services of consultants to help negotiate the regulatory process.
• Non-GE identification of product, e.g. Innate™ potatoes and Arctic apples.
Opportunities and Challenges for Specialty Crops
• NABC should organize an educational campaign for biotechnology, in particular 
vis-à-vis specialty crops. It is clear that the general public has negative feelings 
about foods containing genetically engineered (GE) ingredients because of “anti” 
campaigns.
2Not necessarily exhaustive.
Eaglesham and Hardy
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• A positive marketing plan is needed, concentrating effort on sharing the science 
about specialty crops and combating negative messages.
• To reach the people influenced by activists, social media must be engaged.
• Industry needs a PR campaign in mainstream and social media to prove and 
 publicize the benefits of biotechnology to health, the economy, and environ-
mental and population trends.
• The orange juice/citrus-greening story should be used by industry to demonstrate 
that biotechnology is not only safe and economical, but essential for solution of 
special issues in agriculture.
• Although significant progress has been made by researchers in the public sector 
in terms of improving resistance of specialty crops to fungi, bacteria, insects and 
parasites, including parasitic nematodes, commercialization of GE specialty crops 
has been limited. 
• Biotechnology can reduce the use of agrichemicals on fruits and vegetables, 
improve quality and yields, reduce post-harvest losses, enhance climate resilience, 
and increase nutrient value and economic returns. Good examples are the purple 
tomato3, which has high levels of anthocyanins, increased tolerance of disease and 
strong post-harvest stability, and potato varieties resistant to early blight4.
• The question is, Will the potential for application to specialty crops be realized? 
Given all of the good work that has been done, what’s stopping it? Why isn’t it 
moving forward? The stumbling blocks are not technical, but regulatory, non-
 access to essential technology, and social.
• Our universities are less involved in product development than historically. Lack 
of innovation and entrepreneurship in our public institutions—upon which to 
build new enterprises and refresh established products—has led to a weak pipeline 
of new technologies.
•  Fewer than six public-sector transgenic crops have reached the market.
• A better way forward will not come from multinational companies due to lack 
of trust.
• The key challenges remain around achieving deregulation of traits and genes and 
in accessing technologies resulting from industry investments in first-generation 
GE crops. Opportunities will arise as patents expire.
• It would make sense to deregulate Agrobacterium-mediated transformation and at 
least some Bt genes, including those conferring resistance to Roundup and other 
herbicides. Similarly pathogen-derived resistance to viruses should be deregulated. 
We ought to be pushing APHIS and EPA for their deregulation more actively 
than we are.
3Developed in the UK.
4Developed in the UK and the Netherlands.
7• A significant barrier at the EPA is interpretation of definitions. Virus resistance 
is called a pesticide because it controls a pest. A standard disease-resistant trait is 
not called a pesticide, but a transgenic one, which essentially means that DNA is 
being classified as a pesticide. Also of concern is that genes used to affect climate 
resilience—drought tolerance and so forth—are classified broadly as growth 
regulators. Chemical growth regulators are regulated, therefore genetic growth 
regulators should be thusly regulated.
• The cost of achieving deregulation within country need not be exorbitant. 
Commercialization of virus-resistant papaya in Hawaii in the 1990s cost 
approximately $1.5 million. A new virus-resistant Phaseolus bean cost $3.5 
million from the start to product delivery within Brazil. Obtaining deregula-
tion globally is significantly more costly5.
• A significant challenge in North America is reduced investments in discovery 
research.
• Increases in investment in agricultural science in the BRIC6 nations is directly 
related to their increases in productivity. The United States and Canada are seeing 
flattened or reduced investment;7 we are not keeping up with our competitors. 
It may well be that the advantage will be taken in less economically advantaged 
countries than in ours.
• An additional problem is limited understanding of how to achieve customer 
acceptance of biotechnology, due to concerns over food and environmental 
safety and intellectual property rights. In fact, consumer concerns are grow-
ing, as indicated by the labeling initiatives by activists and organizations who 
recognize that an anti-GE stance is supportive of their fund-raising activities.
• Edamame is a good example of a small-acreage specialty use of soybean that 
USDA funds for exploitation in the United States through the Specialty Crop 
Research Initiative (SCRI). The SCRI is a potential source of funding for GE 
research on specialty crops6.
• Farmers are applying lower levels of pesticides and soil health is improving. 
As a result of these improvements, key environmental groups—World Wildlife 
Fund, Environmental Defense Fund, Natural Resources Defense Council, 
etc.—are supporting GE crops more strongly. Also, we have improved food 
safety as a result of reduced levels of mycotoxin—a carcinogen—in Bt corn.
• Intellectual property is not the obstacle that it used to be.
5 See page 5.
6 Brazil, Russia, India and China.
7However, as mentioned in the preface, the Farm Bill—passed in February 04, during the preparation of 
this chapter—has restored the Specialty Crop Research Initiative funding, to about $80 million per year. We 
are pleased with this reemphasis of the fundamental importance of research in specialty crops, consistent with 
the focus of this conference.
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• Approximately 1 percent of the American public—including educated 
people—actually eat the amounts of fruits and vegetables recommended by 
the USDA.
Genetic Engineering and Specialty-Crop Improvement
• We can transform virtually any plant with any piece of DNA, or RNA for that 
matter.
• In May of 998, just 6 years to the day after ring-spot virus was discovered in 
 papaya in Puna, resistant seed was released to growers. If research had been 
initiated after the virus had reached Puna there would be no papaya industry in 
Hawaii today.
• In Hawaii, non-transgenic and transgenic papaya have been grown for more than 
a decade, because Japan, until recently, imported only non-transgenic papaya. 
This was achieved using identity-preservation protocols.
• Deregulation of GE papaya in Canada was rapid because they acted on informa-
tion from the United States.
• Due to politics and lobbying of activists, transgenic papaya will never be available 
to the Thai consumer and serious damage from the virus will continue to affect 
production and compromise the living standards of those who are most vulner-
able.
• Transgenic papaya remains a public-sector anomaly.
• In 00, worldwide insecticide use on major crop groups cost $0.6 billion. 
Some 45% of the value of insecticides used was applied to fruits and vegetables, 
i.e. specialty crops.
• Our track record with Bt vegetables has been poor. The first was Bt potato, com-
mercialized in 995 to control the Colorado potato beetle, a primary defoliator in 
North America and Europe, resistant to many insecticides, with control costs of 
$40 to $300 per acre. When Bt potato appeared—a Monsanto product—grow-
ers liked it. In the second year it doubled in sales, and in the third year it doubled 
again. However, by 00, it had fallen by the wayside. There were biological 
reasons, business-management reasons, and social reasons for the demise of the Bt 
potato. Activists pressured major producers of french fries not to use Bt potatoes. 
A somewhat similar example is General Mills’ recent decision not to use sugar 
from GE corn for its major Cheerio brands but to use it for their other brands, 
indicating that the motive is marketing-based rather than healthfulness-based. 
Most ironically, a new class of insecticides, the neonicotinoids, had become avail-
able in 995. They controlled aphids and leafhoppers as well as Colorado potato 
beetle. One new science technology won over another.
• At Cornell, new technologies are being taken to developing countries. The 
eggplant fruit and shoot borer is a caterpillar that farmers “traditionally” try to 
98Equivalent to USDA-ARS.
9In Colorado, Illinois, Michigan, Missouri, New York and North Carolina.
10Fire-blight resistance, cold tolerance, early flowering, herbicide tolerance, bacterial resistance, insect resistance, 
vaccine synthesis, anti-cancer agent synthesis, etc.
11Apple, blueberry, brassica, celery, cherry, citrus, grape, peanut, potato and tomato.
control by spraying a cocktail of organophosphates, carbamates and pyrethroids, 
each of which has some human toxicity. Sometimes 80 sprays are required on a 
crop that reaches maturity in 80 to 90 days.
 — It has been estimated that Greenpeace spent $00 million to derail Bt egg-
plant. The minister for the environment, the last gatekeeper for Bt eggplant in 
India, enacted a moratorium in 0, which is where it now sits.
• Bt sweet corn in the United States is a more successful story. In 008 (the most 
recent data) it had ~9% of the total fresh-market acreage.
• In a study in Philadelphia, people looked at the quality of sweet corn, the fresh-
ness and if it was labeled “genetically engineered; they really didn’t care. Quality 
was more important than how it was produced.
• In 0, Monsanto came out with a two-Bt-gene version of its ‘Obsession’ sweet 
corn, which was field-tested in comparison with its non-Bt counterpart. Yields 
were compared after spraying either zero, four, or eight times with the insecticide 
“Warrior.” Without Bt and insecticide, only 6% of ears were marketable, Even af-
ter spraying eight times, only 8% of ears were marketable. ‘Obsession’ with two 
Bt proteins produced 99% to 00% marketable ears, even without insecticide. 
Impressive!
• In Brazil, Embrapa8 scientists are producing a virus-resistant common bean 
(Phaseolus vulgaris). They expect it to be commercialized in 04 or 05, since 
the Brazilian government has the political will and they have scientists like Den-
nis Gonsalves with the passion to carry things through.
• An NABC survey of six land-grant universities9 revealed twenty six instances10 of 
genetic engineering of ten specialty crops11; deregulation had been applied for in 
only two instances.
• Perhaps broad acceptance will occur first in developing countries where food 
security issues are most acute. Technology may be developed in the United State, 
go out to developing countries, and then come back.
• We need political will; we need scientific evidence; and we need social infrastruc-
ture with which to create policies that will foster the adoption of GE specialty 
crops.
• Consumers show little concern related specifically to GE specialty crops. Most 
objections are generic, i.e. to genetic engineering in general, rather than to GE 
fruits, vegetable, etc., in particular
 — Some consumers view GE crops as potential “contaminants” of organic and 
even conventional crops.
Eaglesham and Hardy
0 Biotechnology and North American Specialty Crops
• The demand for mandatory labeling of foods containing GE ingredients is gather-
ing momentum. Much of the underpinning discussion revolves around the issue 
of “right to know.” On the other hand, pro-labeling referenda recently failed in 
California and Washington State.
• A first requirement is comprehensive federal regulation and oversight that ensures 
consumers that GE crops are safe to eat and do not adversely affect the environ-
ment.
• In 99, a voluntary consultation process was established by the FDA on the 
basis that GE crops are “substantially equivalent” to their conventional coun-
terparts. To date, all those who have commercialized GE crops have complied 
with voluntary consultation. However, this voluntary process is not sufficiently 
comprehensive. In the late 990s, NABC recommended that this process by 
required, not voluntary, and in 004, Senator Durbin introduced the Genetically 
Engineered Foods Act, which would mandate the consultation process without 
changing the safety standard or the data requirements. The FDA would provide 
formal certifications of safety. It would not lengthen the process but it would give 
consumers confidence in the federal governments oversight.
• The USDA needs to monitor stewardship more comprehensively. There is evi-
dence of resistance to Bt in corn rootworm and of herbicide-tolerance in weeds, 
possibly resulting from poor stewardship by farmers and by some biotech compa-
nies.
• There is need to anticipate and address issues that affect consumer acceptance of 
GE specialty crops. There is need to educate, inform and listen to the farmers and 
relevant farm organizations. There is need to listen to food-chain actors and to 
educate them, including grocery stores, as well the media.
• It is important to put in place segregation procedures to prevent commingling of 
GE and non-GE seed.
• Although transparency will improve consumer confidence, labeling of GE foods 
should not be mandatory. Strong, but not stifling—“appropriate”—regulations 
will reassure consumers.
• European plum, genetically engineered for resistance to plum-pox virus, was 
successfully registered by an ARS scientist. Clearly, the technologies are in place 
and the regulatory system can work, opening the way to deregulation of other GE 
specialty crops.
• There will be no “hall pass” for devising more precise ways to produce new 
genotypes. Activists are likely to ask “Why don’t we just label that as GE food?” in 
spite of the fact that some eighty research papers have elucidated labeling’s nega-
tive impacts.
• Plant-breeding potential is ever-expanding, particularly with new genome maps, 
RNA silencing, zinc fingers, etc.
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• Until you resolve manufacturing/retailer/consumer acceptance, you don’t know if 
the process of achieving deregulation will be worth it,
• About 5 percent of the public definitely will not buy a GE fruit or vegetable in 
the marketplace.
• A blueberry-genome sequencing effort that will be completed by the end of 
summer 03. It’s a complicated genome that no one else wanted to tackle. The 
database will be open to people looking at cranberry and other plants in the genus 
Vaccinium. Knowing the genomics will leads to understanding beneficial activities 
within the human body.
• The launch of the Plant Pathways Elucidation Project (“P-Squared EP”) is 
planned for June 03. North Carolina State and the University of North 
Carolina-Charlotte will be academic partners. NC State will handle the biology 
whereas Charlotte will handle bioinformatics; the biological data will go into a 
knowledge-based cloud over the whole project to feed information into what a 
plant makes, how it makes it, what’s the pathway it takes to get there, and what 
good the product is for human health. In building this knowledge base, Dole and 
General Mills will be industry partners and Castle & Cooke will be a sponsor. 
Developed technologies will aid understanding of how specialty crops contribute 
to human health.
• General Mills and Dole have opened their files on pathways they have elucidated 
for oat, pineapple, and berries, and they are looking to university researchers to 
pull together teams for analyses of complex pathway analyses. Early efforts will 
focus on four crops: oat, broccoli, strawberry and blueberry.
• A need exists to use synthetic genomics to take beneficial traits that have utility 
under specialized conditions and combine them with photosynthetic efficiency, 
to carbon to be channeled to target molecules and show improved tolerance of 
environmental stresses. One of the most important research areas is improvement 
of photosynthetic efficiency.
Case Studies
Citrus Greening
• The infection rate of citrus greening—discovered first in 005 in Florida—is now 
00% of Florida groves.
• Initial replanting efforts resulted in high levels of infection in less than five years.
• The solution to the disease, will involve four concurrent processes:
 — Research
 — Regulatory approval
 — Horticultural/agricultural production
 — Consumer approval.
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• The major focus of the research is at Texas A&M, on the development of a dis-
ease-resistant tree through genetic engineering. Two genes that confer resistance 
are being transferred to citrus from spinach.
• Accordingly, the solution will involve a plant-incorporated protectant (PIP). Tests 
required by EPA, USDA and FDA are projected to cost in excess of $3 million, 
including the cost of three law firms in Washington, DC.
• Since genetic engineering will be involved, education will be fundamental to gain-
ing consumer acceptance.
• The first most important benefit is that the orange juice industry will survive in 
the United States.
 — Another major benefit will be the elimination of the insecticides now being 
used in large amounts to control the insect vector. 
• At the current rate of progress, resistant trees will not be commercialized until 
09. Effort is focused on accelerating the process.
Non-Browning Apple
• The Arctic apple has no polyphenol oxidase, the enzyme that drives the browning 
reaction.
 — Non-browning can be achieved with any variety.
 — RNAi is used to silence the four genes that encode polyphenol oxidase.
• Growers interested in planting Arctic apples will have to agree to apply a sticker 
to each fruit. It doesn’t say “genetically engineered,” but it does say “Arctic.”
• Achieving deregulation is doable and is not exceedingly expensive. People 
shouldn’t be thinking in terms of millions of dollars. The out-of-pocket compo-
nent isn’t that much.
• Deregulation is expected in the United States and Canada by the end of 03.
• The message to the consumer is short and sweet: it’s just like any other apple; 
it looks like an apple; it grows like an apple; and it tastes like an apple. It just 
doesn’t go brown.
Improved Potato
• J.R. Simplot’s Innate™ brand provides a way to talk about genetic engineering 
without resorting to the less consumer-friendly terms, “intragenic” and “cisgenic.”
 — Explanation of the Innate technology to consumers produced acceptance close 
to that of “plant breeding.”
• The word “biotechnology” elicits greater comfort among consumers than 
“GMO.” 
• Traits being brought to market using “Innate .0” potato are reduced black-spot 
bruise, and reduced asparagine.
 — To achieve these improvements, one of the five or six polyphenol oxidase 
genes and the gene for asparagines synthase were silenced in a tuber-specific 
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manner. Instead of asparagine—a precursor of toxic, carcinogenic acryl-
amide—the modified tuber accumulates glutamine instead.
• Those whose job is to improve potatoes, and who are focusing on the farmer, are 
missing 80% of the potential. Downstream companies that make products from 
potatoes are the big sellers.
 — Farmers produce $3.5 billion worth of potatoes every year, whereas some-
where around $40 billion worth of French fries are sold.
• It can take a while to structure relationships and induce consumer comfort with 
biotech. On the other hand, after they’re comfortable, support can be significant. 
Of 80 comments received—solicited by APHIS—5 have been positive, many 
from growers.
Vegetables
• Monsanto’s major play in vegetables is to take advantage of advanced breeding 
techniques, which entail the ability to associate, at the genetic level, from a trait 
perspective back to a molecular marker, which allows breeders to be more efficient 
in making selections.
• Thousands of markers have been identified in vegetable crops. Yearly throughput 
of marker-based data points has increased 00-fold since acquisition of Seminis in 
005.
• Once the donor source of resistance is identified, the marker for the trait can 
be identified and introgressed into any number of plant types: success has been 
achieved in producing mildew-resistant cucumber, Phytophthora-resistant peppers 
and virus-resistant squash.
The Regulatory Process and Technology Access
• FIFRA is unusual in that it considers benefits, but it can apply to plant-incorpo-
rated protectants (PIPs) in terms of environmental safety and benefits and even 
economic safety and benefits.
• Experimental Use Permits (EUPs) are issued by EPA to facilitate the generation of 
information or data necessary to register PIPs.
• FIFRA dictates that cumulative terrestrial trials of >0 acres (4 ha) or aquatic 
trials of > acre per year per PIP require EPA approval via experiment use permits 
(EUPs).
• EUPs are time limited and require reporting of results, including adverse events.
• Petitions to APHIS involve two evaluations:
 — Risk assessment—as a stipulation of the Plant Protection Act—to answer the 
question: Does the genetically engineered organism pose a plant-pest risk? 
 — Environmental assessment—as a stipulation of the National Environmental 
Policy Act (NEPA).
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• APHIS-BRS has made determinations of non-regulated status in response to over 
90 petitions, comprising 6 plant species.
• In 0, a memorandum was issued by the White House Office of Science and 
Technology Policy in conjunction with the Office of Management and Budget 
and the US Trade Representative’s Office—frequently referred to as the Holdren 
memo—titled Principles for Regulation and Oversight of Emerging Technologies. Al-
though it is not aimed at biotechnology alone, it is similar in tone and emphasis 
to the Coordinated Framework for Regulation of Biotechnology, i.e. favoring innova-
tion, having enough regulation as necessary and to consider that there may be no 
need for regulation.
• The Sanitary and Phytosanitary Agreement under the WTO, which came into 
being in 995 says, in essence: “In the absence of good scientific evidence that 
demonstrates harm to plants, animals or to humans, we should not restrict trade.”
• The Food and Drug Administration (FDA) cannot make consultation mandatory, 
because no law permits it.
• FDA has a program to help developers ensure that food from new plant varieties 
is safe and complies with regulations. Three legal requirements are applicable.
 — Safety: The food is as safe as that generated from traditionally bred varieties.
 — Labeling: The labeling is truthful and not misleading.” 
 — Additives: Is premarket review required?
• Submissions to FDA are evaluated by two centers for different uses:
 — Safety of use in human food is evaluated by the Center for Food Safety and 
Applied Nutrition (CFSAN).
 — The Center for Veterinary Medicine (CVM) evaluates safety of use in animal 
feed.
• A new protein that is neither toxic nor allergenic is considered safe for field 
testing and FDA will not be concerned if low levels appear inadvertently in the 
marketplace.
• As science evolves, new technologies and traits will appear. However, FDA expects 
that the policy developed in 99 will be sufficiently flexible and broad to accom-
modate them.
• Canada differs from the United States in that it regulates novelty: novel feed, 
novel food and novel plants.
• The Canadian focus is on the product, not on the process used to develop that 
product. Accordingly, a regulated product can be developed by any breeding 
 process—including conventional breeding, genetic engineering or mutagenesis—
and this approach allows the Canadian regulatory system to efficiently adjust to 
any new developments in science or plant breeding.
• The main sources of concern expressed by members of the public are adverse 
 effects on honeybees and monarch butterflies.
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• Resistance-management programs are monitored to determine levels of 
 compliance.
• Specialty crops account for less than one-tenth of one percent of the 40 million 
acres of GE crops produced in the world today.
• The comprehensive—if somewhat complicated—regulatory system in the United 
States has worked fairly well since the mid-980s, although it may be argued that 
improvements are now needed.
• Approval times for genetically engineered crops have ballooned from approxi-
mately 6 months to over 3 years.
• Much has been said about the high cost of achieving regulatory approval for 
GE-crop traits. Published numbers have ranged from $6 million to $5 million 
for global approval. A recent study quoted $35 million—even up to $50 mil-
lion—for global approval of commodity crops.
• The concept of a talent agent is relevant. In contrast, researchers don’t have 
agents; they are on their own.
• Scientists should be encouraged to look for opportunities to transfer their research 
vision into results that may change the world.
• The Public Intellectual Property Resource for Agriculture (PIPRA12) was formed 
by the Rockefeller Foundation.
• PIPRA freedom-to-operate assessments for public-sector projects to determine if 
products or processes use third-party proprietary technologies and, if so, can the 
project obtain the rights to those properties? PIPRA also looks at materials used 
and material-transfer agreements, which are always the more problematic.
• The Specialty Crop Regulatory Assistance (SCRA) program was set up in 004, 
under the auspices of which have been held several meetings, mostly workshops 
that have included developers of GE specialty crops and representatives of the 
regulatory agencies.
• How much in addition has to be spent to generate the additional data required by 
regulatory agencies for appraisal of a GE trait? When you do those calculations, 
the marginal cost comes down to the order of a few tens of thousands of dollars.
• Talking directly to the regulators is the best way to find out what information and 
data are actually needed.
• Attempts continue to secure long-term funding to maintain SCRA functions, 
including meetings and direct and indirect assistance to GE specialty-crop 
 developers.
12PIPRA enables access to public innovation. PIPRA supports innovation in agriculture, health, water, and energy 
technologies. In collaboration with 50+ universities and research centers and a pro bono attorney network, 
PIPRA provides intellectual property rights and commercialization-strategy services to increase the impact of 
public-sector innovation, particularly for developing countries and specialty markets.
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• Gaining deregulation is still the major stumbling block to the commercialization 
of GE specialty crops.
• There’s a need to address a range of traits, for which genetic technologies are the 
best tools in the toolbox. This implies the need to overcome public resistance and 
the need to overcome misperceptions about the onerousness of the regulatory 
system. 
References
Alston JM Pardey PG (008) Public funding for research into specialty crops. HortScience 
43(5) 46–470.
CropLife International (0) Fact Sheet: Getting a Biotech Crop to Market. http://www.
croplife.org/PhillipsMcDougallStudy.
Kalaitzandonakes N et al. (007) Compliance costs for regulatory approval of new biotech 
crops. Nature Biotechnology 5 509–5.
Miller JK Bradford KJ (00) The regulatory bottleneck for biotech specialty crops. 
Nature Biotechnology 8(0) 0–04.
USDA-NASS (009) Summary and State Data Vol. . Washington, DC: USDA.
7
Opportunities and Challenges for Specialty Crops: 9
Will They Sell If Developed? 
Roger N. Beachy
Q&A  9
Part II–KeYnote PreSentatIon
8 Biotechnology and North American Specialty Crops
9
With this presentation, my role is to help to stir the discussion. Perhaps it will open the 
dialogue so that we have a sense of where we have been, where we are, and then what’s 
ahead. Figure  shows a photograph from 986, and in Figure  is a photograph taken 
two years later. We developed a tomato phenotype—viral coat-protein-mediated resistance 
to a common disease of tomato—with a technology that we hoped would be applicable 
to other horticultural and agricultural crops. 
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Will They Sell If Developed?
Roger N. Beachy
Global Institute for Food Security
Saskatoon, Saskatchewan
rnbeachy@danforthcenter.org 
Figure . 985: Coat-protein-mediated resistance to virus infection in tomato.
Since the field trial, fewer than six public-sector transgenic crops have reached the 
market in the United States. For the last 5 or 8 years, we’ve asked why it’s been that 
way and if the situation will improve in the near future. If it does get better, what steps 
will be required to get there. I will discuss this in the context of reduction of the use of 
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pesticides and improved sustainability, and the role that this and other sciences play in 
the economy.
Increasingly, the topic of this conference, biotechnology and horticultural crops, is 
about the ability of producers to make a profit, and how future agriculture, globally, will 
include specialty crops. Although we cannot accurately predict the future of technical 
successes or consumer acceptance of new crop varieties, we should be planning ahead, 
as it can take 0 or more years to bring a new technology to the market. We should be 
looking ahead at what the economic picture may be—knowing what farming is like today, 
knowing what smallholders in Africa might want, or what might be useful in the prairies 
of western Canada, in Florida and other regions of the world. 
I want to consider the technical opportunities and market challenges and possible 
solutions in the biotechnology of specialty crops, and then look for trends and goals that 
may portend a brighter future. We know where we’ve been. The technologies that were 
developed in the 980s in transgenesis provided good products that brought value to 
producers and, arguably, to consumers by keeping food available at reasonable cost; also, 
they brought environmental benefits. 
However, progress in applying the new technologies to specialty crops has been lim-
ited. The stumbling blocks are not technical, but regulatory and social. The challenges 
are magnified by the fact that the crops are of relatively small acreage and that consumer 
concerns over genetically modified (GM) crops are not waning. Activists are becoming 
more vocal, and we don’t seem to have a plan for mitigation of damage that they cause 
to the effort to develop useful varieties through biotechnology. Nevertheless, public-sec-
tor scientists have continued their investment in the technology as it fits their research 
goals, and they continue to create products that are likely to have value, should they be 
adopted. As a plant pathologist, it is heartening to see the progress that has been made 
by researchers in the public sector, for example improving resistance to fungi, bacteria, 
Figure . 987: First field trial of genetically modified tomato plants similar to those 
described in Figure , conducted in Jerseyville, Illinois.
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insects and parasites, including parasitic nematodes, in specialty crops. Virus-resistant 
traits have been introduced in many specialty crops. 
Biotechnology has also been employed to enhance nutrient content in tomato, rice, 
maize and other crops. Good examples are the purple tomato with high levels of carot-
enoids, increased tolerance of disease and strong post-harvest stability, vitamin-C-rich 
carrot, and potato varieties resistant to early blight and to late blight. A large number of 
virus-resistant crops have been developed by researchers abroad, showing how science 
and biotechnology have proven to be valuable. The question is, Will the full potential for 
application to specialty crops be realized? Given all of the good work that has been done, 
what’s stopping it? Why isn’t it moving forward? It is not a technical problem. Clearly, 
other issues need to be addressed.
A Long-Term View is Necessary
Let’s look at today’s problems in the context of what the long-term future might bring in 
agriculture, and ask several questions for US agriculture:
• Who is defining the long-term future of US agriculture in competition with 
BRIC1 nations and other emerging economies, and how will decisions in technol-
ogy and markets impact the future? 
 — What will be the impact on US agriculture of increased productivity of 
 commodity crops in Eastern Europe and South America?
 — Over what timeframe will changes occur?
• In the context of: increasing focus on health and nutrition, how will technology 
in horticultural crops be judged? How will value added to agricultural products 
be captured and will it change? What will be the impact of ongoing changes, both 
positive and negative, on farm economies in an era of high land values? And how 
will land values’ impact on the roles of specialty versus commodity crops in the 
US economy change?
• What will be the markets for US agriculture exports when African nations 
 become food self-sufficient in 0 or 5 years (as some have predicted), and 
when/if Eastern Europe produces more wheat and corn for European markets, 
and when Brazil fully exploits the Cerrado2 for production of increasing amounts 
of soybean and corn?
If you ask who is in charge of outlining a plan for America’s agricultural future, you 
may not find a long-term plan, though a mid-term roadmap was developed by the USDA 
in 0. A useful roadmap should identify and address the challenges to the future of 
America’s agriculture. Are increases in yields possible in commodity agriculture and what 
is required to achieve yield goals? What will impact the future profitability of specialty 
crops and how will challenges be managed? At the end of the day, a major issue is whether 
1Brazil, Russia, India and China.
2A vast tropical savanna, the largest of Brazil’s major habitat types after Amazonia.
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or not the farmer/producer can make a living, whether (s)he can still pay the mortgage 
on the land and purchase the equipment that will affect profitability, and contribute to 
the wellbeing of the family. A useful roadmap will plan forward to provide a basis for 
ongoing success in the industry.
In a recent publication—Agricultural Innovation: The United States in a Changing 
Global Reality—Philip Pardey and Jason Beddow (03) enumerated future challenges to 
agricultural economics that can be useful. We in the sciences and business sector, focused 
as we are on our own projects and products, often forget the bigger picture, to our detri-
ment. To capture new value from agricultural products, there’s an increasing awareness 
of the potential value of a growing bioeconomy and of biorefineries. Similarly, the grow-
ing role of consumer preferences and demands for agro-sustainability will continue to 
change agriculture. For example, I am convinced that biotechnology can reduce the use 
of agrichemicals on fruits and vegetables, improve quality and yields, reduce post-harvest 
losses, enhance climate resilience, and increase nutrient value and economic returns. If I 
am correct, investments made in research that helps to achieve these goals will prove to 
be warranted. The risk is that I am incorrect and that consumers will not push to reduce 
agrichemicals. To increase the likelihood that sound research goals are set, it will be help-
ful to engage the broad range of skills from the social sciences—including economics, 
consumer studies and policymaking—in the goal-setting process.
The Right Technologies at the Right Time
Recent advances in the science and technology of molecular plant breeding make it pos-
sible to consider the future of applications of biotechnology to horticultural and specialty 
crops that may be brought forward, for example new energy crops and those that produce 
biopolymers for the rubber and plastics industries. Quality of product and quantity of 
production can now be advanced rapidly by modern breeding and used to improve re-
silience to climate change and extreme weather, and to increase fertilizer-use efficiency. 
Furthermore, previously unexploited specialty crops may be employed for new industrial 
uses by applications of synthetic biology to alter metabolism and create useful products. 
Tools available today are far more powerful and useful than what we used, or imagined, 
in 985 when we developed the first virus-resistant tomato plants. New tools include:
• High-frequency mutagenesis to create variability and select desired changes in 
target gene(s)
• Directed nucleotide changes in target genes to recapitulate known/desired varia-
tions
• Site-specific gene insertion
• Artificial chromosomes to carry multiple genes
• Deletion/inactivation of non-desired gene(s) via meganucleases
• Non-transgenic progeny via segregation in breeding
• Gene inactivation by RNAi-based approaches, including directed methylation 
and knockout.
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We can expect continued technical improvements of course, and some of the new 
technologies will push the relevant regulatory processes to consider advantages of enabling 
technologies as well as the products to which they lead. The objective of the new tech-
nologies is not to circumvent regulatory oversight, but to develop new materials that will 
have increased value for those who take them to the marketplace and to the consumers 
who will use them.
Opportunities as Patents Expire
New opportunities for development will come through the expiration of patents and will 
lead the way to generic products, or will release constraints on commercial development of 
new products. Although patent protection for Agrobacterium-mediated transformation of 
plants will not expire until the late 00s, products that made use of the technology will 
become generic much sooner. For example, the coat-protein gene-based virus-resistance 
patent was issued (7 years after filing) in 003, and will be generic by 00.
Certain technologies for Roundup resistance, and for insect resistance will likewise 
expire in the early 00s and lead to new opportunities for new applications.
Challenges and Threats
The key challenges to development of biotechnology products in specialty and horticul-
tural crops remain around the cost of regulation of traits and in accessing technologies 
resulting from industry investments in first-generation GM crops. We look forward to 
having not only resistances to disease and insects that were developed in first-generation 
crops, but also we look forward to herbicide tolerance and other traits that will come 
off-patent in the next 5 to 0 years.
Many relevant and valuable traits have been demonstrated in specialty crops, but few 
have been introduced in the marketplace. As others have reported, the significant cost 
of deregulating a biotechnology product compared with the value of the trait per se is a 
real and ongoing problem, especially in those cases when a disease or insect pest affects 
a relatively small geographical area. 
In other cases, there is lack of scientific and technical information to bring to bear on 
a problem. A significant challenge in North America—as relevant in Canada as in the 
United States—is reduced investment in discovery research. We all ought to be concerned 
about this. Pardey and Beddow (03) noted that increases in investment in agricultural 
science in the BRIC nations is directly related to increases in their crop productivity. 
In contrast, in North America there is flattened or reduced investment in research in 
agriculture-related sciences in inflation-adjusted terms; we are not keeping up with our 
competitors, although we have built successful agriculture economies on such competition. 
In 0, the United States exported nearly $40 billion worth of agricultural products. 
Yet, in the United States, the Department of Agriculture invests less than $.5 billion 
dollars annually in research, and less than $350 million dollars is available for competitive 
research grants. That level of investment is catching up with us, begging the question of 
agricultural profitability in the continent in 0 to 50 years. The negative impact of less 
discovery research could be substantial.
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The weak history of innovation and entrepreneurship in our public institutions, upon 
which to build new enterprises and refresh established products, has led to a weak pipeline 
of new technologies. I participate as an advisor on several venture-capital funds and the 
paucity of innovation has, to date, been noticeable and is significantly less dynamic than 
from the biomedical community, and far less than for the IT sector.
It’s not that the science itself is not outstanding. It is common to hear venture-fund 
managers reflect on the lack of innovation in this market sector and to relate it to the fact 
that the way to market for products improved by certain genetic technologies is unclear. 
The weak pipeline of new technologies, and the heavy and high-cost regulatory process in 
the United States and globally causes delays in release of new products. This is confounded 
by the lack of harmonized and synchronous approval processes that have together slowed 
product approval, which, in turn, has slowed innovation. This is further exacerbated by the 
weak acceptance of new products by a very vocal minority of consumers—in particular 
products developed by multinational corporations—which affects all of us.
These are some of the significant threats and challenges that affect the applications of 
biotechnology to horticultural and specialty corps. On the upside, the USDA process 
has improved modestly. There are additional requirements, but maybe we should have 
predicted some of the changes, for example the growing need for studies of environmental 
impact of new products, as unscientific as it may seem in some cases. Maybe we should 
have expected the changes. EPA and the NEPA3 rules continue to represent substantial 
barriers to the release of new products.
The global approval process—which negatively impacts release of new products here 
in the United States—continues to be slowed by a variety of factors. And then there are 
events like the GM wheat that appeared recently in Oregon, and you wonder how long 
that tale will last, and how it will be used and by which group. Careful investigation is 
needed to elucidate how that happened in order to prevent recurrence, whether by ac-
cident or by intention.
Consumer concerns around GM crops are no lower than they were a decade ago, 
and are growing in some regions, as indicated by the labeling initiatives that we see in as 
many as 0 states. The same issues apply in Canada and in countries around the globe: 
we as scientists have a lot of work ahead as we take a more active role in discussions about 
GM foods.
Deregulation of Proven Technologies
Many scientists, though not all, are convinced that some of the controversies around 
GM food would diminish () if the benefits of GM varieties were more apparent to the 
consumer, and () if regulatory hurdles were reduced to levels commensurate with risk. 
It would help if agencies would deregulate based on past experience with a technology, 
and based on scientific evidence of no or minimum risk. At the same time, this would 
demonstrate to the public that—while the regulators are watching carefully—this is not 
3National Environmental Policy Act.
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a dangerous technology. We have boxed ourselves in vis-à-vis consumers by saying that 
the technology needs lots of regulation, when, in fact, most in the science community 
recognizes that it does not. Many feel that it is logical to deregulate Agrobacterium-mediated 
transformation, at least some Bt genes, and genes that confer resistance to herbicides 
proven to be effective and safe for the environment. Similarly, pathogen-derived resis-
tance to viruses should be deregulated. Also, I would include all RNAi approaches to 
control pathogens, in particular when siRNAs are shown to be part of an innate defense 
mechanism. However, I am not optimistic that this will happen in the near future. But, 
since we have 0 to 5 years of success with some technologies, we ought to be pushing 
APHIS and EPA to deregulate certain technologies more actively than we are. And if 
APHIS is, as they claim, a science-based regulatory agency, we should expect to receive 
informed responses. This may be a way that we in the academic community could help 
to move beyond the current slow-and-go regulatory process and move new products to 
market more rapidly than they are today.
Perception of Multinational Companies
I am convinced that many of the challenges that we in the public sector face in our 
 difficulties in GM agriculture are because many of us in university research are not seen 
as relevant to local agriculture per se. It is not easy for consumers of food to connect with 
our laboratory research. Instead, they generally see agriculture and the food economy as 
connected to large agribusiness and multinational food companies, which, they are con-
vinced, do not have consumers’ interests at heart. Although we know that not to be the 
case, we academics are either not seen as relevant or are painted with the same brush.
For some time, I have had a sense that this issue has arisen because our universities are 
now less involved in product development than historically. One way to minimize the 
latter may be for regulatory agencies to deregulate essential technologies that are broadly 
applicable, so that we can use them to address local problems. Horticultural and specialty 
crops are regional in their relevance. In the mid-990s, Benigno Villalón who developed 
thousands of varieties of hot chili peppers in Texas, sent a postdoc to my lab to develop 
coat-protein resistance to viruses, which commonly infect chili peppers. However, he 
withdrew the effort on realizing what would be involved in achieving deregulation. 
Similarly, there is much innate interest in using genetic engineering to tackle local pest 
and disease problems in many crops.
Achieving Deregulation
New technologies are developed in public research institutions as well as in small and large 
privately held companies. The deregulation process as it currently stands is poorly defined 
and costly. Achieving deregulation of virus-resistant papaya, led by Dennis Gonsalves4 
of the USDA in Hawaii is estimated to have cost less than $ million. In Brazil, a new 
virus-resistant Phaseolus bean cost $3.5 million from the start of the project to product 
4Pages 37–46.
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delivery. On the other hand, putting a new trait into a globally important crop—maize, 
soybean or cotton—is expensive, estimated to be between $50 million and $50 mil-
lion, depending upon what is required. This discourages innovation, and it certainly 
discourages venture capitalists from investing in projects to which they cannot predict 
an end-point. In some ways we don’t have a discovery problem in certain technologies, 
but we do have an innovation and translation problem. Policymakers are reluctant to 
develop long-term policies for the agriculture/food sector, including regulatory policies 
for new technologies.
An additional problem is limited understanding of how to achieve customer acceptance 
of biotechnology, due to concerns over food and environmental safety and intellectual 
property rights. The past 0 years haven’t worked well for us, yet we have little concept of 
what we should be doing. A better way forward is not likely to come from multinational 
companies due to lack of trust on the part of consumers. But unless we face this impasse 
and find a better way, in 0 years we will still be asking ourselves, “Why isn’t there more 
acceptance of crops developed with new genetic technologies?”
Messaging Agbiotech for Public Consumption
In 0, Graham Brookes and Peter Barfoot published a paper titled GM Crops: Global 
Socio-Economic and Environmental Impacts 1996–2009, which focused on positive 
 economic impacts, and production and environmental effects of GM crops. Within a 
week of the publication of Brookes and Barfoot (0), Vandana Shiva and colleagues 
(0) published The GMO Emperor Has No Clothes: A Global Citizens [sic] Report on 
the State of GMOs—False Promises, Failed Technologies (Figure 3). Certainly this was no 
coincidence. 
At an NABC conference some years ago, I remember standing and asking her, fol-
lowing her remarks to the attendees, “Do you really teach this to your students? Do you 
call yourself a scientist? Do you really believe what you are saying?” My questions didn’t 
matter, of course. Vandana Shiva has been saying the same things, making the same ac-
cusations, for the last 5 years, and because this is the kind of “stuff” that garners publicity, 
the issue won’t go away. The private sector has yet to learn how to message agriculture 
and biotechnology for public consumption and how to address those who attack their 
work unrelentingly. 
What might be done to counter? In my opinion, we should encourage transparency at 
all stages of the process—from research to testing, to product development and regulatory 
approval. Perhaps we should “open all the books”; perhaps that would help. And, there 
should be more public-sector voices in support of science and technologies in food and 
agriculture. And, in terms of transparency in our work, we need to  demonstrate that we 
are, in fact, looking at real advantages, real sustainability, with real reductions in the use of 
agrochemicals, and other important outcomes for the research that we are engaged in.
Meeting Global Food Security.
What we do in specialty crops is part of the challenge of meeting global food and nutrition 
security. According to the FAO, we must feed another  billion people with sufficient 
7
calories and nutrition, from a safe food supply, at acceptable cost, from the same area 
(perhaps up to 0% more) of arable land. This will have to be achieved with less water, 
and smaller inputs of fertilizer and other chemicals. Again according to the FAO, the 
foreseeable future will require a 70% increase in food production, a 43% increase in grain 
production, and a 75% increase in meat production. Specialty crops are part of the solu-
tion, in terms of producer economics as well as part of the solution in nutrition, health, 
and wellbeing of the consumer.
If what we are doing really does matter, the question is: can we broaden the use of 
advanced science and technologies to include horticultural and specialty crops?
Figure 3. 0 report by Vandana Shiva et al.
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Opportunities and Challenges for Specialty 
Crops: Will They Sell If Developed?
Q&A
Moderator: Dan Lineberger
Texas A&M University
College Station, Texas 
Andrea Fonseca (Texas A&M University, College Station): You said that multinationals 
won’t work. Can you elaborate on that?
Roger Beachy: My point is that the multinational companies, who are the most success-
ful in the  science and technology and in product development in GM agriculture, are 
heavily criticized for the appearance that they are “taking over the world’s germplasm and 
will control farmers.” So, while what the report about the safety of GM foods has been 
scientifically validated, the multinationals are tainted in the eyes of some consumers. My 
colleague at Washington University, Professor Garland Allen, a historian of science said, 
“Roger I have a plan to make food available for free for everybody in the world.” While 
some may feel that government should take on this role, others of us believe that the 
private sector plays an important role in food and agriculture. 
Fonseca: Okay, I see what you mean.
Beachy: And he’s not alone. That was my context.
Fonseca: You mentioned EPA barriers. What, in your opinion, is the most significant 
barrier at the EPA?
Beachy: The interpretation of definitions. For example, virus resistance was referred to 
as a pesticide because it controls a pest. In contrast, conventional disease-resistant traits 
are not called pesticidal. Describing a transgenic trait as such implies that DNA, or in 
some case RNA, is being classified as a pesticide. Another one that concerns me is that 
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genes used to affect climate resilience—drought tolerance and so forth—are classified 
broadly by one agency as growth regulators. The definition of a growth regulator in that 
context seems ridiculous. A learning should go on and the learning is called biology. It’s 
called genetics. It’s called plant physiology. It’s called pathology. It’s called information 
that we appreciate as science, and the consensus that results is what we know as scientific 
validation. Those are some of my concerns about the EPA. The need for regulation of 
GM crops of this type is something that I don’t understand. 
Nikhil Patil (Texas A&M AgrLife Research, College Station): You did a great job in 
presenting the whole perspective on local food security. We all know that we cannot 
achieve global food security without GMOs. In the early years, Europeans failed, in my 
opinion, to provide good education about GMOs. In the United States we are doing a 
little bit better in terms of educating people. Do you think we can improve global food 
security by inclusion of GMOs?
Beachy: We have a long way to go. We have yet to see Golden Rice in the market; it has 
been delayed for nearly 5 years. GM technologies are not yet considered part of the nu-
trition solution. We haven’t yet seen Bt brinjal5 in the Philippines, Bangladesh, or India. 
In the early days, China released some GM peppers, cucumbers and tomatoes that were 
virus resistant. So we know it is possible to move products of public sector research to the 
marketplace. There are ongoing field trials in Uganda with a bacterium-resistant banana, 
and I think that there are disease-resistant banana, cassava and sweet potato in trials. And 
there is GM cowpea with resistance to bruchid beetles. It may well be that the advantage for 
use of GM-horticulture crops will occur more effectively in less economically advantaged 
countries than in ours. It doesn’t sound very good for a specialty crops meeting like this 
one, but that may well be the way it will happen. Perhaps we need to think in terms of 
importing sweet-potato fries from Uganda made from GM plants. 
Bob Avant (Texas A&M AgriLife Research, College Station): Recently USDA announced 
they were going to go through an EIS6 process for deregulation of GMOs using the NIFA7 
process. Typically, environmental activists use that as a way to delay or kill projects. Do 
you think that doing EISs on GMOs will have a chilling effect on getting additional 
traits deregulated?
Beachy: I don’t think it will if we do it right. We ought to take our medicine if that’s the 
way it’s going to go before the law is changed, if ever; perhaps we could include EIS-
related studies with every field trial. Create the portfolio and just get it done. Of course, 
this requires that the EPA and USDA define adequately what an acceptable EIS is. We 
should learn the steps and collect the necessary data up front. That way, it won’t cost the 
developer additional years and another few million dollars. Just do it.
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Bill McCutchen (Texas A&M AgriLife Research, College Station): You’ve been through 
the genesis of this. What do you see as the path of least resistance for public institu-
tions—land-grant universities—to actually get our transgenic specialty crops deregulated? 
You pointed out some facts, but why can’t we come together and get it done?
Beachy: I don’t know. Why can’t you?
McCutchen: I don’t know. That’s why you’re the keynote speaker.
Beachy: Something occurred recently that shocked me. At an annual meeting of the 
American Phytopathological Society, I gave a forward-looking speech and a number of 
students who gathered around afterward said they had been told by their professors not 
to consider GM approaches. We have to start in our universities by saying that GM tech-
nologies are part of plant breeding. Everybody in science should know about genetics and 
plant breeding, including genetic engineering, and their role in agriculture sustainability, 
food safety, nutrition, and so on. We’ve got to start with education. The other approach 
may well be to begin talking about our current crop-genetic-engineering research proj-
ects in a transparent way, so that when the results are in we can say, “This is what your 
investment has brought us.” In the world of cancer research, they talk about solutions for 
many years before they accomplish them, which in a way justifies the continuing invest-
ments in cancer research, and why there is a cancer center at a hospital or in a university 
setting near you. In agriculture we are reluctant to describe our goals or that we might 
be using advanced genetics to achieve them. Perhaps there’s a marketing point here that 
universities should pursue. Maybe it should be led by the APLU8. Maybe it should be 
led by science societies, by the groups of plant producers or plant breeders who come 
forward to say that this is a key part of the technology that will achieve drought tolerance 
or insect resistance or lower-glycemic-index rice that tastes like its high-glycemic-index 
counterpart. Whatever the goal, we should indicate it now and that we expect achieve-
ment in 5 to 0 years. Maybe we should be more aggressive in our research reports and 
describe what we in agriculture are working toward.  We have a scientific capacity here 
that is compelling and we have too long been in the closet on so many of these important 
issues. Sometimes we are our own worst enemies; for the first 5 years of crop genetic 
engineering, many public plant breeders were saying that GM would not be a useful to 
agriculture. We have a lot to do in our own universities. At most university campuses on 
which I speak, there are  students of agriculture, among others, who have reached the 
conclusion that GM crops and foods are not good for the environment and not good 
for health. They have either not been taught the facts, or the available information has 
not been taught correctly. If we can’t get it right in our own schools of agriculture, how 
can we expect the mom with three kids to think that GM foods are okay? This is not 
something that I thought about just last night, but something that has been happening 
for a number of years. It will be interesting to see if Dennis Gonsalves9 feels the same way. 
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We have really failed in our schools of agriculture and colleges of arts. People at the little 
college I went to in Indiana thought that Vandana Shiva walks on water. When I gave 
a lecture there, some were sure that I was a devil from Monsanto. It’s an amazing thing. 
Anti-science people, or at least those who are anti-modern agriculture, are from a small 
percentage of the population who demand policies based upon their voices. Perhaps we 
in the field did not do our jobs in the early years; so what should we do now, 0 years 
later? I’m not sure, and that’s why I ask rhetorically, “Why can’t you get it done?” I don’t 
know if we have yet formulated a good suggestion of what to do to counter the mistruths 
that are being promulgated about GM foods. 
Chris Dzuik (H-E-B, San Antonio): I work for a retailer and we try to be transparent 
with our customers. With the pink-slime issue, the social media took over and a product 
that was acceptable is now gone. With new technologies such as irradiation, we can refute 
what some of the activist groups are saying through research. How can I, as an employee 
of this company, contradict what we see on social media, such as posters saying that GM 
creates autistic children, allergens, and so on. Where would I go to find good data?
Beachy: I don’t think it’s at a single location or website; nor is the information being 
used in way that is reaching those who want useful information. Of the population who 
are against GM foods, I would venture to guess that many are also against childhood 
 vaccines. An article by Marcel Kuntz in the October 0 issue of EMBO Reports, asked 
the question, “In the postmodern assault on science: If all truths are equal, who cares 
what science has to say?” If religious truth or philosophical truth or the truth from a blog 
is equal to the truth of science, and policymakers consider them to be equivalent, then 
how do we expect to move forward? I suspect that many who are attending this meeting 
can agree that we have a science-literacy problem;  we as scientists also have a believability 
problem, and for some there is a trust problem.
Bolormaa Jamiyansuren (University of Minnesota, Minneapolis): I do research on inter-
national trade of GMO products. How do you see the future for North American GMO 
producers, especially given that the competition is unfair. For example, the European 
Union had a strict labeling law that provided ample time for them to catch up with 
American producers, and now the law isn’t so strictly enforced.
Beachy: I don’t have a clear answer or a prediction about trade of GMO products. I 
happen to know a little bit about the China situation. A year or so ago, China said that 
they would not allow the growing of GM soybeans or corn, which some interpreted as 
a delaying tactic so that China could build its local industry before permitting cropping 
using foreign seeds. Meanwhile there has been a great deal of investment in agriculture and 
food-related science and biotechnology, and seed companies in China will soon market 
their own advanced seed varieties, and multinational seed companies may then be allowed 
to compete. With the use of non-tariff trade barriers such as this, I don’t know if we can 
expect any legislative or judicial body to exact changes. And, Europe probably will go at its 
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own pace. I am more concerned about barriers that will be raised in Indonesia, Malaysia 
and Vietnam and other countries in southeast Asia. On the one hand, we have APEC10 
and ASEAN11 agreements that one would think could be unified around agriculture and 
food availability. If there were a willingness to talk across science and trade and if countries 
would agree to be part of a larger solution it would help the situation.. 
When I was in Washington, I was privileged to meet a few government officials, and I 
asked one of the ministers of agriculture in South America—I won’t mention the coun-
try—“Would you be willing to work with our secretary to try to create an agreement 
amongst groups of producer countries with regard to trade of GM crops?” Remember, we 
have 6 or 8 countries that are producing and selling GM products; perhaps we could 
bring that group together to establish common goals and common cause. The minister 
said that if we could get a major country to lead it, i.e. the United States, they would join 
in. I didn’t get the same reception when I mentioned it to our Secretary of Agriculture, in 
large part because of broader agriculture trade issues. There seems to often be a trade issue 
that interferes with cooperation in research and crop technologies. I’m being generalistic in 
some of these statements so please take them with a grain of salt, but many issues around 
trade do, indeed, prevent biotech cooperation, issues that are not-related to GMOs. We 
know what the challenges are, but we don’t know how to get around them because we 
are often competing rather than cooperating with each other.
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I spoke at NABC 5, when the title of my talk was The Papaya Story: A Special Case or a 
Generic Approach? In the mid-980s when we developed the transgenic approach, Roger 
Beachy and I were at the epitome of intellectual excitement. We believed that, in 0 years, 
the major crops would be improved through genetic engineering. The technology that 
led to the development of virus-resistant papaya is beautiful, and yet when I end my talks 
these days, I ask, “Really, what has happened over the past 5 years?” If we don’t address 
that question seriously, I’ll guarantee you that in 0 years or even 5 years from now we 
will be asking, “What happened?” At the end of my talk, we’ll see whether my transgenic 
papaya story is a public-sector anomaly, or whether that approach is widespread.
Figure  shows a beautiful, delicious Hawaiian papaya. Roger Beachy and I became 
virologists because we wanted to fight virus diseases. Figure  shows the symptoms of 
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Figure . Virus-free papaya in Hawaii.
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papaya ring-spot virus (PRSV), which has been in Hawaii since 945. No natural resistance 
exists, and it is spread rapidly by insects. 
Advance of PRSV
In 978, the dean of the College of Agriculture pointed out to me that the virus—having 
destroyed the papaya industry in Oahu—had been identified in Hilo, just 9 miles from 
Puna where 95% of Hawaii’s papaya’s was grown (Figure 3).
Figure . Papaya infected with ring-spot virus.
Figure 3. The potential problem.
2Pages 9–8.
He suggested that I do some research to try to develop a means of control. So, way back 
then, in 978, we started by working up a rapid detection method, and then developed 
the pathogen-derived resistance method that Roger Beachy talked about2. Basically, by 
the mid-980s the concept (Figure 4) had been proven with virus-resistant tomato.
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Figure 5. 988–89, Maureen Fitch using the gene gun to transform papaya.
Figure 4. Pathogen-derived resistance.
We decided to take the coat-protein gene of the virus and place it in the chromosome 
of the papaya, in the hope that it would induce resistance, although, back then, in 984 
when we started, DNA sequencing was difficult as was cloning. And the dogma at that 
time was that resistance was coat-protein mediated, whereas our papaya ringspot had no 
natural start signal. So we actually added some amino acids from the cucumber mosaic 
virus to achieve a start signal.
I was fortunate in being at Cornell’s Geneva Experiment Station, where John Sanford 
and his colleague had invented the gene gun. With Jerry Slightom, an excellent molecular 
biologist, and graduate student Maureen Fitch, we cloned the coat-protein gene in 984, 
and Figure 5 shows the “father” of the gene gun in 988. We were still using .-caliber 
blanks to shoot in genes.
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First Virus-Resistant Papaya
Figure 6 shows a picture—taken at Cornell University in April 99—of transgenic papaya 
line 55-, which was a non-transgenic ‘Sunset’ transformed with the coat-protein gene 
inoculated with virus; the plant on the left contained the viral coat protein. This is where 
our group philosophy differed from the conventional wisdom of finding out if progeny 
indicated single-gene resistance. Instead, we cloned plants from tissue-culture, put them 
in the field and, within a year, our first trial was in progress.
Figure 6. 99: Virus-infected papaya, genetically engineered plant on left.
By April 99, cloned plants of this line were in the field in Oahu to see if resistance 
occurred. The long-awaited presence of the virus in Puna was reported in May 99. 
Figure 7 shows devastation that occurred in 994.
4
Having proven the concept, Richard Mashardt backcrossed the female line 55- with 
the non-transgenic sibling Sunset until line 55- was homozygous for the coat-protein 
gene; he called this cultivar ‘SunUp.’ Growers wanted yellow flesh, so he made an F 
hybrid of ‘SunUp’ and non-transgenic ‘Kapoho’ to come up with transgenic ‘Rainbow’ 
Figure 7. Puna: 994.
Figure 8. Transgenic ‘Rainbow’ surrounded by non-transgenic papaya.
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papaya. He utilized the field of less than an acre at the Waimanalo Experiment Station 
on Oahu to develop all this within three years of our first field test in May 99.
Figure 8 shows a solid block of transgenic ‘Rainbow’ surrounded by a non-transgenic 
line in a field trial in Kapoho. There was no question that the transgenic approach was 
working, and growers saw it and requested it. We told them that they could not have it 
until after deregulation. But who would finance the deregulation of a public-sector proj-
ect? John Sanford and I applied for an NSF grant, without success. The team’s first grant 
for the papaya work was for about $5,000.00 for three years—special funds through 
Senator Inouye—it was no million dollars.
Red Zone and Release
So, we scientists entered the “red zone” (Figure 9). I had never done any regulatory work, 
but it was necessary if we were to help the growers. Back then it was easier than it is 
today; the process is represented in Figure 0. I recall a meeting when growers suggested 
that the technology would be too expensive for their adoption because Monsanto would 
likely charge $0 million. They had read that in the newspaper. Within a year, the Papaya 
Administrative Committee (PAC) had the license, and Monsanto did not charge a dime 
for it, showing that it’s a mistake to rationalize yourself out of doing something.
In May of 998, almost 6 years to the day after the virus was discovered in Puna, we 
were able to release seed to growers. If we had started our research after the virus had 
reached Puna there would be no papaya industry in Hawaii today. I’m not a philosopher, 
but I would say that if, under the best circumstances, something is likely to take time, 
start on it immediately. If timing is critical, don’t wait until you have the ultimate answer. 
Use best judgment and move forward (Figure ).
Figure 9. Hawaiian transgenic papaya (995):
Entering the red zone of translational biotechnology.
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Figure 0. Deregulation and commercialization.
Figure . Under the best circumstances, it takes time.
Figure . Coexistence under an identity-preservation protocol.
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Deregulation Elsewhere
In Hawaii, we’ve been growing non-transgenic and transgenic papaya for more than a 
decade, because Japan, until recently, imported only non-transgenic papaya. This was 
achieved using identity-preservation protocols. Figure  shows a photograph taken in 
004, an example of the few fields where this applies. The most pressing problem isn’t 
gene flow, it’s loss of the non-transgenic crop due to the virus.
Deregulation in Canada was rapid because they acted on information from the 
United States. We started trying to deregulate the papaya in Japan a year after it was 
commercialized in the United States in 998; it’s a long story, but in December 0 it 
was deregulated. 
There is a common misperception that the Japanese consumer would be reluctant to 
buy it because it was labeled as being genetically modified. We went there expecting that 
with the first shipment of papaya, which was sold at Costco Japan. The most prevalent 
questions were, “How expensive is it?” and “Does it taste okay?” The Flavr Savr™ tomato 
failed not because it was genetically modified, but because it was unpopular. If you have 
a good product, consumers will buy it.
Addressing the Continuing Threat
In 00, I said, “Don’t forget the past,” and Figure 3 contrasts the papaya situation 
then with how it had been in 994. This is particularly appropriate now because a bill 
was recently introduced by a councilwoman on the big island in the county of Hawaii to 
ban all GMOs on the island of Hawaii where nearly all of the papaya is grown. The GM 
papaya would be “grandfathered” in, but would be grown under BSL-3 conditions. That 
bill was voted down. On July nd they changed the wording to require a 750-ft buffer zone 
Figure 3. Don’t forget the past.
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Figure 4. 0—transgenic papaya at 85% of production.
PRSV remains a threat.
Figure 5. 997—transgenic papaya brought to Thailand.
between transgenic and non-transgenic papaya, which farmers are unhappy about. Now 
that I’m retired and a private citizen, I say that enough is enough. Papaya is the cheapest, 
most nutritious fruit in Hawaii. Four may be purchased for only a dollar in a farmers’ 
market in Hawaii. This is the message that consumers must get across to the politicians. 
Some 85% of papaya now grown in Hawaii is transgenic. It’s reasonably priced, and it 
tastes good; it’s better than non-transgenic papaya. Figure 4 shows why farmers avoid 
non-GM genotypes: PRSV is still a serious threat.
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Thai Story: The Human Element
In 994 we were asked to help tackle PRSV in Thailand. In our lab, Thai scientists devel-
oped locally adapted transgenic genotypes, which, in 997, we hand-carried to Thailand. 
They worked beautifully in field trials. However, due to politics and lobbying of activists, 
our transgenic papaya will never be available to the Thai consumer and serious damage 
from the virus will continue to affect production and compromise the living standards 
of those who are most vulnerable (Figure 6).
In 03, is transgenic papaya still a public-sector anomaly? Absolutely. We must con-
tinue our efforts in the red zone, dealing with people and with politics. We must bring 
the human element into the picture. What will the next 5 years bring? I hope it will 
not be the same old story.
Figure 6. Keep the human element in transgenic efforts.
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As an entomologist, I work on insects affecting vegetables. This puts me in an interesting 
situation because every year when I see the ISAAA1 reports—showing rapid growth in 
cultivation of genetically engineered soybean, maize, cotton and canola—I say, “Where 
are the vegetables? Where are the specialty crops?” It’s ironic that the second crop to be 
transformed, by Monsanto, was tomato, for resistance to tomato fruitworm (Helicoverpa 
zea2), with a Bt protein. That was in 985 or 986, and yet we don’t have any tomatoes 
on the market that are genetically engineered to resist insects. I keep hoping that the next 
ISAAA report will contain data on vegetables.
Vegetables are an important part of the human diet. Calories can be provided by cereal 
crops, but for nutrition—especially in the developing world, where malnutrition, or “hid-
den hunger,” is prevalent—promotion of vegetables is needed. I’m not a vegetarian, but I 
eat a lot of vegetables; they’re good for you, we need more of them in the human diet.
Insecticides Applied to Vegetables
Vegetable farmers usually earn higher incomes per unit area compared to cereal producers. 
Vegetables are high-value commodities, but high cosmetic standards are applicable, as for 
papaya (described by Dennis Gonsalves3). Many are eaten fresh, which means that they’re 
intensely managed with frequent use of “traditional” insecticides. The data in Figure  
will surprise a lot of people. It shows that worldwide insecticide use on major crop groups 
costs $0.6 billion. Some 45% of the value of insecticides used is applied to fruits and 
vegetables. Furthermore, the amount applied to fruit and vegetables is .5 times higher 
than the total applied to cotton, corn and rice. So, the fresh products that we want to 
encourage people to use are getting blasted by insects and diseases.
Benefits of Biotech Specialty Crops:
The Need for a New Path Forward
Tony Shelton
Cornell University
Ithaca, New York
ams5@cornell.edu
1International Service for the Acquisition of Agri-Biotech Applications.
2Also known as the cotton bollworm and corn earworm.
3Pages 37–46.
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Figure . 00 worldwide insecticide use on major crops
(millions of US$).
After receiving an undergraduate degree in philosophy, I wanted to do something 
practical. Being interested in environmental issues, food security issues, and biology, like 
a lot of colleagues my age I read Silent Spring. In the last chapter, “The Road Forward,” 
Rachel Carson says, “Why don’t we use things like insect viruses, insect bacteria, insect 
fungi, and pheromones to control insects? Why are we using DDT and organophosphates 
and carbamates?” That resonated with me. So with my little philosophy degree in hand, 
I went to graduate school in entomology. I’ve always remembered Bacillus thuringiensis, 
a most interesting bacterium. Many strains exist, very safe for humans and the environ-
ment. I used it as a foliar insecticide in my graduate research. You’d spray it on and you’d 
have to spray it on two or three days later because it broke down so quickly in sunlight. 
Then someone had an idea: Why don’t we engineer into plants the gene for producing 
the insecticidal protein? And now this second- or third-rate foliar protein is present on 
about 70 million hectares worldwide, in maize, soybean and cotton.
Bt Potato
We haven’t had a great track record with Bt vegetables. The first was Bt potato, com-
mercialized in 995 to control the Colorado potato beetle, a primary defoliator in North 
America and Europe, resistant to many insecticides, with control costs of $40 to $300 
per acre. When Bt potato appeared—a Monsanto product—growers liked it. In the second 
year it doubled in sales, and in the third year it doubled again (Figure ).
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However, by 00, it had fallen by the wayside. There were biological reasons, business-
management reasons, and social reasons for the demise of the Bt potato:
• It controlled only Colorado potato beetle. It didn’t affect aphids or leafhoppers.
• Only one Bt variety was available. Granted it was Russet Burbank, which is 
 commonly grown.
• There were sporadic yield problems. 
• The need for refuges—planting a non-Bt variety nearby—was new to potato growers.
• There was debate on the safety of GMOs, and
• Market consolidation.
Most ironically, a new class of insecticides, the neonicotinoids, had become available in 
995. They controlled aphids and leafhoppers as well as Colorado potato beetle. One 
new science technology won over another. It’s noteworthy that neonicotinoid insecticides 
are now making the front pages of newspapers because of concern over killing bees and 
other organisms—and we still don’t have Bt potatoes.
Bt Eggplant
At Cornell, we are trying to bring new technologies to developing countries. The eggplant 
fruit and shoot borer (Figure 3) is a caterpillar that farmers “traditionally” try to control 
by spraying a cocktail of organophosphates, carbamates and pyrethroids, each of which 
has some human toxicity (Figure 4). This approach doesn’t work too well. Sometimes 80 
sprays are required on a crop that reaches maturity in 80 to 90 days.
Mahyco, a seed company in India, produced Bt eggplant. Figure 5 shows Dr. Usha 
Barwale Zehr from Mahyco giving seed of genetically engineered eggplant to Dr. C. 
Ramasamy, vice chancellor of Tamil Nadu Agicultural University, who will pass it along 
to his plant breeders for incorporation of the Bt trait into locally grown, open-pollinated 
varieties. The idea is for Mahyco to sell these as hybrids to make some money, but also 
to disseminate the technology. The superior performance of Bt eggplant over its non-
genetically engineered, repeatedly sprayed, counterpart is clear in Figure 6. 
Figure . Rise and fall of Bt potato.
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Figure 3. Eggplant infested with fruit borer.
Figure 4. “Traditional” control of eggplant fruit and shoot borer in India. Although 
insecticides are toxic, farmhands are often unprotected.
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The Bt eggplant (locally “brinjal”) went through ten years of field trials, and safety tri-
als, and then Greenpeace entered the piece. Figure 7 shows a protest in Tamil Nadu. The 
woman, an activist, is giving a member of the state legislative assembly what she called 
the “last non-GM eggplant” that will be had in Tamil Nadu if the Bt genotype is com-
mercialized. Greenpeace is good at attracting publicity, whereas we try to talk science to 
Figure 5. A gift of Bt-eggplant seeds to the vice chancellor of
Tamil Nadu Agricultural University.
Figure 6. Bt eggplant (right) compared with its non-GM counterpart.
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people and it doesn’t always work. Greenpeace also held monthly anti-GM seminars by 
scientists, including Gilles-Eric Séralini (University of Caen, France) and Jeffrey Smith 
(Institute for Responsible Technology, Iowa) and disrupted a field trial at Tamil Nadu 
Agricultural University
It has been estimated that Greenpeace spent $00 million to derail Bt eggplant. Under 
what pretense? They have admitted that they see GM as a good fundraiser, something 
that garners public attention. Greenpeace can talk about global warming, over which 
people feel they have little control. In contrast, they do feel control over the products 
they consume. Consequently, Greenpeace has focused on GM, to their detriment as a 
credible NGO.
What’s the final story? The minister for the environment, the last gatekeeper for Bt 
eggplant in India, enacted a moratorium in 0, which is where it now sits. One lesson 
is that you can’t outspend Greenpeace; they have deep pockets. If there is no political will, 
registration will not occur. On the other hand, if farmers have the will, things can happen. 
And if Bt eggplant is deregulated and commercialized in Bangladesh right next door, it 
will probably make its way into India, as did Bt cotton, which came into India before it 
was legal, smuggled in from somewhere. You can’t control this technology if growers really 
want it. Of course, it would be much better if the minister for the environment had the 
political will to deregulate the genetically engineered, insect-resistant genotype.
Figure 7. Activists present a GM-free bouquet, including eggplant, to a state assembly 
member to protest GM-food-crop commercialization and research in Tamil Nadu.
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Figure 8. Bt sweet-corn product adoption in the United States (acres).
Figure 9. Evaluation of Bt sweet-corn varieties combined
with Warrier II applications against Lepidoptera, 00.
Bt Sweet Corn
Bt sweet corn in the United States is a more successful story. It’s a Bt event from 
Syngenta that was registered for field corn and then crossed into sweet corn. Commer-
cialized in the mid-990s, the ride since then has been interesting (Figure 8). In 999 it 
was grown on about 30,000 acres in the United States, and then, at about the same time 
as the controversy over the Bt potato, it crashed. However, since 000, the acreage has 
steadily increased showing that growers like it. Despite export concerns for processors, 
farmer-adoption continues and in 008 (the most recent data) it had ~9% of the total 
fresh market acreage.
In 0, Seminis Seeds came out with a two-Bt-gene version of their ‘Obsession’ sweet 
corn, which we field-tested in comparison with its non-Bt counterpart. We compared yields 
based on spraying either zero, four, or eight times with the insecticide “Warrior” (Figure 
9). Without Bt and insecticide, only 6% of ears were marketable, with 94% unmarketable; 
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it was a bad year for corn earworm. Even when we sprayed eight times, only 8% of ears 
were marketable. ‘Obsession’ with two Bt proteins produced 99% to 00% marketable 
ears, even without insecticide. That growers like the technology is understandable.
In 0, when this was coming to market, Whole Foods stated that they would not 
carry it, possibly because it was associated with Monsanto, which owns Seminis Seeds. 
Protestors sent 460,000 “anti” signatures via email to Walmart, the biggest food market 
in the world. To their credit, Walmart responded, “No. We are going to sell it. We looked 
at the science and we looked at our customers, too, and we said, ‘Yes. We will do it.’” 
Different customers go to Whole Foods from those who shop at Walmart, but more go 
to Wal-Mart rather than to Whole Foods.
Virus-Resistant Bean
In Brazil, Embrapa1 scientists are producing a virus-resistant common bean (Phaseolus 
vulgaris). They have worked for 0 years to achieve resistance to bean golden mosaic virus, 
which is transmitted by a white fly (Bemisia tabaci). It has been estimated that annual 
losses from BGMV would feed 8 million Brazilians. They expect it to be commercial-
ized in 04 or 05, since the Brazilian government has the political will and they have 
scientists like Dennis Gonsalves2 with the passion to carry things through.
Event-Based Regulations
Will there be other products to come? I keep asking myself why genetically engineered, 
specialty crops are not more widely used. Roger Beachy3 touched on many of the reasons. 
Event-based regulations—as an entomologist, this really floors me. What is the rationale 
for putting together a regulatory package on a CryAb protein for tomato, when we know 
so much about it in other crops? Why do we need a new set of studies on non-target 
organisms? Or on allergenicity? The process should be streamlined to put this technology 
out where it’s really, needed. The Bt sweet corn actually piggybacked on field corn. Groups 
of crops may be packaged together, such as tomato, crucifers and other vegetables that 
are relatively small markets in which large companies have little interest.
Public-Acceptance Criteria
I’m also interested in public acceptance of GM products. Gonsalves pointed out that the 
genetically engineered papaya looked good and tasted good, which is why it has achieved 
broad consumer acceptance. A couple of studies suggest that consumers in North America 
will accept Bt sweet corn. One of my favorite studies was in Canada at a farm market. 
A farmer labeled Bt sweet corn and conventional sweet corn. He labeled one as a GM 
product and explained that it expressed a bacterial protein that would kill insects but 
not harm people. The other product was labeled as having been sprayed with various 
traditional insecticides. The GM sweet corn outsold the conventional corn 60:40. Once 
people became informed, they choose GM.
1Equivalent to USDA-ARS.
2Pages 37–46.
3Pages 9–8.
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In a study in a Philadelphia supermarket, people looked at the quality of the sweet 
corn, the freshness, and if it was labeled “genetically engineered”; they really didn’t care. 
Quality was more important than how it was produced.
What about public-sector production of these vegetables? Figure 0 shows a list of 
genetically engineered specialty food crops—produced at land-grant universities in 
Colorado, Illinois, Michigan, New York, Missouri and North Carolina—and where they 
are in the regulatory process. In most cases, the target is a horticultural characteristic. 
In one case, in Illinois, the target is an anticancer compound. Transgenic specialty crops 
can dramatically reduce the need of traditional pesticides. Dennis Gonsalves has shown 
this. Sweet corn evidence shows it also. But other characteristics would have even greater 
immediate appeal for consumers: products that will make them look better or change 
their health in some positive way.
Clearly, public education is essential, but it’s challenging. Surveys show that 50% of 
people do not want genes in their food, which reveals the scope of the problem. Perhaps 
broad acceptance will occur first in developing countries where food security issues are 
Figure 0. Genetically engineered specialty food crops: research, 
regulation and constraints.
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Figure . Factors necessary for the adoption of genetically engineered specialty crops.
most acute. Technology may be developed in the United State, go out to developing 
countries, and then come back. But what really is needed is a political will. Political will 
and scientific evidence can be combined in an informed society to create good public 
policy. And that public policy can welcome products developed with modern science and 
biotechnology. It was very disappointing in India when the minister of the environment 
overrode his scientific committee. We need political will, we need scientific evidence, and 
we need social infrastructure with which to create policies that will foster the adoption of 
genetically engineered specialty crops (Figure ) that benefit society. 
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6
This presentation has two separate sections.  The first attempts to summarize and explain 
some potential concerns that different non-governmental stakeholders might have with 
genetically engineered (GE) specialty crops. It is based upon a review of publicly available 
written documents from those organizations and review of their internet websites, and 
does not reflect my views or the views of Center for Science in the Public Interest. The 
second section of the presentation is the Center for Science in the Public Interest’s view 
on some issues that GE specialty crop developers should consider as they develop those 
crops and bring them to market.
Product-Specific Concerns
When preparing this presentation, I looked for product-specific concerns—related to GE 
specialty crops—that have been voiced by different organizations. Surprisingly, I found 
few concerns related specifically to specialty crops. I looked through the dockets on the 
GE plum and the GE apple1at USDA and searched websites of stakeholder groups and 
found that most of the concerns raised are not related to specific applications.
I did find some specific concerns over a virus-resistant plum, which has been approved 
but is not yet commercialized. The Organic Consumer Organization had doubts over 
the stability of the inserted genes and raised concerns over potential effects on bees and 
other pollinators. With other organizations, they pointed out the absence of short- and 
long-term safety testing and feeding trials for toxicity and other effects. The Sierra Club 
also was fairly vocal at that time, and they raised some issues around potential harm to 
local bee communities. They suggested the potential for creation of new viral forms via 
Potential Concerns of Different Stakeholders to
Genetically Engineered Specialty Crops
Gregory Jaffe
Center for Science in the Public Interest
Washington, DC
gjaffe@cspinet.org
1Pages 87–94.
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recombination, and even doubted the safety of eating viral proteins. Many would take 
issue with the validity of these concerns; I mention them to illustrate the kinds of prod-
uct-specific questions that have been raised.
The initial public-comment period that is part of the on-going review of the GE apple 
elicited the following concerns from the Center for Food Safety in Washington, DC:
• Changes in resistance to pests and pathogens may occur as a result of the suppres-
sion of polyphenol oxidases.
• Cut and packaged apple slices may support the growth of pathogenic microorgan-
isms.
• The nutritional status of the cut apple slices may be unpredictably affected by 
storage and packaging conditions.
General Concerns
I was surprised to discover that many of the objections to specialty crops are not prod-
uct-specific. Instead, they are what I call generic concerns—objections to GE crops in 
general rather than to any specialty crop in particular. Similar objections could be leveled 
at corn, soybean, apple, plum, broccoli or whatever. I won’t attempt an exhaustive cover-
age; I did look at the website of the Center for Food Safety to examine their concerns 
regarding food safety for GE crops in general. They posed the question, “What are the 
new ‘unexpected effects’ and health risks posed by generic engineering?” and answered 
it by listing six areas:
• Toxicity
• Allergic reactions
• Antibiotic resistance
• Immuno-suppression
• Cancer
• Loss of nutrition
They explained why they thought that each of these could be linked to genetic engineer-
ing. They had similar information for the environmental area, but this provides a good 
example of what consumers are hearing from this group regarding the safety of GE 
ingredients in food.
Food and Water Watch, an environmental group, issued a report in 0, Genetically 
Engineered Foods: An Overview, providing their perspectives on GE foods. The following 
are quotes from the overview, illustrating their concerns over GE crops and the foods 
made from them: 
Genetic contamination is a serious threat to the livelihoods of non-GE and organic 
farmers who bear the financial burden of these incidents.
The environmental effects of GE crops can include intensified agrochemical use 
and pollution, increased weed and insect resistance to herbicides and pesticides, 
and gene flow between GE and non-GE crops.
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The Roundup Ready trait lowers the nutritional content of crops by inhibiting the 
absorption of nutrients, including calcium, iron, magnesium and zinc, making 
the plants more susceptible to disease.
The second statement reflects a commonly expressed concern that the environmental ef-
fects of GE crops include increased agrichemical use and pollution, increased resistance 
of weeds and insects to herbicides and pesticides, and the likelihood of gene flow between 
GE and non-GE crops. I had never come across the third statement before. Many other 
concerns are provided in that report; these three provide just a “flavor.”
Opening the Floodgates
Now I come to even more general concerns. One that appears frequently in literature 
from consumer and environmental NGOs is the idea of “precedent,” that approval of a 
particular GE crop will somehow “open the floodgates.” A quote from one of these is:
This is simply a Trojan horse to get more GE foods and crops on the market.
The Organic Consumer Association expressed it thus:
The approval of GE plums would be a precedent-setting step by the USDA opening 
the floodgate for more GE trees including fruit, nut, ornamental and paper-pulp 
species as well as trees engineered for soil remediation and other traits.
Similarly, people expressed opposition to GE alfalfa during the deregulation process, on 
the grounds that it would set a precedent. So that’s an argument that one needs to be 
aware of in this field. 
Contamination
From the Sierra Club:
The organic and conventional plum markets in the United States will quickly 
be threatened by the first GE plum tree that will contaminate organic and 
conventional plum orchards once it is approved…
This espouses the notion that GE crops will “contaminate” organic and conventional 
crops.
A similar doomsday scenario has been suggested by Friends of the Earth and Food & 
Water Watch:
There could be significant economic impacts to conventional and organic orchards 
if their apples are contaminated with GE applies…
Concerns over co-existence and contamination are commonly raised with respect to GE 
corn, and somewhat less so with respect to GE soybean.
Mandatory Labeling
The demand for mandatory labeling of foods containing GE ingredients is another general 
issue raised for all GE products, including specialty crops. It has become a vocal movement 
in numerous states, having started in 0 with the California Ballot Initiative, which 
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didn’t pass but garnered national press and publicity. Much of the discussion underpinning 
it revolves around the issue of “right to know”: consumers have the right to know what’s 
in their food. A second issue surrounding those calling for mandatory labeling is that they 
say consumers are not sure that GMO food is safe so it should be labeled so that they 
can choose not to eat it. A third argument is often seen: if it is safe and beneficial, why 
hide it? I raise this because it could become a greater issue for specialty crops—which are 
consumed directly—than for corn or soybean, considering that the latter crops enter the 
human food chain mainly as highly processed ingredients such as corn oil, soy lecithin, 
high-fructose corn syrup, etc.
The Genetically Engineered Foods Right-to-Know Act, introduced in April 03 by 
Senator Barbara Boxer from California and Congressman Peter DiFazio from Oregon, is 
a bellwether for the labeling issue. It would require labeling on whole foods and processed 
foods including fish and seafood. According to Senator Boxer:
Americans have the right to know what is in the food they eat so they can make 
the best choices for their families. This legislation is supported by a broad coalition 
of consumer groups, businesses, farmers, fishermen and parents who all agree that 
consumers deserve more—not less—information about the food they buy.
This statement is true of lots of things, not just genetic engineering.
Figure  shows the status of state-level food-labeling bills in June, 03. The states in 
blue have bills proposed. Those in red have some approved. In New York in June, 03, a 
food-labeling bill was voted down in committee. In contrast, the governor of Connecticut 
has stated his intention to sign a GE food-labeling bill, which has gone through both 
houses. However, it won’t come into play until a certain number of neighboring states have 
enacted similar legislation. The implication is that Connecticut would be economically 
disadvantaged if it were the only state in the region with GE-food labeling.
Figure . State-level GE food-labeling bills.
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CSPI’s Views
The Center for Science in the Public Interest is a non-profit consumer organization located 
in Washington, DC working on food and nutrition issues.  We advocate based on the best 
available science on behalf of consumers and try to educate consumers on the relation-
ship between their health, their diet, and the food they eat.  Our Biotechnology Project 
started in 00, and we are devoted to reviewing the evidence and facts surrounding the 
GE crops grown in the United States.  We have found that scientific evidence supports 
their safety, both to grow and to eat.  The evidence also points to benefits accruing from 
growing some of those crops, either to farmers or to the environment, but not necessarily 
directly to consumers.
On the other hand, CSPI does believe that GE crops need to be assessed on a case-by-
case basis, and we do push for functional biosafety regulatory systems that ensure safety 
while allowing safe products to be marketed.  CSPI is supportive of streamlining regula-
tions, where appropriate.  The idea would be to have the regulatory system look carefully 
at crops and traits that are less familiar and potentially risky with more scrutiny, while 
facilitating deregulation of familiar and safe crops and traits in a streamlined fashion.
For those developers who wish to market GE specialty crops, CSPI believes there are 
two critical areas needed for overall product success with consumers in the marketplace. 
The first is ensuring there is comprehensive federal regulation and oversight that ensures 
consumers that the GE specialty crops are safe to eat and safe for the environment.  Sec-
ond, the developer must anticipate and address both consumer and customer acceptance 
issues, which involve market acceptance, coexistence, and transparency.  These two critical 
issues will be discussed in detail below.
Comprehensive Federal Oversight
By “comprehensive federal oversight” I mean:
• A statement from FDA that the GE crop variety in question is safe to eat, 
• A full review by the USDA with necessary environmental analysis under the 
National Environmental Policy Act, and
• Appropriate risk assessment—what many in the industry might call 
 “stewardship.”
FDA
The Food and Drug Administration regulates crops, including fruits and vegetables, under 
the Federal Food, Drug and Cosmetic Act, under which “food additives” go through a 
pre-market approval process, unless they are generally recognized as safe (“GRAS”). FDA 
determined that a GE crop is not a food additive and in 99 set up a voluntary consulta-
tion process for GE plants to ensure that the GE plant was “substantially equivalent” to 
its conventional counterpart. To date, all those who have commercialized GE crops have 
complied with voluntary consultation. However, in view of the fact that food safety is a 
critical issue for consumers, we at CSPI are of the opinion that the voluntary consultation 
process is not sufficient. The reviews by FDA are not comprehensive. More importantly, 
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their stock response—“we have no questions at this time”—implies that Monsanto, or 
whoever is developing the product in question, remains responsible.
We believe that safety determinations by FDA are needed. When the GE-wheat issue hit 
in Oregon in May 03, the most that could be offered by USDA in their press release was 
the wishy-washy comment that FDA had looked at it and had no questions at that time 
on its safety. Other countries have mandatory pre-market food-safety approval processes, 
and it’s ironic that, in the United States, none of these crops can be planted without a 
mandatory review by USDA, yet we can eat the food from them without that. In 004, 
Senator Durbin introduced the Genetically Engineered Foods Act—reasonable legislation 
in this area; it would take the voluntary process and mandate it without changing the 
safety standard or the data requirements. The FDA would formally approve the safety of 
each GE crop. It would not lengthen the process but it would give consumers confidence 
in the federal government’s oversight. Support from those who are developing GE crops 
would help alleviate concerns both around labeling and the technology. 
USDA
The United States Department of Agriculture needs to be involved in overseeing regulation 
of these crops to ensure against agricultural and environmental problems. The USDA’s 
(non)position on herbicide-tolerant Kentucky blue grass—a GE variety developed by 
Scotts Corp.—is revealing. In 00 Scotts requested a determination of the regulatory 
status of GE (glyphosate tolerant) blue grass; none of the DNA cassette (donor gene, 
promotor sequence, etc.) were plant pests and the gene gun was used to achieve transfec-
tion rather than Agrobacterium. Accordingly, the USDA responded in 0 that this GE 
crop is not regulated.
I have been arguing for about ten years that the USDA regulatory system may not 
apply to some GE crops and now we actually have a decision by USDA that they will 
not regulate this crop. So, this GE Kentucky blue grass can be field-tested without any 
oversight, and it can go to market without any oversight. I raise this because some may 
be thinking, “Regulation is expensive. It takes time. We should do what Scotts did.” 
I would counsel against that for specialty crops. You need USDA oversight to garner 
consumer confidence and achieve market acceptance. At the same time, USDA needs 
to do a better job. There has been litigation over glyphosate-tolerant alfalfa and sugar 
beets, where courts have said that the USDA environmental analyses under the National 
Environmental Policy Act were lacking. In response to that, USDA now is in part doing 
an environmental impact statement (EIS) for the ,4-D- and dicamba-tolerant crops. It 
is fundamentally important that USDA does its job well, that they assess environmental 
impacts, and that they avoid litigation. They don’t need EISs in all cases or even in most 
cases, but they need to do a better job. They had gotten sloppy for a number of years, 
and the courts properly slapped them on the wrist. They have a new system in place that 
will, hopefully, be quicker and do a better job.
Finally, USDA needs to insist on appropriate stewardship. There’s evidence of resistance 
to Bt in corn rootworms and of herbicide-tolerant weeds, possibly resulting from poor 
stewardship by farmers and some biotech companies. This technology has the potential 
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to be very beneficial for specialty crops. It should be used judiciously and as appropriate, 
depending on the biology of the specialty crop, with appropriate management practices 
to minimize the development of insect resistance to Bt and other insecticides, and to 
minimize the development of herbicide resistance in weeds.
Anticipating Consumer Acceptance
The second issue is to anticipate and address consumer and customer acceptance, which 
involves:
• Market acceptance
• Coexistence
• Transparency—right to know
Market Acceptance
To achieve market acceptance of a product, there is need to educate, inform and listen to 
the farmers and relevant farm organizations. There is need to listen to food-chain actors and 
to educate them, including grocery stores, as well the media, regulators and politicians.
Coexistence
Coexistence is the concurrent cultivation of biotech, organic, and non-biotech varieties 
of the same crop. It depends on the biology of the crop and the production system. It 
is different for corn than for soybeans than for apples. It requires setting up appropriate 
processes in the food chain. I raise this issue because it may be increasingly important in the 
future, depending on the crop. We saw this in terms of concerns raised by environmental 
consumer groups at the beginning of this presentation, and I think it’s important to put 
in place procedures to segregate seed. Any inadvertent commingling will have minimal 
effect as long as there’s a segregated seed supply. To me, that is key. 
Transparency
Finally, on the transparency issue, CSPI is not in favor of mandatory GE labeling. We do 
think that there should be consumer access to information about whether their product 
is genetically engineered, so for the consumer who wants to know, they should be able 
find it. It shouldn’t be hidden, but that’s different from having a mandatory government-
imposed label. We do think that that information should be available whether it’s on a 
website or electronically; there’s a host of different ways to make information available these 
days. But, with that, there needs to be information about the benefits of these products, 
as well as information about the production process. Consumers don’t know a lot about 
how their food is produced or where it comes from, so hearing “genetic engineering” 
out of the agricultural context can be confusing. There needs to be better education and 
transparency all around.
In Conclusion 
We need strong, but not stifling, regulation to reassure consumers. I call it “appropriate 
regulation.” It can be streamlined by using preexisting data. There is no reason to reinvent 
the wheel, but the primary emphasis should be on issues that pose the greatest potential 
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risk and issues that are most unfamiliar. We want beneficial products and education to 
explain those benefits and their production process. I think that’s really important. People 
don’t know a lot about the quantities of pesticides used in producing unblemished fruits 
and vegetables. If they did understand that, there might be a different view about using 
technologies to reduce agriculture’s environmental footprint. As I said, transparency is es-
sential but not necessarily mandatory labeling. It is more important to be aware of general 
concerns related to GE crops. Genetically engineered specialty crops are not going to be 
treated differently by consumers who have concerns or objections to GE in general. 
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Tom Redick (Global Environmental Ethics Council, Clayton):  I wrote a book on labeling 
issues and so I just wanted to correct points made by Greg Jaffe. Connecticut is likely 
to sign. The other two up in that part of the world, Maine and Vermont, are stuck at 
the house level where a lot of these bills die; the Senates and governors may not comply. 
Alaska is labeling only fish and there aren’t any GE fish so nothing will happen in Alaska 
until the FDA finally gets off its butt. Thanks.
Chris Wozniak (Environmental Protection Agency, Washington, DC): A question specifi-
cally for Dennis Gonsalves although Tony Shelton certainly could address it as well, or 
Roger Beachy. The point was made earlier on that the technology is there for a lot of these 
specialty or minor crops to reach their full potential in the marketplace. The transformation 
techniques are in place; that’s not an issue. Traits are available. Promoters are available. Yet 
we still don’t see a lot of these on the market. We see virtually none. You pointed out that, 
in your development of papaya, things went fairly straightforward. We do, in fact, have 
European plum with plum pox resistance registered by an ARS scientist, Ralph Scorza, 
who did the regulatory work on his own. My question to you is, if the technologies are 
in place and we see that the regulatory system seems to have worked here, then what is 
holding it up? Or is it the regulators and these were just two anomalies?
Dennis Gonsalves:  This was back in the 990s—actually the process that we went 
through was pretty straightforward. We didn’t do anything that was out of the ordinary. 
My personal bias is that a number of people are rationalizing themselves from moving 
forward and, you know, with the papaya it wasn’t so much about whether we were going 
to make money. As public-sector scientists, our goal was to help. We got no support from 
the industry—they don’t make much money. It did not cost that much. It was almost like 
getting a series of grants. So, to answer your question, I think some people are gun shy.
Genetic Engineering and Specialty-Crop 
Improvement
Q&A
Moderator: Dan Lineberger
Texas A&M University
College Station, Texas
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Craig Nessler (Texas A&M AgriLife Research, College Station):  There’s a big difference 
between deregulating coat protein or another known protein from a foreign protein. The 
allergenicity questions have been raised but I don’t know that they are legitimate. Now 
you can just use RNAi—you don’t have to express the protein at all—which may influ-
ence the speed of deregulation. Animal tests on safe proteins from other plant species 
will still have to take place.
Gonsalves:  We went through Japan—people will say that it’s the strictest country—but 
they never required us to do animal tests. They were concerned about allergenicity, food 
safety, we had to do a lot of bioinformatics, and we had to do gastric juices tests, which 
are pretty simple. But they never required animal-feed tests, perhaps because it’s very 
difficult to draw firm conclusions from such studies.
Roger Beachy (Global Institute for Food Security, Saskatoon): Dennis or Tony, have you 
ever worked up the numbers for what it would cost if you needed to do each of these per 
Craig’s suggestion? Have you gone through what it would take to register a product that 
requires animal testing and a lot of the environmental tests that are now sort of expected 
for all crops? Do you know what that number is? Chris, maybe you could clarify what it 
takes to deregulate something novel? Not another Bt, not from RNAi, but from something 
else? Or maybe someone at a private company can provide an estimate.
Wozniak:  I’d like to clarify that question because this is something we’ve tried to address 
before. As you probably know, Nick Kalaitzandonakes, in Missouri, has some pretty good 
data, but even he will admit that a lot of the information that is put under the heading of 
“I had to do this to get this registered or deregulated” are really things the company would 
do themselves anyway for their own peace of mind. Remember that even though—as Greg 
pointed out—the FDA system is voluntary, the onus is still on the person entering the 
food or feed into the marketplace for its safety. They are personally responsible for that. 
So, even if you had no regulation and you were putting out, say, a Bt corn, or whatever, 
are you telling me that you would never do an animal-toxicity test? If you have capital 
investors putting millions of dollars into a large company, for their own peace of mind 
they would want to know, “Is this going to be an allergen?” “Can it be a toxin?” Some 
of these tests are expensive, but some of the allergenicity checks can be done on your 
laptop in 30 minutes.
Beachy:  We are talking about specialty crops that have markets not in the hundreds of 
millions of dollars. We are talking about markets that are considerably smaller.
Wozniak:  Right, and I will address that in my presentation, but the real difficulty for 
me is coming up with that number. If you look simply at the tests that are sort of man-
dated—and Dave Heron can also address this from APHIS’s standpoint—you could 
go to the third-party laboratories and get their costs for doing the tests and you could 
also get all the background information that isn’t a data generation kind of test, plus the 
consultants’ fees. You could do all that and put this all into the proper format, and come 
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up with a realistic number. But the numbers I have seen to date, from Nick for example, 
0, , 4 million, I think are way off base. I don’t know if Dave Heron is here, if he 
wants to try to address that from the APHIS standpoint.
Beachy:  It would be really interesting exercise to have that done from the Canadian 
side and the US side, because the Canadian process is built on food safety. That is their 
benchmark for release or not. It would be nice to have that available for those in the 
public sector and land-grant institutions—to say, this is what it will take to release a new 
pepper, or whatever, to farmers. If that number is a high hurdle, what is that hurdle that 
we have to overcome? What is the role of the experiment station? Or the state? Or the 
farmers, in helping it happen? In Canada, the farmers take an active role in support of 
research. Including developing varieties—farmers pay. Maybe the time is ready for us to 
do things in a different way and realize that those who will benefit—the farmers—will 
pay for product development. Maybe their royalty stream will be lower, whatever the 
number, but think of it differently. We ask about how we move it forward; maybe this is 
in the mix. Because, right now, it seems that we don’t have a sense of what it’s going to 
take to get a new product out. It’s a barrier even to getting experiments done. We could 
just do it by mutagenesis and work for 0 years to get it finished.
Wozniak: Well I have some things to present, some things where I think you can mop 
up the corners a bit.
Gonsalves: We had a conference a while back at the University of California, where we 
asked the same question about specialty crops. My thesis is you’ve got to get other crops 
of this size commercialized, so people get used to it. Even if you lose money on it. I told 
the University of California, maybe the dean should contribute $00,000 to $300,000 
to get a technology like virus resistant, or whatever, that is already developed, then get a 
sociologist to do the work to get it deregulated and commercialized. Then you actually 
can analyze the philosophy, the whatever it takes, because it takes actually doing it before 
you know how to go. With Japan, a lot of it was when to argue and when not to argue. 
You just got to do it and then you can get numbers. But, if you don’t do it, then nothing 
happens. Like I said, there is no reason I should be talking at this conference. We did this 
in 998—my goodness, there should have been other crops commercialized since then.
Wozniak:  I’m waiting for that Roundup Ready tomato.
Alan McHughen (University of California, Riverside): When Dennis and I took our 
products through regulatory approval back in the mid and late 990s, the costs were not 
outrageous. As Chris suggested, most of the information required by the regulators were 
data points that we would have measured anyway just in our regular due diligence, looking 
at allergens, looking at anti-nutritional factors that are naturally occurring in that food 
product in the first place. So we had the majority of the data already. The additional cost 
over and above the cost of doing that due diligence was relatively affordable. Frustrating 
sometimes, but certainly affordable.
Lineberger
7 Biotechnology and North American Specialty Crops
73
Session 2: Case Studies
Orange Juice: Will it be Available to Drink in the Future 75
(Agriculturally or Commercially)?
Ricke Kress
Biotech and Apples: Why They Fit 87
Neal Carter
Bringing Biotech Potatoes to Market 97
Haven Baker
Technology Evolution in Vegetables 
John P. Purcell
Q&A 
74 Biotechnology and North American Specialty Crops
75
Southern Gardens is a wholly owned subsidiary of the US Sugar Corporation, with three 
orange groves located in southern Florida, near Lake Okeechobee, where we have a 0-
million-box capacity processing operation (Figures  and ). In a given year, we squeeze 
0% to 5% of all the oranges grown in Florida: 5,000 oranges a minute producing 
600,000 gallons a day. We store the juice in million-gallon tanks of which we have 56 
that we turn twice a year.
Orange Juice: Will it be Available to Drink in 
the Future (Agriculturally or Commercially)?
Ricke Kress
Southern Gardens Citrus
Clewiston, Florida
rkress@southerngardens.com
Figure . Corporate assets of the US Sugar Corporation.
Citrus Greening (HLB)
Citrus greening—an insect-vectored bacterial disease, also known as huanglongbing 
(HLB)—was first detected in Florida in 005 on the heels of the citrus-canker eradica-
tion program, which elicited a widespread aversion to tree removal. After a 009 study, 
the National Academy of Sciences identified citrus greening as the most serious disease 
challenge they had ever reviewed (NRC, 00).
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Figure 3 shows the symptoms: yellow shoots, mottled leaves and dead trees. Mineral 
and nutritional deficiencies, and so on, can produce similar symptoms (Figure 4), which 
creates a problem.
Figure . Southern Gardens citrus-processing plant.
Figure 3. Gross symptoms of citrus-greening disease.
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The fruit is misshapen, normally smaller—operative word “normally”—and more and 
more mature fruit are showing infection (Figure 5).
Figure 6 illustrates the challenge of finding early symptoms. The insect carrying the 
pathogen—Liberibacter spp.—is as prevalent in Florida as the mosquito. When it feeds 
on an uninfected tree, it can be up to two years before the tree has symptoms.
In October of 005, we owned one of two commercial groves in which the disease was 
confirmed. Although we knew little of the disease, we had to be as proactive as possible. 
By January of 006, we were in Brazil where the disease had been diagnosed 8 months 
previously.
The state did a sampling to identify where the disease was in Florida. Figure 7 shows 
the progression.
Today, every citrus-producing county in Florida is infected. Figure 8 illustrates how 
rapidly it has spread through one of our groves; each block is 0 acres, and each spot is 
a GPS coordinate of a tree that was identified as infected and removed. To date, we have 
lost 30% of our acreage. We are the largest grower and processor of oranges in the state 
that is vertically integrated. We have identified in excess of 700,000 trees that are infected 
by this disease. Figure 9 shows the level of infection in Florida through 0. The data 
apply through 0 because, basically, the industry has quit tracking the progression of 
the disease. We can say, with reasonable certainty, that the infection rate is 00% in the 
Florida citrus industry; not every tree is infected, but 00% of the groves are infected.
Figure 4. Nutritional/mineral-deficiency symptoms.
Kress
78 Biotechnology and North American Specialty Crops
Best Practice
This disease has been in the citrus industry for years, in the Far East and elsewhere. The 
program that everybody started to follow was to inspect groves frequently—four times 
per year—aggressive roguing of infected trees, and full-time scouting for the Asian citrus 
Figure 6. Symptoms in the grove.
Figure 5. Fruit symptoms of citrus-greening disease.
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Figure 7. Spread of citrus greening, October 005, April 006, 
January 007, to June 007.
psyllid, Diaphorina citri, the vector. The industry is working hard to control the psyllid 
with aggressive applications of insecticides; however, we have learned that tolerance for 
the insect is less than zero. You have to assume it’s there. If you do nothing until you find 
it, then it is too late. Our growing costs have risen by over 40%, whereas our juice prices 
haven’t gone up by 40%. 
Challenges
Should different strategies be chosen in high-inoculum-load areas in comparison with 
low-inoculum-density areas? Such decisions have to be made “on the fly” and on a large 
scale. Relevant questions are: 
How long will a grove remain economically productive after the disease is detected?
Will replanted groves be disease free? If not, is there a time horizon or will the 
disease be there forever?
At which point should nutritional approaches be tried?
Kress
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Figure 8. How rapidly does citrus greening spread? Top, Oct. 005–Mar. 006; 
Middle, Oct. 006–Mar. 007; Bottom, Aug. 007–Oct. 007.
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Nutritional Approaches
Nutritional approaches have been adopted on the basis of anecdotal evidence. There are 
many such programs, most of which are combinations of foliar nutritional applications, 
phosphorous acid, and compounds that are thought to be elicitors of systemic acquired 
resistance.1 The goal is to maintain the productivity of existing trees. After spraying, the 
leaves absorb the nutrients and often look more healthy with less dieback. However, where 
these approaches have been tried in the past—in China and South Africa—they have not 
been successful over the long term.
Nutritional approaches cost more than pre-HLB growing costs, but less than psyllid 
control and roguing. On the other hand, the increased costs involved in nutritional 
approaches may be offset by circumventing scouting for psyllids and tree removal. But, 
whether using nutritional approaches or not, most growers are still attempting to control 
psyllids.
A major concern is that these alternative approaches are “forever” in that they involve 
acceptance of 00% infection, begging the questions of whether replanted young trees 
will grow and produce under high inoculum load and of how long the time horizon is 
until recovery is achieved. If psyllid control/roguing is chosen, the nutritional approach 
can also be employed later, but not the other way around.
Where Are We?
There are 8,000 citrus growers in Florida. Roughly 50% of the acreage is controlled by 
about 00 growers. A lot of the production is by small-area growers. There is consensus 
that the current losses result from HLB infection—with contributions from environmental 
stresses—and that the losses will continue to worsen. Initial replanting efforts have resulted 
in high levels of infection within 5 years, with no gain from nutritional approaches. Many 
groves—even those on nutritional programs—are beginning to decline.
Figure 9. Estimated percent of trees infected statewide.
1Analogous to the innate immune system in animals.
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Some 5% of the Florida crop was on the ground in June 03. If that’s a trend, what 
losses will occur in 04? Initial replanting efforts have resulted in high levels of infection 
in less than five years. In a newly planted 40-acre plot, we found 6% infection within 
8 months. On the other hand, that was before we realized that the tolerance for the 
psyllid had to be less than zero.
The solution to this disease, will involve four concurrent processes:
• Research
• Regulatory approval
• Horticultural/agricultural production
• Consumer approval
They have to be tackled at the same simultaneously, because we are not dealing with a corn 
plant, we are dealing with a tree. When we have the solution, we must be in a position to 
commercialize it immediately. Several relevant research programs are in progress:
• Disease-resistant plants
 — Texas A&M University
 — Integrated Plant Genetics, Inc.
• Insect-resistant plants
 — Cornell University
• Identification of synthetic resistance genes
 — AgroMed LLC
• Gene delivery
 — University of Florida
• Screening of potential genes.
 — USDA
The major focus of the research is at Texas A&M, on the development of a disease-resistant 
tree. A second similar project is in progress at IPG, based in Gainesville. Development 
of an insect-resistant tree may be assisted by synthesis of resistance genes for which sev-
eral delivery systems are being investigated. The research projects are at varying stages 
of completion; some are close to the identification of a commercial product. When we 
find the solution, it will be good for the industry as a whole; Southern Gardens will not 
monopolize it.
Gaining Deregulation
We are working closely with the federal agencies and have had multiple consultations 
since August 006 with USDA-APHIS, EPA and FDA. The solution will involve a plant-
incorporated protectant (PIP), therefore approval will be needed from all three agencies. 
With respect to the research here at Texas A&M, we will file for an experimental use 
permit (EUP) with the EPA as soon as possible.
An important question is, How do we challenge the solution? We have developed a rapid 
screening technique to identify resistant plants. In a greenhouse, plants grown under 
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optimal conditions are exposed to infected psyllids. Susceptibility to disease is identified 
within 8 months, significantly more quickly than can be achieved in the field. Plants that 
appear to be disease-resistant in the greenhouse are then evaluated in regulated field trials. 
This confirmation of resistance is the first step towards commercialization, then we have to 
work through regulatory approval of the technology, for which it is necessary to generate 
a significant amount of data to satisfy all of the requirements of USDA, EPA and FDA 
to prove that the product is safe. We are working through that process.
Figure 0 provides a summary of what we expect to have to do; these tests are projected 
to cost in excess of $3 million. Multiple other aspects come into play. For example, three 
law firms in Washington, DC, are working with us on this process. It is important to 
remember that we are not a multinational company. We’re a grower/processor, working 
with a network of people.
Figure 0. Summary of likely regulatory strictures imposed by
EPA, USDA and FDA.
Consumer Acceptance
After the regulatory process is completed, we must ensure that the consumer accepts the 
product. As of today, our research indicates that the HLB greening disease cannot be solved 
without genetically engineering the tree. If citrus-greening resistance were to be obtained 
with a human transgene or one from a crab or a pig, the orange juice would never make it 
to the supermarket shelf. Even though the two genes being transferred to citrus are from 
spinach, the disease-resistant product will have to be marketed carefully.
Kress
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Orange juice is in an interesting category. It’s akin to “motherhood,” so education will 
be fundamental to gaining consumer acceptance.
Benefits
The first and most important benefit is that the orange juice industry will survive in the 
United States. Although the Brazilians have the same disease, they have different regulations 
and larger growing areas, and they believe they can survive. Another major benefit will be 
the elimination of the insecticides now being used to control the insect that vectors the 
disease from infected to healthy trees. At this time, our groves are, essentially, insect-sterile 
because of the chemicals that we are applying to control the insect. When our genetic 
solution is put into practice, the impact on the environment will be huge.
The Future
Our task is daunting, but we have a good approach and our data show that we have 
good potential for resistance to citrus greening. On the other hand, at our present rate of 
progress, resistant trees may not be commercialized until 09, which is not acceptable. 
Figure . Typical fruit drop in 03.
85
We must somehow speed up Mother Nature. If this year’s fruit drop (Figure ) is an 
indication of what’s coming—if we lose 5 percent every year—we could lose the orange-
juice industry. Texas and California are watching closely. California’s challenge is more 
pressing because they produce fresh fruit. In Florida, we blend juice, whereas California 
cannot offer an infected orange for eating. Also, virtually every backyard in the state of 
California includes citrus trees, which will add to the difficulty of disease control.
It’s a daunting task, but we’ve got an end goal in sight. Orange juice is not going to go 
away. Florida fruit is not going to go away. No other citrus-growing region can compare to 
Florida quality, day in and day out. But we have a significant job to do going forward.
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Okanagan Specialty Fruits is a company of seven people, not much different from many 
labs in the publicly funded sector. Our lab is in Saskatoon, and, amongst the seven 
motivated, highly trained staff, we have a research team, we have a marketing director 
and a communications person, and myself running around like a chicken with its head 
cut off.
The Arctic apple is our platform project. We wanted to get involved in increasing apple 
consumption and one way to achieve this was to get them used more broadly, particularly 
when freshly cut. The Arctic apple has no polyphenol oxidase, the enzyme that drives the 
browning reaction; it is truly non-browning. Other apples that don’t turn brown within 
six hours are referred to as low-browning, a consequence of substrate deficiency, not lack 
of the enzyme.
We are often asked, “Is Arctic a new variety?” No. We can do this with any variety. 
We did it first with Goldens and Grannies (Figure ), which are now in the hands of 
the regulatory people. We have done it also with Gala, Fuji, McIntosh, Honeycrisp and 
Jonagold. The trees behave in the orchard exactly like their conventional counterparts, 
until the fruit is bruised, bitten or cut. They are equally healthy and productive. The 
apples in Figure  were cut several days before. The flesh of Arctic apples dries out before 
it goes brown.
Biotech and Apples: Why They Fit
Neal Carter
Okanagan Specialty Fruits
Summerland, British Columbia
neal_carter@telus.net
Figure . First non-browning varieties.
Left: Arctic® Golden vs. conventional Golden Delicious
Right: Arctic® Granny vs. conventional Granny Smith
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Initially we worked on various projects with peaches, cherries and apples, but soon real-
ized the need to focus. We concentrate on apples, and particularly on the Arctic technology 
with the objective of making it available to the apple industry as a whole. If Okanagan 
Specialty Fruits survives commercially, we hope to diversify in due course.
Figure  shows that the overall trend in fruit and vegetable consumption has been 
upwards, with apple a notable exception. The per capita consumption of apples has been 
trending downwards for the past 5 years, which is bad news for growers. The industry 
maintains current production levels because of increasing population, not because we’re 
exporting more. China, the biggest apple grower in the world, now dominates Asian 
export markets that have, historically, bought US apples. 
Figure . Trends in fruit consumption (USDA Economic Research Service).
What could we do to increase apple consumption? We looked for a consumption trig-
ger, and found one in the fresh-cut carrot model that was introduced in 988 (Figure 3). 
Carrots were cut up, tumbled it and bagged, and, by 997, consumption had doubled. 
It essentially saved the carrot industry. Before then, they were used as ingredients for 
soups and stews and rarely eaten raw. The trend has been down since 997 because of 
competition from other products, mostly other vegetables. If we could do this with apples, 
and increase consumption even by  lb per person per year, it would be great news for 
the industry.
Silencing PPO
RNAi is used to silence the four genes that encode polyphenol oxidase. This is like 
 rerouting ten pieces of track on a railway from Los Angeles to New York (Figure 4). Our 
vector has approximately ,800 base pairs and there are 750 million base pairs in apples; 
it’s an exact process. 
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People ask if browning is an important issue. In fact, browning precludes apples from 
many potential markets. The need to be treated with an antioxidant to stop browning 
means that a lot of commercial kitchens won’t handle it. It’s just too much work. 
The control of enzymatic browning in Arctic apples benefits everyone in the value 
chain. Scuffing that occurs during harvesting and post-harvest handling doesn’t show 
on Arctic apples, thus reducing cullage. Similarly, in the packing shed, handling losses 
are mitigated. The fact that the juice doesn’t turn brown provides opportunities for new 
products. Because the pulp doesn’t go brown, fruit leathers look more appealing. From the 
grower to the processor (Figure 5) to the consumer, we can identify quantifiable benefits 
and creative people will find many new uses for these apples. 
Figure 3. Trend in carrot consumption (USDA Economic Research Service).
Figure 4. The science is relatively simple.
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Consumer Preference
What does the consumer think? Every single person in our many focus groups has wanted 
to try an Arctic apple. Even with those who react initially with, “Oh, no, I only eat or-
ganic,” or “Oh, I’d never eat any GM,” 90 minutes exposure to the air without browning 
results in “Wow, I must try one of these things.”
We surveyed ,000 self-professed apple eaters, asking, “What’s the likelihood of your 
buying a non-browning apple?” About 5% said “somewhat likely” or “extremely likely.” 
So then, against the advice of our consumer-survey company, we said, “A non-browning 
apple exists and it was developed through genetic engineering.” Positive responses fell 
from 5% to 49%; we lost % when we used the term “genetic engineering.” So then 
we said, “A non-browning apple exists. It was developed through genetic engineering by 
using the apple’s own genes to turn off the gene that makes it go brown.” With that half 
sentence added, it went to 59%—above what it was initially. When asked, “Would you 
rather eat an apple that is genetically engineered to prevent browning or one that had an 
antioxidant chemical applied?” two-thirds professed preference for the untreated, geneti-
cally engineered slice. Clearly, a little information can go a long way.
Our target is fresh-cut apples in bags, similar to baby carrots. Surprisingly, the whole 
apple is becoming too big a commitment in the world of texting and smart phones; how 
do you eat an apple and text? If apples were offered during our coffee break, few would 
avail themselves:
• What if someone engages you in conversation when you have a mouthful of apple?
• What do you do with the core when you’re finished? 
Figure 5. Fresh-cut apple processors’ benefits.
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In contrast, if apple slices were offered, it is likely that they would all disappear.
The fresh-cut opportunity in apples is huge, but the problem is that the antioxidant 
used to control enzymatic browning is worth as much as the fruit. If we can dispense 
with the antioxidant, we’ll get rid of the citrus-like “buzz” and 40% of the cost. The 
price break will make apples more accessible for packed lunches and for food-service 
and many other uses.
Labeling Policy
Part of our commitment to transparency includes telling people about what they buy. 
Growers interested in planting Arctic apples will have to agree to apply the sticker shown 
in Figure 6. It doesn’t say “genetically engineered,” but it does say “Arctic,” and media 
attention dictates that by the time Arctic apples hit the marketplace, many if not most 
people will know that they have been genetically engineered. Also, our website details 
the underpinning science.
Figure 6. All Arctic apples will be voluntarily labeled.
Carter
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From Then to Now
In 996, we formed Okanagan Specialty Fruits to use genetically engineering tools in apple. 
We licensed a technology from CSIRO in Australia, who had proven the non-browning 
concept in potato. However, we found that the potato method doesn’t work in apple; we 
had to silence four genes. By 00, we had it working in the greenhouse (Figure 7) and 
in 003 and 005 we planted field trials in Washington and New York States. We started 
to build a package of data for regulatory purposes. In the apple business, particularly 
with plants from tissue culture, there is a juvenile tendency. It is essential to ensure that 
everything is stable, so, every year, we took buds, and propagated more and more new 
trees—with larger and larger field trials—and then we started to get fruit from the early 
trees. We felt that we were getting a properly representative data set.
Figure 7. The path to market.
When we had the data we needed, we embarked on the regulatory process in 00 
(Figure 7), which takes us to where we are today. Hopefully, we are close to obtaining 
deregulation.
Obtaining Deregulation
I can’t provide a firm number for the cost of the deregulation process. A major item is 
staff time. We spent $0,000 to $5,000 on the services of regulatory consultant who 
made things overly complicated, so we did it ourselves. I don’t know whether advice 
received from the federal agencies in the end helped us or not. The advice from APHIS 
was “Keep it simple. Don’t bring a trailer in here and dump all sorts of data. We want 
it synthesized and analyzed with good statistics.” In the end, we went a little light and 
93
they came back with questions and we had to add more data and more statistics. It was 
our first time through and we had no benchmarks. We examined other submissions, 
entailing different crops and different traits, and it was hard to correlate ours with theirs. 
However, my major comment is that this is doable and it’s not exceedingly expensive. 
It takes time and a lot of frustration, but if you’re stubborn and bull-headed, you’ll get 
there. People shouldn’t be thinking in terms of millions of dollars. The out-of-pocket 
component isn’t that much.
In Canada we regulate the product, not the process, whereas in the United States, you 
regulate the process, but the submission materials were essentially the same. In Canada 
a significant challenge lies in having to submit all three documents at once, related to 
food, feed and environmental issues. For the United States, we tackled the USDA-APHIS 
petition first, which raised many questions that got us bogged down. Eventually we sub-
mitted the FDA application and the questions coming from APHIS helped us put the 
environmental document in better shape for submission in Canada (Figure 7).
By now, we had hoped to be in the midst of the second public comment period with 
APHIS, but we’re not. The delay results from our petition being one of eleven. I don’t 
know why they can’t be done one at a time, but we hope to be deregulated by the end of 
the year. In Canada, we are working our way through molecular and agronomic ques-
tions with the authorities; we had a constructive meeting with them in April 03. We 
expect to provide the necessary information by the end of July 03, and we have been 
told that we should be finished in Canada by the end of 03.
Figure 8. Preparation for commercialization.
Carter
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Commercial Status
We are talking to growers, industry representatives, retailers, wholesalers, brokers, etc., on 
an almost daily basis to build industry buy-in. Test blocks have been planted by growers 
in Canada and United States. Figure 8 shows Arctic trees planted in the spring of 0 
and now 7–8 ft tall (June 03). They were defoliated in the spring of 03 to prevent 
flowering, pending deregulation; they are grown under permit. We are putting trees in the 
hands of growers so that they can “kick the tires,” and make sure that Arctic trees perform 
to expectation. We have a fair amount of uptake, but there’s also a lot of pushback. Some 
growers don’t want to have to go through the unfamiliar permitting process to put in a 
test block. And then some are concerned about market reaction, and many don’t want to 
plant until after deregulation. If they plant a 0-acre block and then it’s not deregulated, 
what will they do with it? On the other hand, if approval occurs according to expected 
timelines, we will have fruit for test-marketing in 05.
We are heavily in the educational mode, particularly vis-à-vis growers. I have spoken 
around twice per month for the last two years at conventions, conferences and trade events, 
trying to educate. For a company of seven people with two involved full-time in education, 
that’s a huge commitment, but this is what it takes. It’s not about the science anymore and 
the product is worth the effort, but now it’s about educating. As already stated, a strong 
focus is on transparency. Only 5% of people have heard of biotech crops, and many 
people who don’t have a clue are likely to give weight to anti-biotech activists.
Our message is short and sweet: it’s just like any apple; it looks like an apple; it grows 
like an apple; and it tastes like an apple. It just doesn’t go brown. And, associated con-
sumer benefits can drive consumption, by putting apples in more places and reducing 
waste in the home.
Immediate Future
Right now, our lab workers are answering regulatory questions and generating more 
Arctic varieties. But we are also involved in proof-of-concept work in scab resistance, 
fire-blight resistance, and storage scald. We have made a commitment that by the third 
quarter, we will ramp up our research work in those three traits and investigate stacking 
technologies.
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neal caRTeR is president and founder of Okanagan 
Specialty Fruits™ (OSF), a biotechnology company 
specializing in the creation of novel tree-fruit variet-
ies. Outside of OSF, he and his wife, Louisa, grow and 
pack apples and cherries from their orchard in British 
Columbia’s Okanagan Valley. For nearly 30 years, Neal has worked with 
numerous crops as a bioresource engineer around the globe, ranging from 
maize to mango, from growing to harvesting, packing, storage, process-
ing and packaging. It was through this firsthand experience that he was 
 persuaded that biotechnology can help agriculture meet the ever-expanding 
global demand for food.
 The Carters founded OSF in 996 in order to explore opportunities to utilize 
biotechnology to boost fruit consumption and sustainability. OSF’s flagship 
project is the development of non-browning Arctic® apples, which have been 
engineered to resist browning by silencing genes that produce polyphenol oxidase. 
Arctic apples are currently progressing through the deregulation processes in 
Canada and the United States; availability in grocery stores is expected within 
a few years.
 With apple consumption flat-to-declining for the past couple of decades, Mr. 
Carter believes that Arctic apples will provide a consumption trigger for the 
 industry by providing numerous benefits throughout the supply chain.
Carter
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J.R. Simplot is a privately held $6 billion company, with 0,000 employees. We mine 
phosphate and manufacture fertilizers that we sell to farmers. We’ve been a longstanding 
potato producer in the United States, and we’re involved in livestock. Plant-biotechnology 
work was initiated in 00 with a few scientists. Our mission is to create safe, healthy, 
sustainable crop improvements with a focus on potato. We now number about 65 and 
are in the comment period for our first regulatory submission. We will petition for our 
second-generation biotech crop in six to eight months; our objective is to bring multiple 
products to market.
Building on Biotech
Building a biotech business involves a lot more than science. Certainly, commitment to 
good science is essential. Obtaining proprietary technology is often a necessary part of 
R&D. The regulatory side requires submission of sufficient, but not excessive, data. And 
business development includes determination of the value of the trait in question, and 
building marketplace acceptance. Potato production involves four sub-industries. Each is 
large and comprises varied players, therefore good marketing is essential to build general 
acceptance. The last component is commercialization. It is one thing to obtain regulatory 
approval, but it takes much effort and many trials to bring farmers along; much more is 
involved than running regulatory trials for the USDA.
This area of endeavor is not without controversy and your company culture must 
 inculcate willingness to address such controversy with awareness that you won’t be 
everyone’s best friend all the time.
Bringing Biotech Potatoes to Market
Haven Baker
J.R. Simplot Company
Boise, Idaho
haven.baker@simplot.com
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Innate Technology
Our marketing effort involves talking about our Innate™ technology:
An innovative biotechnology approach to improving crops using a process that uses 
plant genes to enhance desirable traits and reduce less desirable ones.
Innate™ is a way of putting a plant’s own genes back into a plant. We needed a way to 
introduce our biotech approach to the potato industry and eventually to consumers. As 
part of our market research, we tested several messages and created Innate™ Brand as a 
face for new plant-biotechnology processes for improvements in crops and foods. Innate™ 
provided a way to talk about our technology without resorting to the less consumer-
friendly terms, intragenic and cisgenic.
We take DNA that elicits either expression of (a) desirable trait(s) or less expression 
of (a) less-desirable trait(s) from a cultivated variety or from a wild-species progenitor 
potato, and put it back into Russet Burbank to produce an Innate™ Burbank (Figure ). 
This is the level at which we want to communicate the technology, both to growers and 
to consumers.
Market Research
We’ve done a lot of market research that shows that results depend on how questions are 
worded. However, with enough studies, trends emerge. The data in Figure  demonstrate 
potential consumer acceptance of the Innate™ technology—having explained that it is a 
Figure . Innate™ technology: How it works.
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Figure . Survey: How likely would you be to purchase fruits and
vegetables that are improved using Innate™ technology?
1Pages 87–94.
plant-based gene transfer—in comparison with genetically modified, traditionally bred, 
and “biotechnology” counterparts. It is noteworthy that use of the word “biotechnol-
ogy” elicits greater comfort among consumers than “GMO.” Explanation of the Innate 
technology produced acceptance close to that of plant breeding, but not quite there. Our 
goal is not to be acceptable to everybody, but to be as acceptable as plant breeding, and, 
clearly, we are close, which is a promising message for all using molecular genetics for crop 
improvement, i.e. consumer acceptance of the technology is potentially good.
First Generation of Traits
Traits we are bringing to market using “Innate .0” potato are:
• Reduced black-spot bruise, and
• Reduced asparagine.
Reduced black-spot bruise is a trait similar to non-browning in the Arctic apple.1 We 
had to silence only one of the five or six polyphenol oxidase (PPO) genes, PPO 5 in 
a tuber-specific manner. And we have down-regulated asparagine in tubers—again 
 tuber-specific—by silencing asparagine synthase. Instead of asparagine—a precursor of 
acrylamide—the modified tuber accumulates glutamine, so the nitrogen content stays 
relatively similar and yield is unaltered, which was an unexpected benefit. If asparagine 
synthase is silenced throughout the plant constitutively, growth is compromised.
Baker
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Four varieties have been improved via Innate .0: Russet Burbank, Ranger Russet, 
Atlantic and Snowden. Russet Burbank and Russet Ranger are the primary French-fry 
varieties, and Atlantics and Snow are the primary varieties used to make chips. The 
improvements result in benefits to growers, processors and consumers. Browning occurs 
not only after cutting (Figure 3), but also when stacked in storage, which causes pressure 
bruising. Usually, tissue change is minimal, but it does occur and is a significant problem 
in the fresh market. In the French fry and chip industries, brown potatoes are removed and 
used for cattle feed; the grower is penalized and the processing plant loses productivity.
Acrylamide occurs naturally and is present in almost all baked and fried foods. It 
forms at around 300°F. California has a labeling requirement for baked or fried potato 
products containing acrylamide above 300 ppb. In response, some companies mitigate 
the problem via enzyme use, whereas other companies have withdrawn their products 
from the market in California. Figure 4 shows that potato chips made with Atlantics 
accumulated acrylamide at 450 ppb, whereas Innate™ Atlantics contained acrylamide at 
30 ppb. Similar patterns were found with French fries made with Russet Burbank and 
Ranger Russet and their Innate™ counterparts (Figure 4).
Two ingredients contribute to acrylamide formation: asparagine and sugars. We control 
only the asparagine component in the first generation of Innate™ potatoes, and, in general, 
we see reductions in acrylamide content of 50% to 70%.
A key ancillary question: Could the benefit of lowering acrylamide overcome opposition 
of biotech?
Uniformity
Those whose job is to improve potatoes, and who are focusing on the farmer, are missing 
80% of the potential. Downstream companies that make products from potatoes are the 
big sellers. Farmers produce $3.5 billion worth of potatoes every year, whereas somewhere 
around $40 billion worth of French fries are sold. The market is controlled by customers 
who demand uniform quality in their French fries and chips. Figure 5 shows a spidergram 
containing a 5-point hedonic scale. Innate™ potato products must give data identical to 
their non-Innate counterparts in terms of performance from a sensory perspective, aroma, 
crispness, toughness, etc. Although we’ve affected the asparagine content and the PPO, 
we have not affected starch pathways or other metabolism that affect sensory perception, 
which is a major consideration for our customers.
Figure 6 shows field data for Innate™ Russet Burbank in comparison with its parental 
counterpart; these trials are expensive to run. Each comprises an acre or two, and yield-
tracking data are generated using modeling software. We’ve done this a number of times 
and find consistently that there is no difference between Burbank and Innate™ Burbank 
(E), and that’s important because some farmers have been led to believe that yield 
“drag” results from biotech traits.
Second and Future Generations
In 03, we are running over 30 field trials across the United States and Canada, including 
a commercial development trial in Texas. We encourage growers to visit our commercial 
0
Figure 4. Simplot research, 0.
Figure 3. Comparison of an Innate™ potato (left) and a traditional
potato 0 hours after being cut.
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trials. Also, we have advanced regulatory trials for the next generation of Innate™ potatoes. 
Figure 7 shows the traits that we are working on.
Generation .0 will comprise low asparagine and low bruising as mentioned, and less 
sugar when harvested. Our projection is to launch Generation .0 in 05. We expect to 
launch Generation .0 in 07 and, to that end, we are working on a gene that provides 
sugar control. Potatoes are stored at between 48°F and 5°F, sometimes at 46°F. That 
temperature is one of the single most important economic drivers in the potato industry. 
The gene that we’re working on for sugar control allows storage at 38°F, at which several 
post-harvest issues are circumvented because of less disease. We have licensed a gene from 
Jonathan Jones’ lab—the vnt gene—for broad resistance to strains of Phytophthora infes-
tans, which causes late blight. In our research pipeline we are also working on resistance 
to potato virus Y (PVY), on improvements in use efficiencies of water and nitrogen, on 
enhanced vitamin content and on improved tuber set.
Figure 8 demonstrates positive effects of the Innate™ .0 technology on fresh-potato 
quality. As a result of storage at 38°F, zebra-chip discoloration (top left), caused by 
Liberibacter spp. is decreased. And dark “sugar ends” (bottom left)—caused by a high con-
centration of reducing sugars—are alleviated by silencing the gene encoding invertase. 
Figure 5. Spidergram: Ranger Russet and Innate F0 Ranger Russet comparisons
with Russet Burbank gold standard—no sensory differences.
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Figure 6. Russet Burbank and Innate™ E yield comparisons
Figure 7. Future Innate™ traits.
Atlantic is an 85-day potato, whereas most others have a growing season of 0 to40 
days. For this reason, Atlantics are grown all over the world, even though they don’t store 
well; they build sugars too quickly, which causes browning that no one wants. Resistance 
to browning after six months at 38°F means a lot to farmers (Figure 9). The 5,000 thou-
sand acres of Atlantics that are grown in the United States must be shipped to processing 
plants a day or two after they are dug. The Innate™ technology will expand the acreage 
of this variety relative to a number of others.
Baker
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Regulatory and Business Considerations
If you create a new potato through biotechnology, using only potato genes, how are you 
regulated? If you used agrobacterium, you’re regulated by the USDA. If you have a novel 
trait, you’ll be regulated by Canada, and if you use recombinant DNA, you’ll be regulated 
Figure 9. Innate Atlantic .0 lines Y9 and Y5 fry with reasonably
good color after six months of storage at 38°F.
Figure 8. Innate™ .0: Impact on fresh-potato quality.
05
Figure 0. Innate™ timeline.
(*There is no guarantee that the USDA will
deregulate Innate™ potato products.)
by Japan. Whether the technology is cisgenic or intergenic, it will be treated the same as 
GM in Europe. New TALEN™2 technology has exciting potential, but it is possible that 
deregulation will be needed to protect export markets. We believe that, over the coming 
5 years technology improvement will move back in the direction of transgenics, having 
used within-species manipulations to gain consumer acceptance of genetic approaches. 
Although we are committed to our Innate™ technology, we keep an open mind and avoid 
disparagement of other technologies.
Figure 0 represents our projected regulatory timeline. At this point, June 03, we 
are in a public-comment period from which we expect deregulation of Innate Russet 
Burbank .0, Innate Russet Ranger .0 and Innate Atlantic .0 in 04, and that these 
three products will be on the market in 05. If we are lucky, Innate™ potatoes from the 
04 growing season will be included as ingredients in products available to consumers 
in 05. In 06, we expect deregulation of Innate™ .0 products, with commercial 
introductions of Innate Russet Burbank .0 and Innate Ranger Russet .0 in 06 and 
07, respectively. Deregulation of Innate™ 3.0 technology will be applied for in 08.
2Transcription activator-like effector nuclease.
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Identity Preservation
From the point of view of identity preservation, potatoes have important inherent 
 advantages:
• Potatoes are largely self-pollinating. The flowers have no nectar, and are not visit-
ed by insects. Separation by 0 m is sufficient to eliminate the risk of outcrossing.
• Potatoes are clonally propagated from tubers, not grown from seed.
• Lines can be easily distinguished with PCR.
Business Challenges
The potato market comprises several segments:
• Chips,
• Frozen products (French fries and hashbrowns),
• Fresh potatoes, and
• Dehydrated potatoes.
Each of these entities is supplied to the consumer as different varieties by separate industry 
players. Satisfying the needs of producers presents a challenge to the potato supplier. Regu-
latory approvals vis-à-vis international markets represent another challenge. The capital 
that needs to go into seed potatoes is another issue. The value of US potatoes at the farm 
gate is $3.5 billion, which represents an initial investment of $350 million. Seed-potato 
cost runs at $400 dollars per acre if not more, which is expensive. 
Another issue is the variety of varieties. With eight varieties, we believe that we can 
capture 60% of the potato market. To get to 90% would require double that, and, since 
backcrossing is impossible, each event has to be deregulated. Of course, it will be impos-
sible to capture the whole potato market. Our goal is to capture the majority of the chips 
and the frozen and fresh markets; we expect to leave specialty potatoes to competitors.
Another challenge is the traditional business model for biotech (Figure ). Critical 
aspects are how much the trait improves the crop and market penetration, i.e. how many 
acres; those two are multiplied together to calculate the revenue. If the crop is improved 
by $00 dollars an acre, the grower nets $66 and we get $33. The problem with specialty 
crops is that few traits are available that will pay back the investment. In potato, there 
aren’t many $300 or $400 traits, and a $00 trait won’t pay the bills.
Traditionally, with row crops, new varieties were produced by plant breeders—mainly 
at the universities—which seed companies multiplied and sold (Figure ). Farmers 
planted them, and the produce became widely available. In the biotech industry as soon 
as a stable transformation is achieved, breeding is initiated to put the trait into appropriate 
germplasm; accordingly, genetic manipulation, breeding and seed dissemination are now 
united in one entity, usually achieved through acquisitions. Like the traditional way, the 
biotech product then goes to the farmer, and then it goes worldwide.
With potatoes—and probably a few other crops—the farmer, the food processor and 
the food processor’s customers are vertically integrated (Figure 3). Accordingly, 95% 
of the potatoes that are planted for the French fry industry are contracted by the food 
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Figure . Revenue model for the biotech industry.
Figure . Crop development.
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processor. The food processor tells the farmer which variety to buy, and, if the quick-
service restaurant (QSR) chain is large enough, it tells the food processor which variety 
to make French fries with.
These three entities operate in unison, so if a new variety is to be introduced, all three 
have to be lined up, or markets must be found where at least the food processor and the 
farmer can line up. Fresh and frozen present those opportunities. And food service is 
another. Customers sometimes aren’t picky, so achieving that alignment may be harder 
that it sounds. 
Final Thoughts
We have found the number of traits that are gene-silencing based, which should mean 
a less complicated regulatory package. In terms of reducing expense, not introducing a 
new protein is a significant advantage.
Another thing we have found is that the traits aren’t always obvious. It took us a couple 
of years to fully understand the benefits of the low-sugar trait and its economic implica-
tions. It was necessary to store potatoes for 6 months and then make fries or chips.
A tricky point: the black-spot bruise trait benefits growers, and that benefits processors, 
which benefits the consumer. It’s win-win-win. But it presents a challenge in terms of who 
pays. Presumably it’s the farmer, who must get some of that money from the processor, 
who then must restructure the contracts with reluctant farmers. Calculating value thus 
becomes problematic.
Figure 3. Potato commercialization.
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Lastly, it can take a while to structure relationships and get people comfortable with 
biotech. On the other hand, after they’re comfortable, we’ve seen significant support. We’re 
in a comment period now, and 80 comments have been received, of which probably 5 
are positive, a lot of them from growers. We are excited about that.
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Biotechnology has played an important role in driving new products for agriculture, and 
has changed the way growers think about controlling insects, for example As head of our 
field organization, I spend a lot of time with growers and see firsthand the advantages 
of modern technologies, and, as a scientist, I get of a lot of satisfaction out of that. We 
should think of this infusion of biology—driving agricultural innovation over the last 
5, 30, 40 years—in a much broader sense.
Innovative Technologies for Agriculture
Transgenic technology was the first generation in using modern biology to improve agri-
culture and bring novel products to the marketplace. This has also driven innovation in 
terms of how we think about breeding, and how we think about trait associations, and 
delivery of new traits to the marketplace, whether it be through transgenics or through 
advanced breeding technologies. It’s now playing out, for us and for other players, in a 
new sector that we call “Ag Biologicals” (Figure ). The more we understand about basic 
biological processes—the more we understand at the genetic level—we can begin to think 
in terms of transforming the biological sector with very innovative technologies.
Technology Evolution in Vegetables
John P. Purcell
Monsanto
St. Louis, Missouri
john.p.purcell@monsanto.com
Figure . Bringing genomics to the field with integrated farming systems
and agricultural biologicals.
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We think about genomics in terms of the ability to understand, at a genetic level, how 
traits play out. It’s a key piece of advanced breeding methodology and we see it also as a 
key piece in understanding how to drive value in the Ag Biologicals sector.
I had the pleasure of heading Monsanto’s insect-control program in the 990s, when we 
were developing YieldGard® and Bollgard® and did the first work on corn rootworm. See-
ing the impact that these technologies have had at the grower level has been tremendously 
satisfying, particularly in terms of reductions in insecticide-spraying (Figure ). Growers 
were applying insecticides to sweet corn up to 0 times in a season. In the southeast some 
had to spray daily or even twice a day in order to prevent visible damage.
Sweet Corn
For sweet corn, the acceptable level of insect control is the absence of worms when the ear 
is opened. There is very little tolerance for damage to the ear, which is why heavy spray 
regimes were necessary. Tony Shelton’s data1 backs this up as well. Clearly, this situation 
is tailor-made for Bt technology (Figure ). The reduced damage that the retail sector is 
looking for is achievable. It’s a tremendous advantage with transgenic technology. On 
the other hand, the advantage is difficult to talk about at a consumer level because most 
people don’t think about how often sweet-corn crops are sprayed before they reach the 
marketplace.
There’s been a lot of discussion at this conference on the regulatory system and costs of 
achieving deregulation. One advantage of this transgenic technology is that the event we 
Figure . Biotechnology: Seminis® Performance Series™ sweet
corn provides protection against insect predation.
1Pages 49–58.
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Figure 3. Advanced breeding: Faster product development tools, 
capability and capacity enable successful delivery as never before.
used in sweet corn was the same as that in field corn. When the event has been previously 
approved, fewer steps lie ahead in the deregulation process. This helped us to justify the 
cost of deregulation in terms of the market size we were going into. This has been launched 
in the United States at the grower level. Some challenges occurred at the retail level, but 
it is now actually working pretty well for us. The overall benefits of this technology make 
it very advantageous. The other product we have in the marketplace—created using a 
transgenic technology—is virus-resistant squash. It’s been available for a number of years. 
Again, it has grower advantages from a productivity standpoint.
Advanced Breeding Techniques
Our major play in vegetables is to take advantage of advanced breeding techniques, 
which entail the ability to associate, at the genetic level, from a trait perspective back to 
a molecular marker which allows our breeders to be more efficient in making selections 
(Figure 3).
2Designed by our engineering colleagues at Monsanto, chipping allows us to determine the genetics of a seed 
without destroying it.
In many cases, known molecular markers are for disease resistance. With those mark-
ers “built in,” breeders can focus their efforts on aspects of quality—size, shape, color, 
taste—that have appeal in the marketplace. With respect to new advanced technologies, 
momentum is driven by the ability to identify and fine map markers and introgress 
them rapidly (Figure 4). Seed chipping2 is proving to be a major driver as it simplifies 
breeding.
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We have identified thousands of markers in vegetable crops (Figure 4). Yearly throughput 
of marker-based data points has increased 00-fold since our acquisition of Seminis in 
005. Similar acceleration is occurring across the industry, not just within Monsanto. 
PhytoPhthora in Pepper
Of course, it does little good to have a lot of whiz-bang technology if it fails to provide 
value to growers. Phytophthora is a major disease of peppers globally, and we have applied 
marker-assisted breeding to improve resistance. The source of resistance can be incorpo-
rated into other pepper types (Figure 5).
Once the donor source of resistance is identified, the marker for the trait can be 
identified and introgressed into any number of plant types: jalapeños in Mexico, blocky 
peppers in the United States, chili peppers in India, etc. Field evaluations visually dem-
onstrate significant improvements in resistance of manipulated peppers to Phytophthora 
(Figure 5). However, this is only part of the story. It is essential that the disease-resistant 
pepper retains the characteristics—heat level, taste, color, shape and size—that growers 
and consumers expect.
Downy Mildew in Cucumber
Another example is resistance to downy mildew, a major disease of cucumbers. By in-
trogression, we have conferred resistance and commercialized American slicer cucumber 
varieties in the United States (Figure 6). With the same technology, we will commercialize 
Beit Alpha cucumbers for the Middle East market, even though these are totally different 
kinds of cucumbers.
Figure 4. In vegetables, advanced breeding capability accelerates
new product development and growth opportunities.
5Purcell
Figure 5. Broadly applying marker-assisted breeding to improve 
resistance to Phytophthora in peppers.
Figure 6. Resistance to downy mildew would improve grower
returns in multiple varieties of slicing cucumbers.
The benefits of technologies that provide fungal resistance are analogous to those that 
provide insect resistance, Bollgard® and Yieldgard®, in terms of conserving yields and 
lowering input costs, in this case by reducing need for fungicide applications. Also, there 
is a systems advantage in achieving less damage from disease by exploiting the plant’s 
genetics.
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BioDIRECT
Ag Biologicals are being more widely used in vegetable crops than in the large-acreage 
row crops, corn, soybean and cotton. They are particularly advantageous when used in 
protected culture, i.e. within net houses, plastic houses, or glass houses, in which finer 
environmental control is possible, allowing the biologicals to be used more effectively.
DNA-sequence-based information is available to identify pest targets and to provide 
active agents that knock out those targets. The pest may be a weed, insect or a pathogen—a 
virus or a fungus—and the ag biological shuts down a key pathway and controls the pest 
or pathogen (Figure 7). We heard from Neal Carter and Haven Baker about gene silencing 
and, basically, what it entails. This approach is in the early stages of development, and a 
lot of work is aimed in this direction globally.
Figure 8 shows examples with lab trials with pepper and tomato; non-transgenic 
 BioDirect technology clearly provides protection in plants infected with viruses. 
We believe that this approach will fuel a resurgence in the use of biologicals and drive 
the ability to make them even more beneficial than they are already. And we’re not alone. 
Several major agricultural companies are investing in this sector; clearly, it’s something 
that people are excited about. The more we understand at the molecular level, the more 
we can target specific processes to shut down—to control pathogens and pests—the more 
advantages we will extract from biological control methods and the more products will 
be launched in that sector. 
Figure 7. Ag biological: A new class of agricultural biological
with the potential to deliver effective crop protection.
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Figure 8. Initial testing indicates that BioDIRECT™ technology
could reduce virus-disease symptoms.
I want to stress that as we think about biotechnology in vegetables, there remains a 
role for “classic” transgenic technologies.  And we, and other companies, have some such 
products in the marketplace. But we also are thinking about this more broadly. The next 
iteration will be BioDirect and other mechanisms. We are early in the developmental 
process, but feel that it will help us make strides in the vegetable sector. 
Purcell
Certain statements contained in this presentation are “forward-looking statements,” such as 
statements concerning the company’s anticipated financial results, current and future product 
performance, regulatory approvals, business and financial plans and other non-historical facts. 
These statements are based on current expectations and currently available information. However, 
since these statements are based on factors that involve risks and uncertainties, the company’s 
actual performance and results may differ materially from those described or implied by such 
forward-looking statements. Factors that could cause or contribute to such differences include, 
among others: continued competition in seeds, traits and agricultural chemicals; the company’s 
exposure to various contingencies, including those related to intellectual property protection, 
regulatory compliance and the speed with which approvals are received, and public acceptance 
of biotechnology products; the success of the company’s research and development activities; 
the outcomes of major lawsuits and the previously announced SEC investigation; developments 
related to foreign currencies and economies; successful operation of recent acquisitions; fluctua-
tions in commodity prices; compliance with regulations affecting our manufacturing; the accuracy 
of the company’s estimates related to distribution inventory levels; the company’s ability to fund 
its short-term financing needs and to obtain payment for the products that it sells; the effect of 
weather conditions, natural disasters and accidents on the agriculture business or the company’s 
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facilities; and other risks and factors detailed in the company’s most recent periodic report to the 
SEC. Undue reliance should not be placed on these forward-looking statements, which are current 
only as of the date of this presentation. The company disclaims any current intention or obligation 
to update any forward-looking statements or any of the factors that may affect actual results.
Bollgard®, VT Triple Pro® and Yieldgard®:
Monsanto Company is a member of Excellence Through Stewardship® (ETS). Monsanto 
products are commercialized in accordance with ETS Product Launch Stewardship Guidance, 
and in compliance with Monsanto’s Policy for Commercialization of Biotechnology-Derived Plant 
Products in Commodity Crops. This product has been approved for import into key export markets 
with functioning regulatory systems. Any crop or material produced from this product can only be 
exported to, or used, processed or sold in countries where all necessary regulatory approvals have 
been granted. It is a violation of national and international law to move material containing biotech 
traits across boundaries into nations where import is not permitted. Growers should talk to their 
grain handler or product purchaser to confirm their buying position for this product. Excellence 
Through Stewardship® is a registered trademark of Biotechnology Industry Organization.
Performance Series™ Sweet Corn:
IMPORTANT: Produce Marketing: Performance Series™ sweet corn has received the 
necessary cultivation approvals in the United States and Canada; however, import approvals in 
all key sweet corn export markets with functioning regulatory systems have not been received. 
Direct all produce from this product for sale or use in the United States, Canada or Mexico. It 
is a violation of national and international law to move material containing biotech traits across 
boundaries into nations where import is not permitted. It is the growers’ responsibility to talk to 
their produce handler or purchaser to confirm their buying position for this produce so that the 
marketing requirements can be met.
Herbicide Information for Performance Series™ sweet corn: Make sure the intended use is 
approved in your state. Do not use this information as the basis for any glyphosate product other 
than Roundup® branded agricultural herbicides. You must have the supplemental labeling for use 
on Performance Series™ sweet corn containing Roundup Ready® technology and the product 
label with you when making the application.
Performance Series™ sweet corn Insect Resistance Management (IRM) – Post-Harvest 
Requirements: Crop destruction must occur no later than 30 days following harvest, but prefer-
ably within 14 days. The allowed crop destruction methods are: rotary mowing, discing, or plowing 
down. Crop destruction methods should destroy any surviving resistant insects.
All information concerning Performance Series™ sweet corn hybrids given orally or in writing by 
Monsanto or its employees or agents, including the information in this communication, is given 
in good faith, but is not to be taken as a representation or warranty by Monsanto as to the per-
formance or suitability of Performance Series™ sweet corn hybrids, which may depend on local 
climatic conditions and other factors. Monsanto assumes no liability for any such information. 
This information shall not form part of any contract with Monsanto unless otherwise specified 
in writing.
All Products:
B.t. products may not yet be registered in all states. Check with your Monsanto representative 
for the registration status in your state.
Individual results may vary, and performance may vary from location to location and from year 
to year. This result may not be an indicator of results you may obtain as local growing, soil and 
weather conditions may vary. Growers should evaluate data from multiple locations and years 
whenever possible. 
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ALWAYS READ AND FOLLOW PESTICIDE LABEL DIRECTIONS. Roundup Ready® crops 
contain genes that confer tolerance to glyphosate, the active ingredient in Roundup® brand 
 agricultural herbicides. Roundup® brand agricultural herbicides will kill crops that are not tolerant 
to glyphosate. BioDirect™, Bollgard®, Genuity®, Performance Series™, Respect the Refuge and 
Cotton Design®, Roundup Ready 2 Technology and Design®, Roundup Ready®, Roundup®, 
VT Triple PRO® and YieldGard® are trademarks of Monsanto Technology LLC. Respect the 
Refuge and Corn Design® and Respect the Refuge® are registered trademarks of National 
Corn Growers Association. Seminis® is a registered trademark of Seminis Vegetable Seeds, 
Inc. ©2014 Monsanto Company.
John PuRcell is vice president for technology development 
for Monsanto Vegetables and serves on Monsanto’s vegetable 
leadership team. In this role, he heads a global effort respon-
sible for supporting the commercialization of vegetable seed 
products in diverse markets. He is also a senior technology 
fellow at Monsanto.
 Previously, he served on Monsanto’s technology leadership team, in which 
capacity he oversaw a portfolio of technologies and products in the pipeline 
that bring increasing value to the cotton industry globally. Prior to that role, he 
held numerous positions in Monsanto’s technology organization. He headed a 
research site in Mystic, Connecticut, and led a research program in Cambridge, 
UK, focusing on corn and wheat, respectively. Dr. Purcell spent more than 0 
years at Monsanto’s biotechnology R&D center in St. Louis, where he held 
jobs of increasing responsibility in the biotechnology research organization. For 
several years, he headed Monsanto’s insect-control program. His role was later 
expanded to include all plant-protection research including insect, fungal and 
nematode pests.
 Prior to joining Monsanto, he was a postdoctoral researcher at the US Depart-
ment of Agriculture. His PhD was granted from the University of Massachusetts 
at Amherst in molecular and cellular biology with an emphasis on insect biochem-
istry. He is an inventor on several patents and an author of numerous scientific 
papers, reviews and book chapters.
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Alan Bennett (University of California, Davis):  This question is for Ricke Kress on citrus 
greening. I recall in the National Academy report some discussion of delivering a resistance 
trait through rootstocks. Is that being explored in terms of delivery through a transgenic 
rootstock, for citrus or other woody species?
Ricke Kress:  Yes. It is part of the industry-research effort. It’s a determination to elucidate 
the relative importance of the scion or the rootstock or both.
Chris Wozniak (US Environmental Protection Agency):  I have a question regarding some 
of the surveys a couple of you mentioned relative to people’s perception of putting DNA 
back into the same species and whether you want to call it intragenics or cisgenics or Innate 
technology or whatever. Do you think that the people answering those questions really 
understand the difference as to whether you are plopping in an ORF or a new promoter? 
Do they really understand differences in, say, the amount of the trait that will be expressed 
in your version of the plant versus where you are getting the gene from?
Haven Baker:  The answer is no.  
Wozniak:  That’s pretty much what I figured.
Carter:  We didn’t try to differentiate between transgenic, cisgenic and intergenic.
Case Studies
Q&A
Moderator: Daniel Lineberger
Texas A&M University
College Station, Texas
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Wozniak:  I’m curious because in years of talking with people who are in this research—and 
reviewing grant proposals—everybody seems to tout their own version of what is cisgenic 
and what is intergenic and why theirs is better than the last guy’s. One of the things that 
we have considered is that if you do manipulate control elements, promoter sequences, 
then you are dealing with a different scenario because then you are changing the tissue 
and expression pattern of that trait protein or whatever it is, as compared to, say, eating 
the same thing you have always been eating because the gene came from potato and it’s 
in potato. Whereas when you do those manipulations it’s not really the same, at least to 
some ways of thinking.
Baker:  Scientific distinctions are usually lost on the general population. It’s confusing 
if you use Google alerts of the reports of what you think the public perception is. Data 
generated by the International Food and Information Council is reasonably neutral—I 
hope—when they ask people, “Do you support biotech in your food?” They get answers 
similar to ours. Then you ask the next question, “Do you know if biotechnology is in your 
food?” and two thirds of Americans say they don’t know and another 0% say no. So you 
are asking for opinions on subjects that consumers are largely uninformed of and probably 
want to stay that way as long as it’s safe. So, yes, these distinctions get lost on the majority 
of the population, but 8% of people—it correlates highly with the organic crowd—are 
very against technology and very vocal. That’s generally who we think about and who we 
hear about. It’s a hard thing to get your arms around what people really think.
Audience Member:  My question is again related to cisgenic and intragenic versus trans-
genic. When you are dealing with USDA-APHIS, FDA and so on, does that make your 
life easier?
Neal Carter:  We never made the distinction. We just call it transgenic. The regulatory 
process essentially is the assessment of risk and the data package addresses that. If you 
can build a vector that is simpler, or do something that is going to require less data, than 
the regulatory process will be easier. But, at the end of the day, you have to address the risks.
Haven Baker:  One more thing on why we did what we did. In the case of potatoes—and 
also tomatoes—you’ve already had market failures. Growers have long memories and so 
do industry participants. We talk about the Innate™ technology, partly to differentiate it 
from past efforts. That’s not really geared toward the regulatory aspect. It’s geared towards 
consumers, and, in our case, towards industry.
Roger Beachy (Global Institute for Food Security, Saskatoon):  Two questions. We heard 
from oranges about $3. to $3.4 million for all the tests for regulatory approval of a new 
protein entry, and I didn’t hear that in apples. I wonder if you would comment on the 
differences there and what does that reflect? Then I want John Purcell to address the is-
sue of would you have done Bt sweet corn if you had to go through the whole process of 
deregulating the event rather than crossing it in?
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Carter:  From our perspective it’s hard to define regulatory costs. I’m not sure what is meant 
by that. A lot of the costs—such as for field trials—you will incur anyway. I think I heard 
Dennis say a quarter of a million dollars—that kind of range—nothing like three or four 
or five million. But we haven’t finished yet. Maybe we are going to see more costs.
Kress:  We have looked at what we feel we have to do to work our way through the process 
identifying all the potential tests and data collection and so on that we have to put into 
our package. We are going to do what we have to do. I also have a board of directors that 
is very interested in what we are doing as well, so I need to give them some insight as to 
how this can work.
Carter:  There’s an important distinction, in that we are not going through the EPA. 
Also I’m not including the cost of the field trials and the 0 years of field data that we 
generated that we wanted to have ourselves. I’m thinking more of the incremental cost 
of putting those data together and doing the statistics on it in a way, shape and form 
that the regulatory people wanted to see it done. Maybe there’s a few additional studies 
that we did, and then the sequencing of the events themselves. We hadn’t fully sequenced 
them, we relied on Southern data and we went ahead and sequenced them—just some 
extra things we did for regulatory purposes.
Kress: In the scheme of economics, the regulatory package might be the cheapest part. 
When we start to build these trees and to commercialize them and move into the growth 
side of it, it’s going to be expensive because with the new regulations on nursery opera-
tions, and so on, for every 00,000 trees in citrus right now it’s about a million dollars 
to build a structure to meet all the requirements and handle it all. There are 60 million 
trees in the state of Florida, so there’s a lot more to the puzzle.
Daniel Lineberger: There is a follow up question for John about sweet corn.
John Purcell:  Let me provide a little context first. At Monsanto, as a scientist, you feel 
fortunate because there are significant investments in R&D, but there is also a stringent 
process for every project, and one of the milestones it hits is when it goes into the regula-
tory phase, because that’s when you start assuming the regulatory costs. In each stage of 
the discovery process, we make priority decisions on which projects move forward. The 
challenge is in a lot of the vegetables. If you look at the number of markets in which we 
have to go for cultivation approvals alone. Look at tomatoes: It’s a big market opportu-
nity, but it’s not like corn, cotton and soybean. It’s a very distributive kind of market. 
It’s $500,000 to $ million at a time. So, when you look at those kinds of markets it’s 
difficult to say whether you go a product-development route that will require the regula-
tory piece. Looking at that many cultivation approvals and then the import approvals for 
where those products are flowing, the numbers don’t pencil out. Part of the stringency is 
what’s called APV: at present value. When you look at the cost of developing the product 
and what will be the eventual return, and then the other piece that is in there is the risk 
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adjustment on that, which is what is the chance of getting all those approvals in order to 
have that commercialization. So a lot of these vegetable products from the transgenics 
just don’t pencil out. The corn one—that’s an interesting question. We started with the 
approval and so it wasn’t a hard decision for us. I haven’t done the numbers but I’d be 
skeptical. When you pencil it out could you justify it with the US market and then you 
look where else that corn would have to be produced if you didn’t start with mon88 and 
mon89 which are already approved?
Peter Schuerman (Texas A&M Agrilife Research, College Station):  The Arctic apple 
story is fascinating and it’s particularly interesting that such a small company would take 
on that task. Your future plans include some protein traits. How will you finance those 
enterprises in the future?
Carter:  We have to do this with Arctic to prove that we can do it. We have a grower group 
that I am part of that has always known that there is a lot of money in something that 
is new and different. With a GM apple, we aren’t sure if that’s still going to be the case 
because of the consumer push back. We have learned a lot regarding how to do it faster. 
We’ve learned how to negotiate the regulatory process. The science is actually relatively 
straightforward, and the great thing about it is that it works. We will chase the money, I 
guess, and apply for grants and leverage, we’ve been able to leverage our shareholder capital 
about 4 to  from a research point of view. It’s very easy to fund the research. You don’t get 
any leverage on the precommercialization component, which is the shark pit—the chasm 
you have to walk through that is very, very difficult. Dennis called it the Red Zone. The 
Red Zone for him included the regulatory piece. For us it’s more the precommercializa-
tion phase, understanding the industry that you are working in, having an intimate idea 
of whom to talk with and how to sell it and maybe how to get a few key big companies 
involved to help steer that process. In fact, in all of the new traits we are working on, we 
have large tree-fruit-growing companies, usually vertically integrated, that are interested 
in that product and they will help partner in that cost.
Lineberger: So, they are investors?
Carter: They’re not shareholders. It’s fee-for-services-type work.
Schuerman:  Venture capitalists?
Carter: Yes. These are people who got in early before they read the fine print: “Neal, what 
did you talk me into?” My wife and I are the two largest shareholders and so I guess we 
are just stupid or something. We have about 40 shareholders and half of them are fruit 
growers—people who are willing to speculate on being part of something new. I’m lucky. 
I’m involved in some other business activities and I dragged some of those guys in too, 
and maybe they aren’t feeling so lucky, but I’m feeling lucky.
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Purcell:  With the portfolio process, it’s rarely the technical feasibility that kicks things 
out on the vegetable side—insect control, virus control, those kinds of things we know 
we can do. Being with growers pretty much every day the value in there is there but when 
you think about how all the elements in the chain have to come together to do that, and 
then the international elements as I discussed, that’s where it gets really problematic.
Tony Shelton (Cornell University, Ithaca):  We’ve all heard about how great this technol-
ogy is, but the main issue seems to be communication with the consumer. And I see, 
Neal, that you have a nice little friendly label, and people can go to your website and 
learn more about it. What happens if, all of a sudden, you have to slap a label on there 
that says “genetic engineered” and you don’t not have control over the friendliness of the 
message. How will you deal with that?
Carter:  If mandatory labeling laws come in with a skull and crossbones or something, sure 
it’s not going to help. But identifying Arctics as Arctics with point-of-sale literature avail-
able—and these kinds of things—I don’t think it will change much. I think that there is 
going to be fairly widespread understanding that this is a genetically engineered apple.
Shelton: And Rick, what about that for citrus? It’s not going to apply to the fresh market, 
it’s more for the juice.
Kress:  No, it will be fresh as well. Although we are in Florida this is going to be a pro-
cess that is going to have to go through the entire regulatory approval for the United 
States. It will affect all of citrus in all directions. From our perspective, we recognize the 
work that we are going to have, education-wise. With the various research that we have 
going, we are kind of in a horse race. We have several horses that have broken from the 
gate and as we go towards the third pole we will start to narrow that down and when we 
start looking towards the fourth, the finish line, that’s when we will step out and become 
more involved in that overall education process because we will know the direction we 
are going. We can’t work on an education process today with three different directions. 
That won’t work. When we get to the direction we are going in and then we will move 
forward on education before we get commercial.
Christiane Deslauriers (Agriculture and Agrifood Canada, Ottawa): The objection that I 
hear most of the time from industry is the unpredictability of the regulatory system. The 
biggest impediment to progress in this kind of work is not knowing what the regulatory 
system is going to be. Given your experience, do you think it is realistic to ever think you 
will be able to know ahead of time—the question will be knowable ahead of time? And 
to what extent has that applied for each of you?
Kress:  Part of our challenge has been that we are working with a tree. We are not work-
ing with a corn plant, potato or other annual. There is a gap in the information that the 
agencies have. The first time we went to DC and met with the agencies, we went with the 
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intent of asking a lot of questions and we were very open with what we were doing. So, 
we are working very closely with all three. I judge the quality of the meeting that we have 
when we are in DC by the number of questions that I come home with, and generally I 
come home with more questions than answers. That’s okay, because that’s what we have 
to do to get through this. That’s how we are looking at it. We wish there were a template, 
but there isn’t. We are going through step by step, and trying to be proactive.
Purcell:  Roger Beachy talked about the inconsistency on the world stage and that’s where 
we, a global seed company, see much unpredictability. Think about emerging and growth 
markets in Asia market where they might not even have a regulatory system in place. So 
you are developing your product while the regulatory system is being constructed and 
that’s where a lot of the uncertainty comes in because you don’t have harmonization. In 
many cases the rules are being written as people are trying to develop products and that, 
obviously, introduces a lot of uncertainty in when you can expect an approval or even 
what you have to do to put a submission together. 
Carter:  The smaller the company the bigger the uncertainty in terms of risk caused be 
regulatory timelines. You have a burn rate, but you don’t know if it’s going to take two 
years, three years, four years or five years. It’s hard to know when you are going to get 
into the marketplace and start to see return on investments. In January 0, we met 
with APHIS and FDA and a timeline was given. But, you leave the meeting and im-
mediately there is slippage, and then they come out with their new timeline process and 
immediately there is more slippage. Such uncertainty builds risk and, typically, boards of 
directors and shareholders don’t like risk. If you are trying to raise money they are going 
to say, “Yes, but what about the regulatory thing, where are you with that?” And you say, 
“Well I don’t really know. We thought we would be done but we’re not.” These things 
are definitely impediments to raising capital.
Tom Redick (Global Environmental Ethics Counsel, Clayton):  We’ve seen the labeling 
laws in Europe cost us literally billions in trade, measured by European economists who are 
very objective. The Connecticut labeling law has to include at least four states contiguous 
states. Assuming a bunch of states in the northeast enact a GM-labeling law, would that 
significantly impact your ability to go forward with your orange or apple or potato?
Kress:  It’s not going to slow us down because if we don’t find a solution to this disease 
we’re not going to have citrus. That’s the bottom line there. Another thing, which, in a 
backhanded way, is in our favor, we won’t be introducing tomorrow. We’ve got some years 
yet, still involved in this, so we are anticipating that this is all going to get sorted out. 
Again, a lot of companies that market orange juice are interested in how this will play out. 
On one hand we have time, and on the other hand we don’t. It’s all got to work.
Juan Landivar (Texas Agrilife Research, College Station):  I think you said that you have 
until 09 for deregulation. Where are we going to get our orange juice? From Brazil? 
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What is the plan? What is going to happen? Is there any way that the process can be 
accelerated?
Kress:  I didn’t go into all of our research. We have some other approaches that could 
provide interim solutions to shorten that timeline. One has to be optimistic. My board 
of directors asked me one time how we were addressing all of this and I said that I’m 
optimistic six out of seven days. They said, “What day aren’t you?” And I said, “Well, 
that’s the problem, I never know which day it’s going to be.
Tom Turpen (Citrus Research and Development Foundation, Lake Alfred):  For Neal—I 
thought it was brilliant—the selection of the trait and how it benefits the participants 
along the whole value chain. And also the communication of the technology—it was the 
best description of RNAi I’ve ever seen, with the railroad tracks. I wonder if you could 
preview for us the story you will use for the infectious-disease traits, because those will 
be adding a PIP. You did such a good job of communicating your Arctic apple story, how 
will you communicate your infectious-disease traits?
Carter:  I don’t quite have that story mapped out yet, so I can’t answer your question, 
sorry. It would be premature at this stage. But, a couple of things—we go to see US Apple 
in Washington and they say, “Oh, if you had an agronomic trait, we would really like 
it because our growers would be behind it.” And we respond, “Yeah, but consumers are 
the ones you have to please.” So, we are really frustrated by the fact that every industry 
group we meet with—growers, grower/packers, shippers, their industry representative 
groups–they all want agronomic traits, and they are willing to support those and stand 
behind them and promote them and all the rest, so maybe we won’t need to. We chose our 
trait because we felt that we needed to get the consumer on our side and that if we just 
jumped into scab or fire blight right off the start, we would be dead in the water. So they 
will be Arctic plus. They will be non-browning with fire blight resistance, non-browning 
with storage scald resistance—that sort of thing.
Lineberger:  Just to put a little plug in here for Neal—if you go to his website there is a 
link to his TED talk on the integration of biotechnology. It’s fascinating. He uses some 
very common-sense non-technical easy-to-understand approaches.
Lineberger
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A plant-incorportated protectant (PIP) is a pesticidal substance produced by a gene that 
has been inserted into a plant through transgenesis. EPA does not regulate the plant; in 
contrast to other regulatory agencies, we regulate the gene and the gene product.
As pointed out by Roger Beachy1, the definition of a pesticide has been around since 
947, when the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) was promul-
gated. In addition to language about destroying, repelling, and/or mitigating pests—“pests” 
are defined in the statute—it deals with plant regulators (not plant-growth regulators). 
Admittedly the category is broad, but then “pesticide” is difficult to define.
As far as I know, there is no inclination or intention to regulate plants expressing 
plant-growth regulators as pesticides, although, certainly, a policy statement to that effect 
might be helpful. Today, I am speaking specifically about plants that are disease- and/or 
pest-resistant.
Four statutes influence our authority to regulate PIPs (Figure ) of which I will focus on 
FIFRA, the main pesticide law, and the Federal Food Drug and Cosmetic Act (FFDCA) 
that we share with our colleagues at the Food and Drug Administration (FDA) regarding 
residues and tolerances.
FIFRA is unusual in terms of environmental statutes in that it considers benefits as 
well as risks, which is crucial with compounds that are inherently more toxic—typical 
nematicides, insecticides, etc., for example—but it can apply to PIPs in terms of envi-
ronmental safety or benefits and even economic safety and benefits. This does not apply 
to the Food Drug and Cosmetic Act.
Regulation of Plant-Incorporated Protectants
by the US Environmental Protection Agency
Chris A. Wozniak
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Washington, DC
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1Pages 9–8.
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In terms of initiating the process of achieving deregulation, most typically applicants 
start with an experimental use permit (Figure ) to generate field data. It is particularly 
noteworthy that we do not generally regulate field trials at less than ten acres. Trials in 
excess of 0 acres are likely to be under an APHIS permit or notification process. If 
you’re clever about it, you can plant multiple 9-acre plots, depending on how you design 
them. It is about cumulative acreage, but addressing a specific question with each cumu-
lative 9.9 acres is acceptable and is not regulated by EPA as long as different pest-crop 
combinations are being evaluated in the plots of less than 0 acres. The point is to assist 
in the development of data characterizing the product and/or its chemistry that will be 
needed to ultimately achieve registration; it is not about producing seed for commercial 
purposes and the data generated cannot be used for promotional purposes. Of course, 
we need to know the origin of the transgene, its DNA sequence and the deduced amino 
acid sequence. Where Agrobacterium has been used, a plasmid map will be necessary. 
Also protein-expression levels are needed, typically determined at multiple stages in the 
plant’s growth as well as at multiple locations; this need results from oversight being 
defined through a law governing pesticides. The content of the pesticidal substance must 
be elucidated, which is true for all pesticides, whether it’s a liquid, a PIP, or a microbial 
compound. In addition, for purposes of insect-resistance management, it’s important to 
know the accumulation of the protein in a leaf at whatever stage. That’s particularly true 
with corn and cotton, and then, of course, an analytical method is required to detect the 
pesticidal substance, which is particularly important in trade.
Each event has a unique OECD2 identifier. Although we often look at things parochi-
ally, we must keep in mind that we are in a global economy. From a scientific standpoint, 
I understand why people often say, “We are familiar with Bt and it would be nice to just 
give it a pass from now on.” On the other hand, the Chinese, Koreans, Japanese, Austra-
lians, Brazilians and others may not agree with that. Putting a new product on the market 
Figure . EPA’s regulatory role.
2Organization for Economic Co-operation and Development.
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Figure . Experimental use permits.
Figure 3. Test substances.
needs to be done with some forethought prior to actual commercialization. Asynchrony 
in approval is an ongoing problem in international trade.
For the vast majority of our guideline studies, test substances are proteins, which are 
often generated in a yeast or E. coli-based fermentation system (Figure 3). It is then the 
responsibility of the applicant to demonstrate the equivalency of the protein produced in 
the model system to that produced in the plant. To assess human-health effects of PIPs, we 
run acute oral toxicity maximum hazard dose tests with animals. Admittedly unrealistic, 
they are run for short periods to show any potential toxicity. In some other countries, 
long-term feeding studies are the norm, to reveal chronic and sub chronic toxicity. We 
have this option available if the first-tier testing indicates that there might be an issue.
Wozniak
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Biochemical properties are assessed. If the protein is an enzyme or a toxin that binds 
something, that needs to be demonstrated. Importantly, we do a lot of hematology 
comparisons both for toxicity and for allergenicity, based on known toxins and known 
allergens. In addition, digestibility studies assess allergenicity as well. This raises another 
point: when choosing a gene for transgenic work, it’s best not to use a shellfish or a tree 
nut as the source, as it will raise red flags. That’s not necessarily an insurmountable issue, 
but it may be costly in time and money.
In terms of the environmental or eco-assessment, non-target effects are a chief concern, 
on vertebrates and invertebrates alike (Figure 4). Because we are dealing with pesticides, 
environmental fate is also an important issue. What happens to the pesticidal substance: 
does it bind to clay particles, does it dissipate or is it degraded? In addition, does the 
transgene in question move outside of the cropping system to an indigenous or even feral 
relative? If so, it is something that we would consider in terms of potential adverse effects 
on the environment. If a tolerance is in place—in other words if we approve the gene 
product for consumption in animal feed or human food—then crop-to-crop gene flow 
is not an issue for us, although it may be an issue for USDA-APHIS. We require that, 
once you get to the field-trial stage, tolerances should be in place.
Figure 4. Data required for ecological effects on non-target organisms.
Figure 4 also shows some instances where corners may be rounded off to save some 
money. Some are very likely to be applicable—avian oral toxicity for a protein, for 
example. Typically, the mammal test has already been done; for human food tolerance, 
that study suffices. Although all of these data requirements need to be fulfilled, not all 
of them need to be fulfilled with empirical data generation; some may be fulfilled with a 
waiver rationale. My attorneys warn me not to call it a “waiver” because that has specific 
legal connotations. But it’s a rationale. It may be a couple of paragraphs, a paper from 
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the literature, or it may be based on an exposure argument showing that the PIP will not 
affect a target organism or other source of concern. There are ways to get around that. 
We have never had a PIP produced in a marine or estuarine environment, so we’ve never 
asked for a grass-shrimp test.
We don’t put a lot of weight in the 4-day poultry-feeding study, although other 
countries require it. Many of our registrants submit that, in which case we review it, but 
good data are needed from several other tests prior to getting to that stage.
Navigating EPA
EPA sets tolerances—maximum residue levels—for pesticides in or on food and feed 
products. A pesticide residue present in or on a food or feed product that is not covered 
by a tolerance, or an exemption from the requirement of a tolerance, means that the 
product is considered “adulterated” under the FFDCA and the FDA is responsible for 
enforcement. That is to be avoided.
Tolerances are set by considering data from acute oral toxicity tests, sequence compari-
sons to known toxins and allergens, in vitro digestibility and the source of the gene. We 
look at homology to known allergens; a good database is available at the University of 
Nebraska. It’s important to do such searches prior to progressing significantly, e.g. when 
building the constructs to verify that, by chance, the protein of interest doesn’t have a hit, 
i.e. a 35% or greater homology over an 80 amino acid stretch. If that is triggered then 
more testing will be called for.
Frequently, people call and take advantage of our guidance. It’s best to do so early on 
and not while in the midst of field trials only then to discover a problem.
As mentioned, most data requirements are designed for proteins as the test substance. 
If an RNA-interference approach is possible, it is likely to save time and money. People 
are spraying double-stranded RNAs, and bacterial vectors are being used to move RNAs 
into the environment. Although they’re not proteins, questions remain in terms of how 
bioinformatics may aid predictability of action toward non-target organisms. For example, 
do the RNAs quickly degrade after contact with the soil? A number of questions need data 
generation. Clearly, RNAi won’t solve everything, but where its use is possible, it should 
be considered. In addition, when inclusion of inert ingredients is needed, e.g. antibiotic 
and herbicide-tolerance markers, it makes sense to choose those that have been previously 
approved—glucuronidase, NPTII, EPSPS, PAD, etc.—again to save time and money.
Approval of green fluorescent protein has not yet been requested. The first such re-
quest will incur the cost of the required assessment. People have told me that a viable 
alternative approach will be to fuse NPTII and GUS. On the other hand, the tolerance 
for each of those individually may not apply to the fusion protein because truncation 
will change the sequence. Little things like that can cost more time and more money 
and, again, it’s wise to contact us early—which doesn’t cost anything—and hopefully, 
we can be of some help.
Now, in terms of the “barriers” that EPA’s Office of Pesticide Programs promotes, PRN 
-3 (Figure 5) denotes the third notice issued in 0 that provided guidance—in strong 
terms—for provision of data for applying for pesticide registration under FIFRA section 3 
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and FFDCA sections 408 and 409. The agency has a history of requiring particular format-
ting, to which there are advantages. In terms of record keeping, it lends efficiency when 
things are put together similarly and we have to find a piece of information pertaining 
to one of the thousands of products that we register. Initially it can be intimidating. We 
produce a registration manual that provides basic information (Figure 6). However, if 
you’ve never been through the process before, it can be helpful to employ an experienced 
consultant for guidance. We can provide a list of those who have worked with us, but we 
don’t recommend specific people. On the other hand, some people have gone through the 
process without a regulatory consultant. Ralph Scorza and colleagues at USDA-ARS wrote 
a chapter for a book3 that Alan McHughen and I edited in which he describes—without 
sugarcoating—his trials and tribulations in obtaining deregulation of pox-virus resistant 
plums. I think he’s correct, particularly in terms of his criticism of formatting require-
ments, which can be onerous. On the other hand, he did make it through the process, 
demonstrating that it is doable. Dr. Scorza is a good resource, particularly for academics 
who don’t have a regulatory staff.
Figure 5. PRN -3 formatting.
3Wozniak CA McHughen A (Eds) (0) Regulation of Agricultural Biotechnology: The United States and 
Canada. New York: Springer.
The Pesticide Registration Improvement Act—not a policy of the agency—is a statute 
passed by Congress. It was put together by stakeholders, NGOs, and industry and agency 
representatives in 004 (Figure 7). In its third iteration, it sets fee schedules. Companies 
with 500 or more employees have a particular fee schedule. For a university or USDA-
ARS scientist, waivers apply. For example a PI at Texas A&M will likely be eligible for a 
75 percent waiver in comparison with the company fee. If a large company applies for 
deregulation of a new active ingredient for first food use, the fee may be $400,000 to 
$500,000 upfront. Tables are available setting out fee schedules for different groups of 
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pesticides, These tables also provide firm timelines. These do not define when a registration 
will be granted, but rather when a decision will be made, on the assumption that a full 
and complete data package was submitted on day one. Some registrants have expressed 
approval of this approach because it removes some of the uncertainty; the previous queue 
system was inefficient. 
Figure 6. Where to begin.
Figure 7. Pesticide Registration Improvement Act (PRIA 3).
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Figure 8. Summary—navigating EPA.
Summary
Consultations can be very informal. It’s best if the applicant can visit EPA, but, otherwise, 
the initial consultation may be achieved by telephone, possibly a conference call, or email 
(Figure 8). Even a pre-submission meeting will be treated as confidential. At no cost, 
meeting minutes are generated, laying out what was discussed, what was agreed upon, 
what is left open, etc., which initiates the process. It is advisable to have consultations early 
on because they may lead to beneficial alterations, for example in terms of generation of 
less data or discovery of a waiver rationale. As mentioned, the formatting requirements 
are mandatory, and assistance of a consultant is recommended. However, absence of a 
consultant should be not considered as a deal breaker. Others have achieved deregulation, 
and EPA staff—regulatory specialists—are there to assist. 
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Figure 9. Sources of assistance.
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Several websites are available for guidance; they are continuously updated and improved 
(Figure 9). Kimberley Nesci or I may be contacted to set up a pre-submission meeting 
or to answer other questions.
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In this presentation, I will include a retrospective, breaking things down into arbitrary 
timeframes. I am defining the past as from the 950s through 99, the present from 
993 to 03, and the future from today onward (Figure ).
Reflections on the Past, Present and Future of
USDA’s Regulation of Agricultural 
Biotechnology
David Heron
USDA-APHIS Biotechnology Regulatory Services
Riverdale, Maryland
david.s.heron@aphis.usda.gov
Figure . Past, present and future.
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Past
Not long ago, DNA was identified as heritable material, and last year—0—we cel-
ebrated the 40th anniversary of the creation of the first recombinant-DNA organism, 
a bacterium (Figure ). The scientific community came together in the mid 970s, and 
as a group said:
Let’s take a break. Let’s look at the issue of safety. Let’s make sure that this new 
technology can be used safely.
They called on the National Institutes of Health to develop guidelines for the safe use of 
recombinant-DNA organisms in contained facilities; the guidelines were promulgated in 
976. The first commercial product from a recombinant organism was human insulin, 
marketed in 980. And, in 983, a recombinant plant was first described in the litera-
ture. I remember hearing about this as a beginning plant pathologist, and thinking that 
it would be a great tool for breeders as it touched upon the bedrock principle of using 
the best possible genetic basis to obtain resistance to pathogens.
The term “modern biotechnology” typically includes recombinant-DNA organisms 
(Figure ). In the United States and other countries, cell-fusion refers to combination 
of distantly related organisms; however, relatively little work has been done in this area. 
The note at the foot of Figure  is a reminder of the varied terminology that is used. Even 
the federal agencies use different terms, therefore one system cannot be laid on top of 
another, nationally or internationally. Internationally, “living modified organism” (LMO) 
is sometimes used, e.g. within the Cartagena Protocol. Everyone is familiar with GMO 
and “transgenic” is commonly used, whereas GEO seems almost archaic
Figure . Techniques of modern biology.
In my work for a regulatory agency, not only has my background in science been of 
utility, but so have my high-school civics classes. The combination has been essential in 
understanding the legal context within which the system operates. A necessary part of this 
is technical practicality; regulations must be enforceable. Of course, safety is a fundamental 
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consideration and public policy has a role. Some countries enact public policy aimed at 
promoting innovation or at tying their regulatory approach into a national system that 
assists development of the agricultural or the science and technology sector. And in recent 
years, international obligations have come into play increasingly.
The Coordinated Framework for Regulation of Biotechnology—proposed in 984 by 
the White House Office of Science and Technology Policy and finalized in 986—spells 
out the basic federal policy for regulating the development and introduction of products 
derived from biotechnology (Figure 3). This regulatory policy framework was developed 
to ensure safety of the public and to ensure the continuing development of the fledgling 
biotechnology industry without overly burdensome regulation. It applies as much today 
as it did in 986: in essence, the employment of these techniques does not, in and of 
itself, raise safety concerns. Also, federal laws, already enacted, cover any safety issues, 
and, if further regulation is needed, it should be based on the best available scientific 
information. Furthermore, applications for deregulation should be dealt with on a case-
by-case basis.
Figure 3. Coordinated Framework (986):
Federal role in the safe use of biotechnology.
APHIS regulation of GE organisms is pursuant to the Plant Quarantine Act (PQA) of 
9 and the Federal Plant Pest Act (FPPA) of 957. The original acts, which had nothing 
to do with genetically engineered organisms, were set up so that the federal government 
would have the ability to prevent plant pests—insects and pathogenic organisms—from 
coming into the country and moving interstate. These statutes were rolled together, along 
with the Noxious Weed Act, into the Plant Protection Act of 000. After vigorous de-
bate—should the USDA operate under federal regulations or operate under an advisory 
system akin to the National Institutes of Health Guidelines—it was decided to go with 
a legally binding system under regulations, put in place in 987.
Every regulation basically comes down to two parts: the item regulated and the activities 
of that item, which, under APHIS regulations (7CFR Part 340) is termed a “regulated 
article,” which has two parts to the trigger (Figure 4). The plant has been modified or 
produced using recombinant-DNA technology to modify the organism; and there has to 
be a possibility that the genetically engineered plant has a pest risk associated with it. In 
other words, if a recombinant DNA technique has been employed to modify an organism, 
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Figure 4. What does APHIS-BRS regulate?
and the donor organism, the recipient organism or the vector agent is a plant pest, then 
the resulting genetically engineered organism is called a “regulated article.” 
Over the years, people contacted us: “I’ve read the regulation and still don’t understand 
whether I have a regulated article.” A few years back, APHIS set up a website (Figure 4) 
that gives instructions on how to put together a letter of enquiry regarding a proposed 
or actual organism. No risk assessment involved. The feedback from APHIS is in terms 
of, “Yes, that meets the definition of a regulated article,” or “No, it does not meet the 
definition of a regulated article.” Fourteen such letters and APHIS’s responses are posted 
on the website. This has been an eye-opener for some who thought that if genetic en-
gineering techniques are involved, the item automatically falls under the regulations, 
which is not the case.
Figure 5 shows the activities that require authorization: importation to the United 
States; movement from state to state (not intrastate movement); and/or release into the 
environment. One of two authorization mechanisms may be applicable: the original 
permitting procedure that has been part of the regulation since 987; the notification 
procedure which was introduced in 993 to provide a more streamlined approach. Both 
procedures set out how the regulated article is to be authorized for importation, interstate 
movement and release into the environment. 
Present
Twenty years, 993–03, is a generous time span for “the present” (Figure ). In 993, 
we added something that the original regulations had no provision for: the commer-
cialization of genetically engineered plants. A farmer could not be expected to obtain 
permits and notifications every time (s)he moved genetically engineered seed or planted 
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Figure 5. Introduction of regulated articles.
a genetically engineered crop. We established a procedure whereby someone can petition 
us, in writing, for review to request that their genetically engineered organism should 
no longer be a regulated article because it doesn’t pose any plant-pest risk. Also, the US 
public was given the opportunity to be involved in these reviews, which is unusual. 
The dossier of information submitted to the agency supporting the contention that the 
genetically engineered organism is not a plant pest is available for public review—and 
comment—before final APHIS determination. 
These petitions involve two evaluations by APHIS. We make a risk assessment—as a 
stipulation of the Plant Protection Act—to answer the question: Does the genetically en-
gineered organism pose a plant-pest risk? And we make an environmental assessment—as a 
stipulation of the National Environmental Policy Act (NEPA, signed by Richard Nixon in 
970, setting standards for federal agencies to appraise the significance of environmental 
impacts that might arise from their decisions1). Under NEPA, the public again has the 
opportunity to provide input. This does not determine the agency’s decision, but it does 
inform the decision-making process.
To date, APHIS-BRS has made determinations of non-regulated status in response to 
over 90 petitions, comprising 6 plant species (Figure 6). Once non-regulated status is 
granted, the petitioner’s obligation under the regulation is finished: there is no license; 
there is no permit; nothing needs to be reviewed. Progeny derived from the organism 
through traditional plant breeding also has non-regulated status. For example, hundreds of 
varieties have been developed from the first glyphosate-tolerant soybean (“HT” in Figure 
6) to receive non-regulated status from us in the 990s. Likewise, hundreds of varieties 
1Back then, the decisions had nothing to do with genetically engineered organisms; they applied to federal 
agencies responsible for building bridges, dams, roads, etc.
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that have been developed from the early Bt corn genotypes (“IR” in Figure 6), with no 
obligation to apply for deregulation. Our statute is unrelated to commercialization; it 
strictly deals with safety issues. Some genetically engineered plants under regulation are 
actually being used as sources for commercial purposes, but all are being grown under 
permits.
Figure 6. Genetically engineered species with non-regulated
status under 7CFT part 340.
Commercialization is not under APHIS’s authority. Whether a product is commercial-
ized is market-driven. The left column in Figure 6 shows products that are on the market 
as of June 03, including the high-profile cases of herbicide-tolerant alfalfa and sugar 
beet, and less well known tobacco with reduced nicotine. Dennis Gonsalves’s2 papaya 
is also in the left column, And we have everything from insect resistance (“IR”) and 
drought tolerance (“AP”) in corn, through herbicide tolerance in canola (“HT”) to high 
oleic acid content in soybean (“PQ”). The right column includes the FlavrSavr ® tomato 
and another slow-ripening high-solids tomato. Male-sterile chicory (“AP”), sometimes 
called radicchio—developed in Belgium in the mid-990s—has non-regulated status, but 
does not have consumer approval in Europe. Several herbicide-tolerant rice lines have 
been through the system, but commercialization is pending, subject to approvals in other 
countries. The blue rose (“PQ”) and Ralph Scorza’s plum3 (“VR”) are also in the column 
on the right; they are gearing up for commercial release of the virus-resistant plum. Some 
others are on track for commercialization . 
2Pages 37–46.
3Page 36.
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Recent APHIS-BRS Initiatives
In 007, we initiated a voluntary compliance-assistance program, with early input from 
large companies, medium-size companies and public research institutions. An extensive 
effort in recent years has examined the petition process to make it more efficient. Over 
the years, we went from a six-month timeframe for completing reviews, to where it was 
taking up to several years. Petition-process improvement was put into place in 0. 
And in 008 we proposed amending the regulation. In the United States, a regulation 
is proposed and followed by a public-comment period, after which the regulation may 
be finalized. In this case, after announcement of the initial proposal, 66,000 comments 
were received and are still being appraised.
Figure 7. Guiding principles for regulating new technologies.
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Figure 8. For more information.
Future
In 0, a memorandum was issued by the White House Office of Science and Technol-
ogy Policy in conjunction with the Office of Management and Budget and the US Trade 
Representative’s Office—frequently referred to as the Holdren memo—titled Principles for 
Regulation and Oversight of Emerging Technologies. Although it is not aimed at biotechnol-
ogy alone, it is similar in tone and emphasis to the Coordinated Framework for Regulation 
of Biotechnology, i.e. favoring innovation, having enough regulation as necessary and to 
also consider that there may be no need for regulation.
Figure 7 shows key principles espoused in the Holdren memo. International coopera-
tion is becoming increasingly important, especially in the biotechnology area. Again, the 
benefits of a regulation should justify the costs it incurs. Are regulations the best approach? 
How much leeway is in the system? Technically, if you set up a class of things that are 
regulated, can you distinguish them from counterparts that are not regulated? Safety, of 
course, comes into play as part of public policy. The Holdren memo is an example of 
public policy that sets out international obligations. 
The Sanitary and Phytosanitary Agreement under the WTO, which came into being 
in 995 says, in essence: “In the absence of good scientific evidence that demonstrates 
harm to plants, animals or to humans, we should not restrict trade.” This lens may be 
applied to the regulatory systems in the United States and elsewhere.
The Secretary of Agriculture’s Advisory Committee on Biotechnology and Agriculture 
has, over the past two years, taken up the issue of coexistence. Although this has to do with 
crops after they’re out from under our regulatory system, APHIS-BRS has been involved 
in helping to bring stakeholders together for on-going discussions.
Figure 8 provides our website and means to obtain stakeholder-information updates 
via email.
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A key aspect of the authority for regulating genetically engineered crops is the legal basis 
of that authority. For example, in contrast to what some people think, the Food and Drug 
Administration (FDA) cannot make consultation mandatory, because there is no law to 
permit it. In 99, FDA published an article in the Federal Register—The Statement of 
Policy: Foods Derived from New Plant Varieties—in which was discussed its legal framework 
for considering new plant varieties as a whole, including genetically engineered varieties. 
The article’s focus was chiefly on elements already in the Food, Drug, and Cosmetic Act 
(FD&C Act), and it explained the agency’s thinking about safety and regulatory issues 
pertaining to new plant varieties, based on several parts of existing food law.
The first issue is adulteration, the second is food additives, and the third is labeling 
(Figure ). There are two basic elements to US food law. The first is the responsibility 
of purveyors—which include crop developers, farmers, and manufacturers—to ensure 
that the foods they market are safe, wholesome, and comply with all applicable legal and 
regulatory requirements. The second element is what FDA does to enforce the law, using 
regulatory tools to remove unsafe or illegal foods and ingredients from the marketplace. 
These include seizures, recalls, and denial of entry of food from abroad.
We have a program to help developers ensure that food from new plant varieties is safe 
and complies with laws and regulations. Three legal requirements are applicable.
• Safety: The food is as safe as that generated from traditionally bred varieties.
• Labeling: The food labeling is truthful and not misleading.” 
• Additives: Is premarket review required?
Ensuring Food and Feed Safety:
US Food Law and FDA’s Biotechnology 
Consultation Process
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Figure . FDA’s authority: the FD&C Act.
Figure . FDA’s legal framework for foods from new plant varieties.
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FDA’s Authority
There are two basic elements to FDA’s authority. The first is post- market authority (Figure 
), under the adulteration provision of the FD&C Act, which, generally, applies to whole 
foods. A food is considered adulterated if it contains a poisonous or otherwise deleteri-
ous substance known to harm humans or animals, if it contains an unsafe food additive, 
or if it contains an unsafe pesticidal chemical. The second element is FDA’s premarket 
authority governing food additives, unless data show that they are generally recognized 
as safe (“GRAS”) by qualified experts in their intended use.
Under what circumstances would a food additive be present in a genetically engineered 
plant? It would be a new protein or the product of a new protein for which safety informa-
tion is not publicly available or widely accepted. Accordingly, FDA would require a review 
before marketing. So far, the only example of a food additive in a genetically engineered 
plant was the NPTII enzyme used as a selective marker in the FlavrSavr tomato. At the 
time Calgene submitted its food-additive petition, there was no experience with using 
proteins of this type in food.
Labeling
According to the “misbranding” part of the FD&C Act, a label on a food must be truthful 
and not misleading. A label must be changed if a meaningful difference is created by confer-
ring a change in a food; it must be called something different. To date, the best examples 
are modified oil crops, e.g. high oleic acid soybean and stearidonic acid soybean. 
1992 Policy
In summary, the 99 policy considers whether the product in question is as safe as other 
foods. It provided guidance to industry via decision trees and includes a suggestion that 
developers consult with FDA early in the development process, so that potential issues 
may be identified before they become problems.
CFSAN and CVM
Submissions to FDA are evaluated by two centers for different uses. Safety of use in hu-
man food is evaluated by the Center for Food Safety and Applied Nutrition (CFSAN), 
whereas the Center for Veterinary Medicine (CVM) evaluates safety of use in animal 
feed. Again, we advise early consultations at FDA to advise us of what you are doing, 
then return to the lab to run tests for potential toxicity, allergenicity and antinutrient 
content, and potential for bioavailability alteration. This is followed by submission of 
a dossier—hopefully not too lengthy—describing why the use of the plant as food or 
would be safe and legal.
What are the issues? Regarding safety, there’s the potential for toxicity, the potential for 
allergenicity, and for changes in levels of anti-nutrients and in bioavailability. Regarding 
regulatory considerations, there’s the question of whether a new substance is an unap-
proved food additive or GRAS, or whether there’s a meaningful change requiring a new 
common or usual name.
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In essence, we ask people to tell us their story—about their new plant variety and why 
it’s safe for food use. As for FDA’s role, we recognize that there’s widespread variation 
in plants in nature, including among domesticated varieties, affected by environmental 
conditions and the genetic background (Figure 3). We have developed a process whereby 
we evaluate final submissions and if there are aspects we don’t understand, we will seek 
clarification. We then develop our own document, and conclude by sending a letter. We 
mail the letter to the submitter and place a memo on our website—a scientific evaluation 
that establishes whether the new variety is as safe as those already in the marketplace.
We added a new piece in 006. When preparing for field trials with a protein that hasn’t 
been used before, our early food-safety evaluation (Figure 4) is worthy of consideration. 
This guidance is termed a “new protein consultation” (NPC). If a new protein is neither 
toxic nor allergenic, then it would be considered safe for field testing and FDA would 
not be concerned if low levels appeared inadvertently in the marketplace. 
Figure 3. Consultation procedures: FDA’s role.
Safety Assessment
As far as safety assessment is concerned, we understand that agronomic and quality issues 
will eliminate some lines from consideration at the very beginning of the process (Figure 5). 
We need to have information on new substances, including identity and source, using the 
weight-of-evidence approach. And we need to look at composition, and perhaps at some 
agronomic aspects. The intended effects must be clarified in terms of overall effects on 
the food and compositional changes. And, finally, unintended effects may be important. 
Does the insertion result in expression of (a) new or altered protein(s), or even fusion 
proteins? Are there unanticipated actions of a new enzyme on other components within 
the plant?
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Figure 4. Early food-safety evaluations (NPCs).
Figure 5. Safety assessment–.
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Figure 6. Safety assessment–.
The safety of genetically engineered plants for food and feed is judged using a case-
by-case approach. Generally, the genetically engineered plant is compared with a closely 
related conventionally developed plant, with the focus on new substances, i.e. toxicants, 
anti-nutrients, allergens and toxins. Bioinformatics are used to address the possibility 
that unintended new proteins are likely to be expressed, and if so, are they safe? The 
sequences of new proteins are compared with the sequences of known toxins, allergens 
and anti-nutrients.
For the molecular assessment, we require several pieces of information (Figure 7):
• Data showing which portions of the introduced DNA have been incorporated 
into the plant’s genome.
• Confirmation that there’s no vector backbone, with examination of the fidelity of 
insertion of the construct.
For safety assessments, three basic components are applicable (Figure 6). Genetic 
analysis focuses on stability and unintended effects. Chemical and nutritional analyses 
focus on dietary impacts and toxicant levels. And allergenicity and, to a lesser degree, 
toxicity are assessed. Resources for use in safety assessments can be pooled from the 
 following sources:
• The Statement of Policy on FDA’s website.
• The Codex Alimentarius guidelines.
• Guidelines set out by the Organization for Economic Cooperation  and Develop-
ment (OECD).
We have certain flexibility about format and how the necessary information is presented 
to us. 
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Figure 7. The molecular assessment.
Figure 8. Compositional analyses.
• Evidence that no unintended proteins resulted from open reading frames. 
 Ordinarily, that’s based on bioinformatic analysis of the junction sequences of 
the insert.
• Information about copy number and stability, using genomic DNA blots or other 
appropriate technologies. 
Next, compositional analyses are generally performed on field tests at multiple sites 
and usually over two growing seasons. The objective is to ensure that nutritional value 
is conserved, by comparing the new genetically engineered variety with a related control 
and/or a similar entity in the marketplace. Figure 8 illustrates the process for row crops. 
Key nutrients comprise proximates, i.e. fatty acids, fibers, amino acids, and vitamins 
and minerals. Again, we look at anti-nutrients, endogenous toxicants and endogenous 
allergens. For other types of crops, the analyses may be less comprehensive; in the case of 
fruit, the analyses usually comprise mostly fiber and sugar.
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Figure 0. Types of traits.
Figure 9. Traits and crops evaluated by FDA.
Experience to Date
Corn, cotton, soybean, and canola have been the focus of most of our consultations. 
We have seen many varieties of these crops. Traits that we’ve covered can be classified as: 
herbicide tolerance, virus and insect resistance, altered oil composition, male sterility, 
delayed ripening, other altered composition, and agronomic changes (Figure 9).
As for the types of traits, we can group them in three basic categories (Figure 0). 
Both EPA and FDA have roles to play in assessing plant-incorporated protectants (PIPs). 
59
Figure . Transparency.
Generally, FDA looks at stability and nutritional composition, whereas EPA looks at 
 human and environmental safety via genomics and proteomics. For non-pesticidal pro-
teins, FDA alone looks at food and feed safety. And FDA has had some submissions that 
utilize RNA inhibition.
Risk Communication
Regarding risk communication, we try to be transparent to the degree that the law 
 allows. Our inventory is available on the Internet (right side of Figure ). If something 
is required of FDA that is not available on the Internet, a Freedom of Information Act 
request may be submitted. Also, we are happy to communicate directly via email, con-
ventional mail, or by telephone. Figure  provides a list of resources; our main page is 
www.fda.gov/geplantfoods.
Figure . FDA’s Internet resources.
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PhD in microbiology from the University of California, Davis. 
After postdoctoral studies at the University of British Columbia 
and UC-Davis, he joined the Food and Drug Administration 
in 99, where he did research on the outer surface of Listeria monocytogenes, 
acid tolerance in Yersinia enterocolitica, and the food safety of apple-cider 
 production. In 000, he became a consumer safety officer in the Office of Food 
Additive Safety.
 He participated in the working group for the development of a Codex Alimen-
tarius “Guideline for the Conduct of Food Safety Assessment of Foods Produced 
Using Recombinant-DNA Microorganisms.” He also has worked on a wide variety 
of biotechnology-related issues for FDA, and was a member of an interagency 
task team that has developed and maintains a joint Internet site for government 
information about regulation of the products of modern biotechnology.
 Dr. Merker was selected as a supervisory consumer safety officer in the Division 
of Petition Review in the Office of Food Additive Safety in July 007, and moved 
to the Division of Biotechnology and GRAS Notice Review in 00, where he 
supervises several regulatory and environmental specialists. He oversees FDA’s 
Consultations on Food from New Plant Varieties.
In Conclusion
Our safety evaluations are based on the premise that genetically engineered plants are as 
safe as their traditionally bred counterparts. We encourage developers to engage with us 
prior to marketing, and we communicate with our sister government agencies and inter-
national groups to ensure that we’re using both the best science and the best practices. We 
understand that, as science evolves, we will see new technologies and new traits; however, 
we expect that the policy that was developed in 99 will remain sufficiently flexible and 
broad to accommodate them.
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In this presentation, I will represent not only Plant Biosafety Office of the Canadian 
Food Inspection Agency (CFIA), but also Health Canada and the Animal Feed Division 
within the CFIA. 
Canada differs from the United States in that it regulates novelty. We regulate novelty 
under three different acts applicable to three different groups: novel feed, novel food and 
novel plant assessments. The first is the Seeds Act and Regulations. The group that I repre-
sent—the Plant Biosafety Office—is responsible for the environmental authorization of 
plants with novel traits. A plant with a novel trait (PNT) is defined as: 
…a plant into which a trait have been intentionally introduced and where the 
introduced trait is both new to cultivated populations of the species in Canada 
and has a potential to affect the specific use and safety of the plant with respect 
to the environment and human and animal health.
Under the Food and Drugs Act and Regulations, a novel food is defined as: 
…a substance, including a microorganism, that does not have a history of safe 
use as food, a food that has been manufactured, prepared, preserved or packaged 
by a process that has not been previously applied to that food and causes the food 
to undergo a major change.
My Health Canada counterparts often use the example of high-pressure processed ham 
as an example of a novel food because that’s the process side, but products of novel plants 
are also considered novel foods. Under the Feeds Act and Regulations:
The Canadian Regulatory Process 
for Plants with Novel Traits
Patricia McAllister
Plant Biosafety Office
Canadian Food Inspection Agency
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…only feed ingredients that have been approved and evaluated by the Animal Feed 
Division may be used in livestock feeds; approved ingredients are listed in Schedules 
IV and V of the Feeds Regulations. Any feed ingredient that is new ( i.e. not listed 
in the Schedules) or has been modified such that it differs from conventional 
parameters, is required to undergo a premarket assessment. This concept applies 
to all novel feeds, including those derived through biotechnology.
Many entities, including microbial feed additives, are regulated under these feed 
 regulations. 
Novelty Triggers
A PNT being assessed for unconfined release may also trigger a novel food/feed assessments 
by Health Canada and/or the Animal Feed Division of the Canadian Food Inspection 
Agency (CFIA).
A PNT is not necessarily a novel food or feed or vice versa. For example, genetically 
engineered turf grass is a PNT, but not a food or a feed. Genetically engineered timothy 
is a PNT, but not a novel food. And genetically engineered cotton is a novel food and 
feed, but not a novel plant—it does not trigger and environmental assessment—because it 
doesn’t grow in the Canadian environment. Juice from genetically engineered citrus would 
only be a novel food because citrus trees don’t grow in Canada and we would not expect 
anyone to import any citrus by-product as a feed. Therefore, the orange-juice people1 
have to deal only with Health Canada, whereas apple pumice is considered to be a feed 
ingredient, therefore Neal Carter2 has had to go through the “feed” piece.
The basis for this is to ensure that an application is made only to the applicable group. 
If multiple applications are required, they should all be submitted at the same time to 
the applicable groups. After 000, coordinated authorizations were ratified (Figure ) 
whereby Health Canada and CFIA agreed to a no-split approval process. If multiple groups 
determine that a crop is novel, then the assessors work together to evaluate the product, 
and the authorization of the product is coordinated, usually within days of each other. 
This is done to minimize the potential for unapproved products to enter the Canadian 
food or feed supply.
To review: the Canadian process is unique. The focus is on the product, not on the 
process used to develop that product. Accordingly, a regulated product can be developed 
by any breeding process—including conventional breeding, genetic engineering or mu-
tagenesis—and this approach allows the Canadian regulatory system to efficiently adjust 
to any new developments in science or plant breeding. Also, biotechnology is defined 
more broadly in Canada than in most other countries.
Figure  illustrates how the different groups come into play together under the manda-
tory premarket regulatory requirements for novel plant products. “Novel plant products” 
is the term that we use when referring to all three, but I’ll use “plants with novel traits” 
(PNTs) because that is typically what we deal with.
1Pages 75–85.
2Pages 87–94.
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Figure . Coordinated authorizations.
Figure . Mandatory pre-market regulatory requirements for novel plant products.
The environmental assessment is done by CFIA under the Seeds Act, with a confined or 
unconfined release. Confined release I’ll describe in more detail below. Unconfined release 
is when a product has been authorized for release into the environment and is considered 
as safe as its conventional counterparts. The livestock feed assessment is done by CFIA, 
based on the Feeds Act, when a product becomes authorized as livestock feed. The novel 
food assessment by Health Canada uses the terminology “no objection”; when they are 
done, they go through a food-ruling process and indicate a letter of no objection, which 
is posted on their web site. Other regulatory requirements may apply prior to commercial 
use. For instance, if the crop requires a variety of registrations in Canada, like soybeans or 
canola, then we have a variety of registration processes that must be completed prior to 
commercialization. And commercialization is always the decision of the developer.
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Feed Regulation
We are often asked why we regulate animal feed (Figure 3). Part of the reason is that, 
typically, the domestic animal’s diet is made up of a small number of products at higher 
levels than we ever see in a human diet. Also, different components are consumed; humans 
may eat a different part of the plant from what animals eat, and no processing or differ-
ent processing may be involved. Animal health and productivity impinge on the food 
chain and it is important that nutritional value or safety of products such as milk, meat 
and eggs are not affected. Assessments ensure that the feed is efficacious for its intended 
purpose and safe in terms of animal and human health. 
Figure 3. Why regulate feed?
Novelty Determination
When it comes to novelty determination, it is the proponent’s responsibility to charac-
terize their plant and to self-identify to the CFIA a product requiring authorization for 
environmental release. We expect the developer to approach us and say, “I have a product 
that I think may be novel.” Communication is key, and the earlier that communication 
takes place, the better.
The CFIA has the ultimate decision-making authority regarding regulatory status de-
termination and reserves the right to require a proponent to provide scientific justification 
for determination that a plant is not a PNT. If we feel that it is and the proponent feels 
that it isn’t, then the latter must provide justification in writing. Our assessment will be 
science-based and done on a case-by-case basis. Accordingly, this regulatory approach, 
again, is based on the product, not the process. Figure 4 shows essential questions to ad-
dress whether a product is novel.
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Figure 4. Regulatory approach: product not process.
Is the plant intended for release into the environment?
The CFIA does not have a regulatory requirement as long as the product is contained in 
a greenhouse, laboratory, etc. 
If environmental release is intended, is there a history of use of the germplasm 
prior to 1996 (i.e. when the Seeds Act regulations came into effect for plants 
with novel traits)?
If the product was released into the environment prior to 996, then, again, it is exempt 
from this process.
Are there new traits that were not previously observed within a distinct stable 
cultivated population of seed of this species in Canada? 
This trigger may affect a conventionally bred product if it involves new germplasm con-
taining a brand new, or very different, trait. For instance, in Canada, our list of regulated 
plant products includes a herbicide-tolerant wheat and a herbicide-tolerant sunflower, 
neither of which was developed through genetic engineering. Sometimes this causes us 
grief when people see “wheat” on the list, whereas wheat is not considered a living modi-
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fied organism (LMO) and, therefore, in most countries is not regulated as a product of 
biotechnology. Because these wheat and sunflower genotypes each have a new trait, they 
become PNTs. 
Has a significant change occurred in traits that were previously observed within 
a distinct stable cultivated population of this species in Canada?
If the answer is no, then it isn’t new, but if it’s yes, then it is a PNT. 
When ascertained to be a plant with a novel trait, the next issue is whether it is of 
 domestic or imported origin. If the latter, then an import permit policy has to be followed, 
on the application for which the PNT status is declared and it comes to my office—the 
Plant Biosafety Office (PBO)—for review. Once imported, if it is held in containment, 
then we would track that it stays in containment, whereas if it is to be tested in field 
trials, those trials would need prior approval. Along the left edge of Figure 5, “Ongoing 
communication with regulators,” signifies a critical aspect whereby we can help applicants 
to expedite the process.
Figure 5. Regulatory pathways for PNTs.
Again, whether the PNT is imported or developed in Canada, if it stays in containment 
no further action is required. As soon as it is moved outside of the contained use into the 
confined release research trial program, then a confined field-trial application form must 
be submitted through the PBO, the purpose of which is to minimize risk by preventing 
entry into the animal and human food chains. When we receive a confined field-trial 
application, we notify the provinces, requesting comment in a minimum of 30 days. 
Therefore, our confined field-trial process takes at least 30 days. No deadline is stated on 
our website, but the earlier in the year that the application is received, the greater is the 
chance that the product will be approved for planting that year. 
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Figure 6. Regulatory approach for environmental release of PNTs.
Many inspections are made under the confined release research program. Once the 
grower’s data have been collected, the environmental assessment—the novel-feed, novel-
food assessment piece—comes in, with the application for unconfined release, and from 
an environmental side, again, when unconfined release is authorized, we say that it’s as 
safe as its conventional counterparts.
Again, commercialization is an industry decision, and if the PNT is a crop or a com-
modity that requires registration under the Seeds Act, then a variety of registrations must 
be completed before commercial sale of seed is possible.
Environmental Release of PNTs
Risk equals hazard times exposure. A confined release is necessary when the environmental 
hazard is unknown or not fully characterized (Figure 6), i.e. the plant developer’s research is 
ongoing, some of our questions are unanswered, and the regulatory program concentrates 
on environmental exposure and the evaluation and mitigation of risk.
An unconfined release is possible when the risk is known and maximum exposure may 
be assumed; the regulatory program concentrates on evaluation of the environmental 
hazard, and we may introduce stewardship conditions that, sometimes, are referred to as 
“safety assessments” to distinguish them from risk assessments. 
The purpose of our confined research field-trial program is to provide opportunities 
for plant developers to cultivate their PNTs in agronomic settings while minimizing 
environmental exposure. These trials are subject to conditions intended to minimize 
persistence and spread of the plant in the environment, and to prevent contamination of 
food and feed with unapproved plant material. Each trial is inspected multiple times by 
CFIA representatives to assess compliance with conditions, including post-harvest checks 
to determine that plant material has been adequately disposed of and to verify that it was 
produced exclusively for research purposes.
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The purpose of the unconfined environmental-release program is to allow release of 
PNTs into the environment with limited or no restriction. It may require stewardship 
plans; for instance, prior to our authorizing a herbicide-tolerant crop, we require that the 
proponent tells us exactly how it will be managed and how development of resistance will 
be minimized. And for insect resistance, management requirements include refuges. The 
authorized products will have been assessed to be as safe as comparable products with a 
history of safe use. A question we ask is: “Does the addition of one or more traits change 
the plant’s impact on the environment in comparison to the same crop grown in the 
agricultural setting?” Once we have authorized a PNT, it is not handled any differently 
from its conventional counterparts.
We are often asked how many acres of genetically engineered crops are currently grown 
in Canada. It is approximately 99 percent of our canola and 97 percent of our corn, but 
the only way we can estimate acreage would be based on the adoption of the technologies 
in the various commodities.
Required Scientific Information
Scientific information required in PNT applications includes:
• Identification and classification, comprising taxonomy, history of use and 
 organism description
• Intended use of the PNT
• Description of the novel trait(s)
• Method used to detect the trait
• Molecular and agronomic data specific to the trait
• Optional: Participation in a public Notice of Submission initiative.
Regarding the optional item, the CFIA doesn’t have authority to have a mandatory 
comment period. We have what we call a “voluntary comment period,” in which most pro-
ponents participate. The invitation to make (a) comment(s) is a brief document—unlike 
what is posted in the United States—summarizing the data that we have received. We 
indicate that we will accept scientific comments, which only rarely are received, but the 
summary tells the public what we’re looking at and gives them the opportunity to tell us, 
typically, how opposed they are to genetically engineered technology in general.
Environmental Safety Assessment
From an environmental perspective, we have what we consider the five main criteria or 
pillars of PNT environmental safety assessment; we look at the:
• Potential of the PNT to become a weed or invasive
• Potential for gene flow from the PNT to related species, the hybrid offspring of 
which may become a weed or be invasive
• Potential for the PNT to become a plant pest
• Potential impact of the PNT on non-target organisms
• Potential impact of the PNT on biodiversity.
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Vis-à-vis the plant-pest criterion, the issue is whether the change in the plant makes it a 
potential sink for, say, fungal disease that could then impact neighboring crops. Regarding 
effects on non-target organisms, the main sources of concern expressed by members of 
the public are adverse effects on honeybees and monarch butterflies.
Food- and Feed-Safety Assessments
Regarding food and feed safety assessments, eight general considerations are applicable: 
• A history of safe use
• Dietary exposure
• History of the organism(s)
• Characterization of the derived line in relation to the parental varieties
• Genetic modification 
• Nutritional change
• Toxicology and allergenicity
• Chemical change.
More information on these factors is on our website.
Assessment Principles
Essentially, we follow basic assessment principles (Figure 7), the first being tiering of data 
requirements, i.e. the degree of the scientific support required is adjusted based on the 
complexity, or our familiarity with, the product. Acknowledging that every product is 
unique, each has to be judged on a case-by-case basis. Products vary greatly in terms of 
their characteristics and no one set of prescribed data requirements is feasible. Certain 
Figure 7. Assessment principles.
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considerations have to be addressed in every case, but again, each product is unique. Data 
requirements are determined on the basis of the characteristics of the product in question. 
Our familiarity with a particular product and its characteristics impacts the amount of 
information we require. A “valid scientific rationale” can be used in place of data or to 
bridge data. If it’s something that we have seen before, the proponent can present infor-
mation from referee journals or the proponent’s own information to demonstrate that 
it’s the same as something that we’ve seen in a previous product.
A word of warning: we don’t like summary data. Companies that have submitted 
 numerous dossiers to us sometimes include all kinds of summary data, which are not 
what we need. We need a rationale as to why we should look at the information we 
looked at with the prior product, which is much more acceptable than giving us copious 
summary data.
Other assessment principles are:
• The weight of evidence—the sum of the overall data submitted that provides the 
context for determining efficacy and safety
• Efficacy and safety side—the assessment considers the likelihood that unintended 
effects may be present in the modified plant in question
• Comparators must be appropriate for the product in question.
The last of these principles is included because often we receive submissions that refer to 
submission to the US Environmental Protection Agency, for example. When submitting 
for a product in Canada, relevance to Canada is preeminently important. For instance, for 
corn rootworm products in Canada, the corn-production system frequently includes crop 
rotations and other differing factors, which should be included in the story. Providing us 
with information on how a product is used in the US environment can complicate our 
assessment instead of making it easier.
Decision Making and Post Authorization
While a file is under review, we often ask for more information to provide clarification. 
When all of our questions are answered, we may “flat-out” authorize a product. Or, we 
may authorize it with conditions, such as stewardship requirements. Some companies are 
now indicating to us that they never planned for a product to be marketed alone, that it 
would always be combined with another product. Accordingly, sometimes our conditions 
now reflect the fact that a product is authorized for combination with another, which 
affects the stewardship conditions that we will put in place. Of course, authorization 
may be denied. On the other hand, we’ve had files withdrawn, we’ve had files for which 
we have asked questions and are still waiting for answers, but CFIA has never refused 
an authorization. 
We do not provide split—food/feed/environment—approvals. Separate decisions are 
posted on both the CFIA and the Health Canada websites. The applicant is required to 
notify CFIA and Health Canada immediately if new information on the plant becomes 
available, a condition always included in our authorization letter.
Compliance monitoring of conditions of authorization by the CFIA is ongoing. For 
instance, with Bt corn, resistance-management programs are in place which we actively 
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monitor to determine levels of compliance. Also, we work with Crop Life Canada to 
monitor levels of compliance from their perspective.
Stacked events constitute a special case. After a PNT has been authorized for use by the 
CFIA, the plant can then be traditionally bred into new varieties. However, if two or more 
events are combined, PBO must be notified prior to intentional release, so that we may 
ensure that the conditions of authorization of the individual plant lines are compatible 
and that a “stack” isn’t likely to create a problem. PBO must notify the proponent within 
60 days of any concerns regarding unconfined environmental release of a “stack.” 
In Summary
Canada’s regulations are product-based, not process-based. We have authority within the 
regulations for departments to approve products derived from biotechnology after the 
completion of the required safety reviews, and—once authorized—products of biotech-
nology are not treated differently from other foods, feeds or crops.
Applicants should plan for 4 months or more from submission to authorization. 
Ideally, less time will be required, but, especially, if we are dealing with a product type 
that we haven’t seen before, allowance of more time is recommended. We have biology 
documents that become part of our assessment, so if you know we’re going to be seeing 
something completely new, the more advance notice we can be given, the better.
More information may be accessed via the website URLs shown in Figure 8. For novel 
foods, it’s Health Canada. For novel feeds, it’s the Animal Feed Division of CFIA. Plants 
with novel traits is the CFIA, and there’s a CFIA Agricultural Biotechnology site for 
direction to various other pieces.
Talk to the regulators early and often. That’s what we’re here for and we want the process 
to progress as smoothly as possible for you. Again, avoid US-centric submissions.
Figure 8. For information concerning novel foods
and plants with novel traits in Canada.
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Alan McHughen (University of California-Riverside, Riverside).  Patricia, thank you 
very much for your overview of the Canadian situation. I’m curious to know how many 
genetically engineered plants cultivated in Canada are not considered PNTs1, and so 
didn’t go through your approval system?
Patricia McAllister:  There are none.
McHughen:  Then, I’m confused about what your definition of a novel plant is. With Bt 
corn in the United States, of course we use event by event. It sounds like that’s what you 
do in Canada as well, which would seem to be contrary to the PNT concept. 
McAllister:  At this point, all genetically engineered products that have been put forward 
have met the definition of a plant with a novel trait. The ones we have that are more 
unique are the ones that we regulate that the US wouldn’t regulate. For instance, turf grass 
without question would have hit a novelty trigger in Canada. And we have sunflowers, 
lentils and wheat that are herbicide tolerant that were not developed through genetic 
engineering, and those ones are regulated in Canada as PNTs. So, we capture a broader 
number of products.
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McHughen:  Right, you capture more in terms of the mutagenesis and non-recombinant 
things. I recognize that and appreciate that, but I also thought that the point of the plant-
with-novel-trait product trigger was so that once you get an event through—a Bt corn, 
for example—the next Bt-corn event would not be considered novel. How do you then 
define the second and third and subsequent Bt-corn varieties as being novel?
McAllister:  There is certainly a lot of talk about where it will go, but at this point each 
one is triggering the regulations as it comes through.
McHughen:  Is there something in the trait? I’m confused about that now because I 
thought that the system was developed in Canada so that subsequent things that don’t 
have new traits would not be captured. What is the scientific basis for a new trait that 
is the trigger? 
McAllister:  I am unable to answer that question. I have been with this group since Sep-
tember and my job has mostly been issues management. A few things—like alfalfa—have 
created havoc for us. I was not part of the development of these regulations and I simply 
work with what we are given. But, believe me, our major players are frequently asking 
us, When are you going to the “me too” products—when you’ve already looked at a trait? They 
certainly can go into conventional breeding. We don’t have to approve individual varieties, 
but, if you are modifying your event, we are still going back and looking at it again.
Julie Svetlik (Texas A&M AgriLife Research, College Station):  I think Patricia already 
answered this question for me—thank you—so the question is for the US agencies. As-
suming a plant or product has cleared the regulatory process in your agency and has been 
authorized and has entered the market, are there procedures in place at your agency to 
reevaluate status if new data come out that indicate that the plant or the product is not 
safe for humans or the environment? 
David Heron:  I’ll go first since ours looks like once our hands are off, they are always 
off—but if new evidence demonstrates a risk as a plant pest, then we do have the authority 
to bring it back under the regulation. We have not seen that yet.
Robert Merker:  We have seen a number of instances in which new data have been brought 
back to us at some point or other, but it has always been data that do not change the 
final conclusion of safety.
Chris Wozniak:  Our statute is a bit different. FIFRA is a licensing statute, so as long as 
you want to distribute, sell or use that pesticide in the United States, then you are under 
the license, meaning you pay an annual maintenance fee, you have to supply reports on 
sales figures, etc. But you are also beholden to a clause referred to as “6(a)(),” where, if 
there are any adverse effects—and that is determined by the agency not by the individual 
so much—anything unusual has to be reported to the agency in a timely manner and we 
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maintain a database of what we call “6(a)() events” and determine whether they require 
follow up. In addition to that, because it is a license, all of the registrations have a term 
of expiration and these will vary. For example, with the Bts, part of it depends on the 
durability of the product. The product seen as being durable in terms of resistance to 
insects might get a 0- or -year registration. If it’s a single-trait product, it’s more likely 
to get a 3- or 4-year registration and, at those times, they are reassessed and they may 
enter what is called a re-registration or re-review process, where people basically look at 
the literature and look at what is known, and anything else that may have come up since 
the initial registration and then make a determination of whether data ars required. We 
have a process that is called “data calling,” where, if something comes up, we can request 
that information.
Robert Wager (Vancouver Island University, Nanaimo):  Each of you, in your own way, 
has mentioned that GM crops and non-GM crops with similar traits are regulated roughly 
the same way. My question goes to Cry proteins, and it appears to be that that’s not 
 always the case where you have significant regulatory requirements for a GM crop with a 
particular Cry protein engineered into it, whereas I don’t seem to see—perhaps I’m wrong 
on this—any real regulations involving using the in vivo whole bacterium expressing the 
same proteins and I’d like to understand if, in fact, that is true and, if so, why ?
Wozniak:  If you are speaking in terms of using either a spore or spore-plus-cell prep as a 
biopesticide—yeah, we certainly regulate those. We have both engineered and non-engi-
neered forms of Bt as well as dozens of other microbes for use as insecticides, nematicides 
and even some as herbicides. So I’m not sure why you are picking on Bt. Any microbial 
agent, whether it’s a virus, bacteriophage, protozoan, alga or fungus, that has a pesticidal 
claim associated with it—in other words preventing, destroying or repelling some disease 
or pest—is a pesticide under our law. I think, at last count, we have 97 active ingredients 
and from those stem hundreds of products.
McAllister:  From the Canadian perspective, those would not be regulated by the Canadian 
Food Inspection Agency, but would be regulated through Health Canada’s Pest Manage-
ment Regulatory Agency.
Bob Avant (Texas AgriLife Research, College Station):  Recently, the USDA said they are 
going to go into a full blown EIS evaluation of new genetically engineered events, and I 
would like to hear some conversation: does that really change much about what we are 
doing? Is it going to delay the process? The conventional wisdom is, anytime an EIS is 
required it costs millions of dollars, it takes years to do and it’s a good way of delaying 
things. Does it represent any change or is it just another hurdle we are going to have to 
cross to get down the path?
Heron:  As far as whether everything is going to require an EIS, no it won’t. An EIS, 
for those of you unfamiliar, I referred to as environmental assessments under NEPA, 
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the National Environmental Policy Act. If an agency cannot come to a finding of “no 
significant impact on the environment” when they do an environmental assessment, if 
they want to proceed with considering the action, then they can go to an environmental 
impact statement, which is a more involved process and, like the environmental assess-
ment, has public involvement. The agency has interaction with the public throughout 
the process. But, the fact that these are now being open for public comment on the 
process called “scoping” to see the extent of the environmental impact statement, it does 
not mean that it is going to happen for all. These were seen as issues that are very closely 
related and it would be difficult to consider them separately. The decision on whether 
federal agencies choose environmental impact statements or environmental assessments 
is rather complex. It involves legal reviews with the department, interaction with the 
Council on Environmental Quality, which is a lighthouse that takes a look at NEPA and 
its obligations to federal agencies. Maybe that’s a long way of saying that no, this is not 
going to be the standard and yes, it is a more involved process.
Bill McCutchen (Texas AgriLife Research, College Station):  A scenario here for you to 
think about. What would be the steps if, let’s say, a spinoff company from Texas A&M 
or another university were put in place for a specialty crop whereby—and I know this is 
a big “if ”—if we had freedom to operate and we had a license for a previously approved 
herbicide and or Bt gene and we wanted to put that into onions or another vegetable, 
would we be required to go through the entire process again in terms of digestibility, 
allergenicity? Because, a big expense is the non-target organism piece—doing the types 
of tests that require, as you know, a lot of work and money. So, would it be possible to 
license from Monsanto or DuPont, let’s say a spinoff company for our university of a 
previously approved gene for herbicide and insect resistance and assuming we had freedom 
to operate for agrotransformation, etc., what would be required?
Heron:  We regulate organisms. We don’t regulate genes. Congress set out the definition of 
a plant pest, so that sets the parameters. When we are making a decision for non-regulated 
status it’s for the organism. It’s not for the gene. The information we may have in looking 
at a gene in another organism may inform our review subsequently but that would not 
mean that you don’t come in if you take a Bt or herbicide tolerance cassette and put it in 
onion instead of cotton. The onion would still come through us.
McCutchen: I understand that. I’ve been through this process many times in a former 
life, but if this has already gone through tox tests, non-target organisms, from a scientific 
standpoint—I understand there is law and regulation—why can’t we get together and 
streamline some of these things and help our producers help themselves? Can we work 
across agencies and with institutes to develop new products that aren’t so new but are in 
different vehicles if you will?
McAllister:  From the Canadian perspective, if we are more familiar with things it can 
make it easier. It’s how you can communicate your story, but, in reality, you would need 
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to speak directly to our specific assessment group. If it’s in a new plant, it’s definitely going 
to be assessed as a new product, but whether you’d have to redo the allergenicity data 
and the other toxicity data for genes that we are very familiar with, that would require a 
very specific discussion.
Wozniak:  Where it truly is the same gene and not some modification or a similar type 
gene, there is a process called “data compensation” where you can compensate the com-
pany that originally submitted supporting data. So that’s one avenue. In terms of the 
environmental side of the equation where you are looking at non-target effects, if you 
are changing the exposure scenario then it is likely you are going to have to look at some 
data generation for specific pests. In other words, the beneficial insects you choose that 
might be representative of a corn field in Iowa may not be the same as that represented 
by an onion in Texas. So that would be up to the risk assessor to determine what types 
of studies would have to be generated de novo and which ones could be bridged. We do 
occasionally bridge data, particularly so with microbial agents, but certainly it’s plausible 
with some of the PIPs. Now, as for the larger question in getting away from event by 
event transformation even within the same species, you can take a PIP that’s been regis-
tered in field corn and do the appropriate crosses, you know, typical sexual, traditional 
breeding crosses, move it into popcorn, and you are covered as far as the tolerance goes 
and all that. However, one of the arguments that has been made—and I’m not saying I 
agree with it 00 per cent—but if you generate a new event through transgenesis, either 
through Agrobacterium or the gene gun or whatever your mechanism, then your position 
within the genome, as far as where your transgene inserts, can influence the pattern of 
gene expression. So, in our case, one of the things that we look at relative to non-target 
effects but also just for the overall accumulation of your pesticidal substance, which needs 
to be recorded on a confidential statement, that requires an assessment. You know, is it 
identical just because you used the same promoter and the same open reading frame and 
the same termination sequence if it’s in two different crops or even within the same crop 
but it’s in two different positions? That’s the crux of the argument. At what point do 
you say, Well, we’ve seen this enough and the likelihood of that happening is small enough, I 
think that, in some respects, is what we are moving toward, but as far as going between 
different species, like, say, onion and corn, that’s a larger question.
Merker:  I defer to EPA on pesticide issues, but, for food and feed safety, if we’ve seen the 
proteins before, essentially we’ve seen the proteins before. The allergenicity assessment 
and the assessment for toxicity would be the same and could be done either by incorpo-
ration by reference or by summarizing what information we had seen before and where 
we could find it. Certainly we wouldn’t make somebody do that over again, and, as a 
for instance, if you were dealing with our favorite antibiotic resistance marker, NPTII, 
we actually approved that as a food additive, and even if you were using it in one of the 
crops for which it wasn’t approved, if you pointed us to that approval, certainly we would 
want to know the specifics of how it got integrated, but the safety of the protein could 
be referred back to our regulation.
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Wozniak:  One thing I want to clarify—just to make sure—there is a difference between 
what’s ruled under FFDCA like the tolerance action, versus what’s under FIFRA, which 
would cover, for example, non-target effects but also human health effects. So, for example, 
if you are working with CryAc as your insecticidal protein and it’s already covered by 
a tolerance, then you don’t have to redo the studies that are associated with that toler-
ance. It could be an oral tox test, allergenicity, etc. However, on the FIFRA side, if the 
concern is more about exposure of non-targets then that is where the data compensation 
would come in—where you would likely pay another company to utilize their previously 
submitted and accepted data.
Charles Rinerson (Texas AgriLife Research, College Station):  Dr. Merker, the basis for 
the consultation and regulation you were talking about earlier was based on the FD&C 
Act. Do you see a different consultation process or considerations if the plant or product 
were regulated under the DSHEA Act2?
Merker:  Certainly, if it comes in for something in a dietary supplement, and there has 
been a history of exactly one of those coming in. It may fit the criteria for consideration 
as a new dietary ingredient and it would be the substance going into the dietary supple-
ment that would need to be looked at, not necessarily the whole crop.
Roger Beachy (Global Institute for Food Security, Saskatoon): I’d like to take us back 
just a bit—and maybe this is too big a question to answer today—but, in 987, when 
the coordinated framework was developed, it was expected that there would be a full 
reexamination of the coordinated framework in some period of time, 7 to 0 years, and 
that we would learn from those 7 to 0 years about what to go forward with. In fact, 
some of the original challenges were to try to eliminate regulations based on what we’d 
learned in the first 0 years. We haven’t done that yet. We’ve learned more about what to 
regulate, what we think we know about to regulate, but in fact, regulation is not simpli-
fied, it’s made more difficult because we keep adding more on each time someone raises a 
possibility of potential damage or danger. When is it time to re-evaluate the coordinated 
framework and come up with a new framework? We are now more than 0 years in and 
we haven’t re-evaluated. When is it time to take the learnings of science since 987 and 
redo the coordinated framework based upon what we’ve learned and what we expect 
to see in the following two or three decades? I ask the question because most of us feel 
that, given what happened in 987— and I was involved in that process too—but Nina 
Fedoroff and others have reminded us that this is the way that we would start, but we 
expected to deregulate it more fully and make it easier to innovate, and it’s not. I do 
 appreciate the learnings and the ability to cross back and go back to old data and restate 
them. It should help Texas A&M to simplify, but it’s still a more expansive program than 
had been imagined in 987.  Can you help me understand where we might be in 5 or 
0 more years?
2Dietary Supplement Health and Education Act.
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Merker:  I don’t think—from FDA’s point of view—that it really has changed. I actually 
think that our 99 policy is pretty flexible. Certainly, it’s a situation where if the 
 developer wants to seek us out they can and we are available. And the issues are going to 
be the same: safety and nutrition. As long as those get covered we are happy to consider 
things. We actually didn’t think we would be doing this for this long, but the developers 
seem to want it, I think mainly for international trade issues, and the public seems to 
want it as well.
Heron:  Yeah, that’s an interesting point because, actually in 99, OSTP3 put out a 
second document that was actually calling for what you are saying here Roger, to dial 
it back wherever possible. What I have seen is that unless there is a sustained push in a 
certain direction it doesn’t happen, so the status quo stays in place. And so, at the regula-
tory agencies, we try to run the mousetrap as best we can whether the mousetrap itself 
has a faulty design, that has to come from outside. I mean, this administration with the 
Holdren memo, has restated the principles of the Reagan administration. But, in terms of 
what it actually means in practice—and this is where the distinction between what is in 
the law and what is placed in regulation and how that works—you can see now that this 
whole premise of presumed innocence of things developed through genetic engineering 
has been turned on its head, and so now we are trying to prove a lack of harm, which we 
all know is impossible to do.
Wozniak:  Certainly, I understand your frustration with the lack of change. I think Dave 
Heron makes an excellent point though, in that it is the actual practice of what is per-
formed, in terms of regulation or deregulation or consultation, depending on the agency. 
But, in terms of the coordinated framework, I don’t think it’s a bad idea to reassess that. 
One of the decisions that was made was to use existing statutes to cover the bases and 
I’m not going to voice an opinion one way or the other on whether that was a smart 
idea, but what I will say is that some of the changes that you are talking about require 
legislative action and have to be done on Capitol Hill, not at EPA or APHIS or FDA, 
unfortunately. And I think that’s part of the frustration, but, again, Dave’s point: those 
changes require forward-thinking people who aren’t afraid to take some risk and perhaps 
some backlash from the public in terms of making some bold moves. Now, one of the 
things that we have heard about—and it’s very obvious to everyone in this room—the 
lawsuits, for example, that APHIS has had to endure over these last years are always part 
of the battle. If you try to be progressive and say, Well, we’ve seen this enough we don’t 
 really need to regulate this, there are going to be a whole bunch of people on the other side 
who say, Oh yes you do. The Federal Register notices get 50,000 to 60,000 comments, etc. 
But I think you are right that it certainly is time to move forward and use some of the 
familiarity we have with these products such that, even if we do regulate them, we do 
it a much reduced level—basically you would be more cataloging them than regulating 
them. Again, it’s going to take somebody with a bold heart who is willing to take a beat-
3Office of Science and Technology Policy.
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ing to move that forward. Certainly, there is still the issue—although I don’t think it’s an 
insurmountable one—where I talk with a lot of foreign governments and it makes them 
very nervous to think that we’re going to have certain things that aren’t really scrutinized 
properly, but some of the companies also tell me, Don’t worry about that. We’ll deal with 
those individual countries in terms of trade. We’ll work around whatever their requirements 
are. I want to mention one of the proposals we are considering, or reconsidering, and 
that is a cisgenic exemption with cisgenics defined a little bit more broadly than perhaps 
is done in the literature. We are in the early stages of reviving that, which is part of a 
previous data-requirements rule that never got off the ground a few years back. So, that’s 
one instance where, I think, philosophically, it’s a major move for the agency to consider 
a product of recombinant DNA that doesn’t require regulation. It’s not going to solve the 
problem for everybody for sure. Those people who still rely on basic transgenesis with 
foreign genes—it’s not going to help them one iota, except in terms of moving that ball 
forward and saying, Here’s something where we don’t have to be concerned just because it’s 
genetically engineered.
8
Session 3-2: The regulatory Process
and technology access for Specialty Crops
(continued)
Getting to Yes: 83
How to Achieve Pre-Market Approval
Scott Thenell
Cultural Shift: Innovation is a Process 95
Peter Schuerman
Intellectual Property for Crop Transformation: 03
A Continuing Saga for Agricultural Innovation in the Public Sector
Alan Bennett
Q&A 7
8 Biotechnology and North American Specialty Crops
83
Thenell & Associates is a regulatory consultancy that provides expert advice and support 
to companies that make and market genetically engineered plants for food, fiber or fuel. 
We help clients plan and execute product approval strategies and support their R&D 
programs from discovery through commercialization. Our clients include start-ups, early 
and late-stage product developers, mature multi-nationals, and universities. With more 
than 0 years of practical experience working with US federal and state regulators, we’ve 
helped two dozen companies advance their commercialization goals. 
We also do some biopesticide and biofertilizer work, and have also done work with 
genetically engineered microorganisms for industrial purposes. In 006, together with 
three colleagues in the United States and Europe, I co-founded the Agricultural BioTech 
Regulatory Network. The ABTR Network is a group of regulatory professionals serving 
the agricultural biotechnology industry from product concept through commercialization. 
It’s a network of well qualified regulatory experts who specialize in genetically engineered 
plants and plant products. Today, we have members and affiliates on four continents 
serving major ag-biotech markets (Figure ). Through the ABTR Network, we are able 
to offer clients global understanding and support typically found only in multi-national 
companies. We need to be able to offer this perspective because what is cultivated here 
in the United States doesn’t necessarily remain here in the United States.
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Specialty Crops: Premarket Approval
It is not uncommon for scientist who have deployed genetically engineered traits in spe-
cialty crops to fail to initiate the process of obtaining premarket approval, or—having 
initiated the process—have failed to complete it. Commonly heard reasons for cessation, 
from university research directors, include: 
• “It’s not the objective of our research. We are here to do the proof-of-concept, the 
discovery, to fulfill the obligations of our grant without the intent to commercial-
ize. We publish papers and then move on to the next grant.”
• “We don’t know where to start.”
• “It’s too complicated.”
• “It’s too expensive.”
• “There are intellectual property constraints.” 
• “We have concerns over product liability and stewardship—potential for lawsuits.”
• “Without a commercial partnership, there is no obvious outlet for the discovery.”
• “No mechanism exists within my university to commercialize.”
Taken together, these are daunting impediments. On the other hand, with good planning, 
the regulatory issues are not overly complicated. I will describe some of the lessons I’ve 
learned from working in ag-biotech regulations since 990 in hopes that it will de-mystify 
the product-development process and demonstrate that pre-market approval for genetic 
traits produced by public-sector researchers is possible. My intention is not to make you 
an expert, but to convince you to hire the best help you can afford when you need it.
Where We Are and How We Got Here
By some measures, biotechnology has been remarkably successful. Since commercial 
deployment in 996, global acreage has increased at double-digit rates for 7 years. It 
has been claimed that agricultural production has increased by nearly $00 billion in 
that time. Myriad environmental benefits have accrued from changes in weed and insect 
control measures, from conservation tillage, from reduced mycotoxins, etc.
Data published by the International Service for the Acquisition of Agri-biotech 
 Applications (ISAAA) indicate that 8 countries have approved some 35 unique crop/trait 
combinations to date (Figure ). And although specialty products were the very first ap-
provals, the vast majority of today’s production is limited to variants of two genetic traits 
in commodity crops. Specific numbers are hard to come by, but I submit that specialty 
crops account for less than one-tenth of one percent of the 40 million acres of GM 
crops produced in the world today.
The power of this technology isn’t finding its way to green grocers’ shops and produce 
aisles; the regulatory environment is often cited as one reason for the dichotomy between 
agronomic and specialty crops. With divergent regulatory requirements around the world, 
premarket approvals have to be acquired country-by-country. Only certain countries have 
regulatory systems in place, and only some of these have functional systems. Furthermore, 
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Figure . Agricultural BioTech Regulatory Network.
Figure . Global GM-crop status.
pre- and post-market requirements vary considerably. Global registration is necessary 
because, as said before, many of these crops move in international trade. Specialty crops 
are not necessarily an exception. In the tomato industry, for example, fresh-market pro-
duce is the primary outlet, but, additionally, tomatoes go into processing. Similar crops 
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have components that become ingredients of foods that move in international trade, 
and issues come up needing regulatory approvals in other countries. Also, only certain 
countries have functional regulatory systems and certain countries have higher impedi-
ments to commercialization than does the United States. Internationally, regulations are 
not harmonized although there are some reasonably harmonized regulatory risk-assess-
ment criteria. The net effect of this is that when amortized over the thousands of acres of 
specialty-crop deployment versus the millions of acres in agronomic crops, certain of the 
regulatory costs make it prohibitive to deploy technology in specialty crops. For this and 
various other reasons, specialty crops lag behind. I would like to help change that.
Other global instruments have to be considered (Figure 3). The Cartagena Protocol 
established minimal requirements on trans-boundary movement and use of living modified 
organisms. It’s particularly important in less-developed countries that don’t have national 
legislation governing genetically engineered organisms. Established in 003, it’s based 
on the precautionary principle, and it has some additional issues concerning advanced 
informed consent before one initiates trans-boundary movement, as well as liability and 
redress provisions for environmental contamination that are still being worked out. As 
of 03, the Cartagena Protocol has been adopted by 65 countries. But the United 
States, Australia and Canada are not signatories. Risk-analysis principles—pertaining to 
genetically engineered food—were promulgated under Codex Alimentarius also in 003; 
they are internationally recognized as meeting WTO commitments. Those principles are 
generally consistent with US safety standards and with the Biosafety Protocol. In addition 
to the WTO agreements, a number of bilateral agreements are in place to facilitate trade 
including trade in genetically engineered foods and feeds. The WTO agreements have 
been invoked in trade disputes between members with varying success.
Upcoming negotiations between the United States and Europe will probably include 
genetically engineered foods.
US Coordinated Framework
In the United States, we operate under the Coordinated Framework for Regulation of 
Biotechnology Products. Three federal agencies share primary responsibility for assur-
ing safety of genetically engineered plants and plant products, in accordance with their 
respective legal authorities:
• USDA-APHIS (US Department of Agriculture-Animal and Plant Health 
 Inspection Service)—safety of genetically engineered organisms in agriculture and 
the natural environment,
• FDA (Food and Drug Administration)—safety of foods from genetically 
 engineered organisms used for food and feed,
• EPA (Environmental Protection Agency)—safety of pesticidal substances 
 produced in genetically engineered plants or microbes.
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Figure 3. Other global instruments.
USDA-APHIS1 is the agency likely to be encountered initially when developing and 
deploying a genetically engineered plant product, in terms of environmental safety, field 
testing, and/or interstate movement. Bob Merker2 with FDA mentioned early food-safety 
assessment for novel proteins that are introduced in field testing so that, should there 
be any adventitious presence, the food/feed safety concerns would already have been 
addressed, at least at a preliminary level. And Chris Wozniak3 with EPA talked about 
the safety of biopesticides and plant incorporated protectants. This comprehensive—if 
somewhat complicated—system has worked fairly well since the mid-980s, although it 
may be argued that improvements are now needed.
Continuing Controversies
However, even after two decades of commercial use, many recent headlines have focused 
on controversies around the deployment of genetically engineered plants (Figure 4). 
Litigations over stewardship lapses and disrupted trade have cost technology providers 
hundreds of millions of dollars, with lawsuits over intellectual property rights and over 
government approvals, some of which have made their way to the Supreme Court. As a 
result, approval times for genetically engineered crops have ballooned from approximately 
6 months to over 3 years. Happily, in 0, USDA implemented process improvements 
to reduce approval times considerably. 
1Pages 4–48.
2Pages 5–60.
3Pages 3–39.
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Figure 4. Recent headlines.
Labeling
Controversy continues around labeling. In 0, Californians failed to approve a labeling 
initiative at the ballot box, and, more recently, the Senate struck down a labeling amend-
ment in their version of the Farm Bill. Some people remain deeply passionate about the 
need for labeling of foods with genetically engineered ingredients although no health or 
safety reason justifies it. The advocacy group, Center for Food Safety, claims that 5 states 
have introduced bills to require labeling or restrict genetically engineered foods.
All of these issues play some role in the decision to deploy a genetically engineered 
trait in specialty crops or not.
Product Development
Despite all of the challenges, genetic engineering still holds tremendous potential for 
improving agricultural yields in the face of continuing challenges from pests and dis-
ease, climate change, and population growth. So the question is: How does one deploy 
this technology and bring a genetically engineered product to market? The process involves 
multiple disciplines working to address various interests that are, oftentimes, not well 
aligned (Figure 5). The regulatory piece is just one discipline, the purpose of which is to 
meet all domestic and international approval requirements premarket in those countries 
wherever one intends to cultivate, to export, or to otherwise market the plant product. 
The challenge, of course, is to coordinate these efforts to achieve timely completion and 
enable product introduction to the greatest extent possible. Fulfilling regulatory require-
ments is often critical to success.
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Figure 5. Product development–.
Figure 6. Product development–.
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In the product-development scheme, the major technology providers have adopted 
some type of systematic approach to creating new crop traits (Figure 6). The process can 
be organized in stages with defined criteria that must be achieved before advancing to the 
next stage. By adopting a system of “stages and gateways,” the process is more disciplined, 
thereby helping management of risks and costs at each stage. It can transit from a gene-
discovery phase through proof-of-concept, often in a model crop and ultimately in the 
crop of interest. It moves into an early-development phase in which the trait and its utility 
are validated, generating pre-regulatory data for the crop intended for market. It advances 
to trait integration in other germplasm, with field testing to generate regulatory data, and, 
finally, into prelaunch activities, bulking up seed, and premarketing activities. Duration 
can vary. Success rate increases in accordance with decisions around event selection, and 
the number of transformants—the number of candidate lines—decreases until, at the 
end of the process, focus should be on one, maybe two, commercial events. By adopting 
this “stages and gateways” approach the process is more disciplined, and it helps manage 
costs and the risks at each stage.
Regulatory Activities
Each development stage has characteristic regulatory activities and defined criteria for 
passage to the next stage (Figure 7). The earliest stages involve preliminary analyses of 
the crop biology and the product concept, and looking at some issues that might occur 
with deployment of a particular trait in a particular crop species. At proof-of-concept, 
early work comprises evaluation of whether the active molecule or the technical effect 
has some human health or safety or environmental safety issue; also analytical tools and 
reagents are being developed, and protein production and characterization, particularly 
if additional animal testing is needed, for example. The early stages involve generating 
protein-safety data on the introduced traits—so-called “core-package” data—and sup-
porting field evaluations and testing. In the later stages, the heavy lifting begins from 
the regulatory point of view: a number of studies are needed to characterize and create 
safety data on the lead commercial transformation event—so-called “event package” 
data—assembling the registration dossiers and managing their submissions. Critically 
important decisions must be made before entering this phase, as the costs of generating 
data increase dramatically and the cost of failure at this stage can be high. Molecular 
characterization is involved as are compositional analyses, agronomic studies, effects on 
non-target organisms, animal-performance studies, and determinations of environmental 
fate and toxicology. Finally, at the prelaunch stage, dossiers are compiled and regulatory 
submissions are managed through to completion.
Much has been said about the high cost of achieving regulatory approval for genetically 
engineered crop traits. Published numbers range from $6 million to $5 million for global 
approval. A recent study quoted $35 million for global approval. Although these costs 
are real, they are inflated inasmuch as they reflect the fully loaded costs of supporting 
expensive infrastructures to support global deployment. In fact, regulatory approval can 
be obtained for considerably less—at least in order of magnitude less.
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Figure 7. Regulatory activities.
Product Design
Early in their deployment, novelty seemed to drive introductions of genetically engineered 
foods. However, it soon became clear that market pull trumps technology push. So when 
asking whether to move forward with the genetically engineered specialty crop, critical 
questions are:
• Why this?
• Why here?
• Why now?”
The market needs to be assessed efficiently and effectively. It is vitally important to “map” 
stakeholders to gauge market acceptance and vulnerabilities. Products can achieve techni-
cal success, but fail in the market because of lack of acceptance somewhere in the value 
chain; it can be an expensive lesson.
Regulatory guidance in product design is important (Figure 8). There are myriad places 
to stumble, but they are largely avoidable vis-à-vis regulatory activities. With expert and 
timely guidance, significant savings are possible in the cost of a regulatory dossier while 
maximizing the chance of timely approval. On the other hand, I have seen examples of 
products designed without regulatory input, mainly proof-of-concept projects: “We threw 
some genes in the plant, we got a great phenotype, so let’s make it a commercial product.” 
This can cause significant regulatory heartburn due to poor construct design choices or 
incomplete information. Seeking out regulatory guidance in the early stages is likely to 
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Figure 8. Regulatory guidance in product design.
be a good investment. Strategic and practical regulatory decisions should be considered 
in product design (Figure 8), including:
• New breeding techniques like precision genome editing can lead to products that 
are outside the scope of certain regulations and their associated compliance costs.
• For other genetic modifications, early regulatory input on the source of genetic 
elements, construct design, transformation and selection methods can reduce 
regulatory data costs later on.
• Conducting a detailed regulatory assessment, at the product-concept or the 
proof-of-concept phase of product development, is highly recommended.
A good-quality assessment by a consultant will identify the prospective data set, the costs 
involved, and the timeline to be expected. Once you’ve “pressure” tested your product 
design with an expert, it’s a good time to consult with your regulatory authorities.
Representatives of USDA-APHIS, FDA and EPA are an excellent resource, and each 
federal agency has a mechanism by which a developer can meet to discuss their project 
development. The purpose of such meetings is largely to confirm the regulatory strategy 
and inform the regulator(s) of the project. It is also an opportunity to confirm the scope of 
data necessary for pre-market approval before commitment to expensive studies. Depend-
ing on how novel is the crop trait or technique is to the particular agency, there should 
be several consultations during the course of product development (Figure 9). 
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Figure 9. Consultation with regulators.
Analytical Tools
Analytical tools and reagents are a vital part of preparing the “core-package” data for 
pre-market approval. Consultation with regulators is particularly important if novel 
methods have to be developed, to produce the right kind and quality of safety data. One 
also needs to make sure that these methods are validated in the matrix that you’re using, 
and under actual conditions. Good laboratory practices (GLPs) can be expensive. At a 
minimum, work by contract labs should be conducted with GLPs, including analytical 
chemistry, animal testing, compositional studies and nutrient analyses. Whether field 
work is hired out or is performed within an intramural non-GLP research program, it is 
vitally important to maintain careful records for regulatory compliance.
At each developmental stage, the transformation events created must be screened for 
various characteristics and only those meeting specifications selected so that they will 
eventually gain regulatory approval. Approval can be delayed or even derailed because 
they have not had the appropriate selection.
For regulators, transparency is particularly important. They like to see peer-reviewed lit-
erature describing performance and safety of a new trait. It contributes to their familiarity, 
and it can make their decision making appear not solely based on proprietary company 
data. Accordingly, publishing results of efficacy and other testing is recommended.
Stewardship
Good stewardship—vital to obtaining pre-market approval of genetically engineered 
crops—may be thought of internal quality-assurance procedures. Stewardship practices 
are largely, in my view, internal quality assurance procedures applied at each stage of 
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 development to ensure product integrity throughout the lifecycle. It’s important to main-
tain unique identifiers and meticulous records to ensure that the commercial product 
is nothing more or less than it is intended to be. Although good stewardship practices 
cannot eliminate human error or natural phenomena, they go a long way to minimizing 
events that lead to “front page news”; shortcutting can be costly.
In Summary
The challenges involved in bringing a new genetically engineered crop trait to market 
can be daunting. There are many possibilities for things to go terribly wrong. Regulatory 
expertise will not necessarily solve all of the impediments to achieving market success. 
On the other hand, with careful planning, regulatory approval doesn’t have to be an 
insurmountable impediment.
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Presentations at this conference demonstrate that the commercialization of genetically 
engineered traits in specialty crops is a complicated process. Furthermore, university 
researchers are more accustomed to thinking about innovation as an event rather than as 
a process. Within Texas A&M AgriLife Research we are taking on the challenge of how 
to look at innovation as a process and how to steward innovation beyond simply publish-
ing, to create opportunities for our industry partners. In so doing, we are addressing a 
fundamental problem: the weakness of the pipeline.
University Culture
We are not trying to change the university, but rather to change the boundaries of what 
it can do, because university culture is vital and important for society. For us, innovation 
is about exporting something—our product. Every transaction with the world is about 
innovation. Resources come in; innovations go out. Although research is not a simple 
matter, conceptually it’s simple. Conducting research is complex. When research results 
are generated, they are interpreted and captured in a form that can be communicated as 
a channel to the marketplace. Principal investigators are a type of entrepreneur in that 
they convert resources from their stakeholders, federal and state agencies for the most 
part, and turn them into products: publications, which create professional success. It’s a 
well understood process.
Cultural Shift: Innovation is a Process
Peter Schuerman
Texas A&M AgriLife Research
College Station, Texas
Peter.Schuerman@ag.tamu.edu
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Corporate Culture
For corporations, innovation is about a product or a service. Regarding plant-biotech-
nology traits, the method of production is far more complex than just research. Even 
when a new trait has been evaluated and deregulated—having gone through the regulatory 
 approvals process—it still has to have a channel to the marketplace which involves having 
freedom to operate, involving patenting, and thorough understanding of the marketplace. 
It’s a dynamic process. 
The Contrast
Contrasting the two, one has a fairly quick turnaround whereas the other is like a slog 
through mud. The challenge for universities is to figure out how to be part of this whole 
process. Dennis Gonsalves1 talked about his work in terms of a public-sector anomaly. 
I give him a great deal of credit for having the fortitude to take on that task. A lot of 
researchers, not just those developing in plant biotech traits, are unwilling to face the 
challenges involved in commercialization. Publishing papers is a much more immediate 
fix. There’s nothing wrong with publishing, but if we are to work in plant biotechnol-
ogy, we should be ready to take on the challenge of being good stewards to the point of 
translating valuable opportunities to industry partners.
Universities: Thinking Differently
You cannot bring damaged goods to the game with industry. If a research result has been 
published, the ability to obtain patents is damaged, affecting the investment opportunity. 
The high cost of investment to obtain deregulation has been discussed by other speakers. 
Scott Thenell2 mentioned that the expense may be reduced by an order of magnitude; 
nevertheless, a lot of money would still be involved.
Criticisms leveled by the public and NGOs against genetically engineered crops 
 include:
• Big chemical companies are marketing these for profit.
• They are not in the best interests of consumers.
Big chemical companies are involved in these projects, because commercialization requires 
commitment and significant investment over a long period of time. On the other hand, 
if we can stand behind the traits that we’re developing, there’s an opportunity to build 
university/industry trust.
Why should universities be involved in this beyond publishing research papers? In 980 
the world changed as a result of the Bayh-Dole Act (BDA), which permits a university/
small business/non-profit institution to use federal research funding to pursue ownership 
of an invention; prior to the BDA, federal funding obligated inventors to assign inventions 
to the government. Universities responded by forming offices for intellectual property 
1Pages 37–46.
2Pages 83–94.
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management and technology transfer, which resulted in the formation of Association of 
University Technology Managers (AUTM), the first incarnation of which was the Society 
of University Patent Administrators (SUPA). At the time, they believed the important 
thing was to file patents, and this thinking set the stage. As a result, we now see universities 
carrying huge portfolios of unlicensed IP because patenting is the priority.
This is still a new process for universities, but it is endorsed by Texas A&M, which has 
the following mission statement:
To provide education, conduct research, commercialize technology, offer training, 
and deliver services for the people of Texas and beyond through its universities, 
state agencies and health science center.
The mission statement clarifies the importance of commercialization of technology, which 
is a consideration toward tenure in the Texas A&M University system.
Working Assumptions
We have the legacy of viewing innovation as a researcher-initiated and -driven event. 
Now the “eureka” moment is viewed as justification for commercialization. Often, the 
first thing that the researcher does, to ensure compliance with federal laws, is to go to the 
website and start filling out a form to disclose the invention. The next order of business 
is to file a patent and license it to someone and obtain a “commercialization” notch in 
the belt. This eventuality may not happen very often, but it’s a common framework, a 
baseline expectation; it is what the BDA says should happen. 
The Reality
On the other hand, this doesn’t fit well for biotech traits, because nowhere in this process 
have patenting and partnering strategies been developed. Universities do not typically 
engage in freedom-to-operate analyses, which is something that companies often have to 
deal with. Certainly, university researchers don’t think about freedom to operate when they 
are putting together gene constructs. We may receive an invention disclosure on a new 
trait composed of pieces and parts from six other collaborators, provided under individual 
material transfer agreements (MTAs) that preclude commercialization; complex conversa-
tions may be needed if the invention is to see the light of day. We have a distressed asset 
at that point, which is, unfortunately, not uncommon across universities.
A problem here is that universities are places for researchers who have decided that—for 
whatever reason—they don’t want to work in industry. Traditionally, professors have 
run self-directed programs of research within the support structure that the university 
provides. But, this is changing. Now we expect researchers to not only be experts in their 
fields, but also to be educated in commercialization and partnering with industry, which 
is unfair. My hat is off to productive scientists who have had the fortitude to negotiate 
the process of gaining regulatory approval. 
Many times, I have been approached by scientists with new, useful transgenic plants 
that they now wish to patent and on which they initially published data a couple of 
years before. In contrast, the people in the university patent office are less interested in 
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immediate usefulness than in whether the invention is novel and non-obvious, in which 
case they would have patented the invention two years before. Different ways of thinking 
are involved due to how researchers are schooled.
On the subject of schooling, it is a false premise that researchers simply need more 
education on intellectual property. The concept of a talent agent is relevant: artists, au-
thors and athletes all have agents. In contrast, researchers don’t have agents; they are on 
their own. Historically, scientists haven’t needed agents, whereas they now have to face 
the challenges of getting transgenics deregulated and marketing related technologies. 
Strategies are needed to ensure that assets are not damaged inadvertently through actions 
that may seem very reasonable from a research perspective. They should not be expected 
to be skilled in all subjects.
Culture Shifting
Managing innovation is not just about filing an invention disclosure, getting a patent and 
licensing it. One of the things that people often don’t appreciate is that, at a very early 
stage, a new innovation is not separable from the innovator. Therefore, if a researcher is not 
interested in innovation, there should be no negative consequence. The university should 
still allow the advancement of knowledge through publication. Professors should not be 
dictated to, should not feel forced to do something they are not comfortable with.
On the other hand, that comfort zone should not be overemphasized. Scientists should 
be encouraged to look for opportunities to transfer their research vision into results that 
may change the world. An important element of that change is leadership. Those in leader-
ship positions should not be saying, “Commercialization is not that important. Working 
with industry is not that important.” Within the Texas A&M University system, high-level 
leadership espouses the philosophy that commercialization is important. 
Although it is clear that researchers need assistance, sometimes they are unaware 
of that need. Also, deeds speak louder than words; it is important for us not to just 
philosophize, but actually show results. In 006, what was then the Texas Agricultural 
Experiment Station—now Texas A&M AgriLife Research—hired Bill McCutchen, who 
not only had industry experience but also had a track record as an innovator and as a 
researcher (Figure ). He was exactly what Texas A&M AgriLife needed to be able to 
effect the culture change.
Shortly after joining AgriLife, Bill hired Bob Avant (Figure ) to head up the bioen-
ergy effort, which is a pilot program to explore the concept of working with industry in 
 different ways. It has been enormously successful, and has matured such that we now have 
a corporate relations program. Bob has assembled a team who now work with industry as 
project managers and who act as intermediaries between our industry partners and our 
scientists who focus on research, and so we have project managers who mediate deliverables 
and assist in communication, because sometimes some translation is necessary.
In 007, I joined as the Director of Innovation Management and transformed the 
Office of Technology Commercialization as a liaison with Texas A&M AgriLife Research 
(Figure 3). I came from UC Berkeley where I’d had the opportunity to form the Industry 
Alliances Office, which tripled industry support for Berkeley in the first year. The simplest 
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Figure . Leadership in innovation–Bill McCutchen.
Figure . Strategic hire–Bob Avant.
way to describe what innovation management is at a university is to say that it’s the same 
as business development anywhere else. We have created three integrated teams:
• Innovation Management
 — They help researchers recognize opportunities and advance those opportuni-
ties through strategic planning.
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• Corporate Relations
 — They foster strategic partnering so that, instead of thinking about the rela-
tionship between industry and academia as just a way of outsourcing some 
research tasks, they create audacious collaborative projects to make exciting 
things happen.
• Technology Commercialization
 — Protecting intellectual property and assisting licensing, understanding that 
they need to focus; every time we say “yes” to something that isn’t any good, 
we are saying no to something that is. By setting priorities, they are masters at 
creating win-win arrangements with our industry partners.
Value Generation
From 003 to 007, things were pretty flat, but the creation of resources and infrastructure 
within Texas A&M AgriLife has met with success since then (Figure 4). The bar graph 
shows engagement from outside. The line graph shows engagement from inside.
There is opportunity for continued improvement; we’re still innovating in how we 
manage innovation, but we think that we are on the right track with an infrastructure 
that supports researchers. The first questions we have for them are:
• “What is it you’re trying to do?
• “What is your vision?”
• “How are you trying to change the world?”
And we are asking our industry partners:
• What is it that’s keeping you up at night?
• What are you trying to achieve?
Figure 3. Strategic hire–Peter Schuerman.
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Figure 4. Generating real value.
Schuerman
The university is vast with much going on; it is impossible to keep track of it all. It’s like 
Google; we invite industry: “Give us some search terms. Tell us what it is you’re looking 
for.” Then we search within the university and put things together in a way that would be 
an impossible task for an individual researcher to take on. We broker these relationships. 
We identify opportunities, and then we make sure that our partners are being taken care 
of and we make sure that our researchers have the opportunity to participate in audacious, 
ambitious projects from which amazing things develop.
Texas AgriLife Research, having assembled the personnel and resources to steward 
traits from discovery to commercialization, is now the number-one Texas A&M System 
member for disclosures, licenses and royalties.
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Figure  shows Cohen and Boyer’s fundamental recombinant-DNA patent, issued in 
980. They were founders of the startup company Genentech. The patent was managed by 
Stanford and the University of California together. In a climate like today’s, it might have 
been licensed exclusively to Genentech. If it had, how many biotech companies would there 
now be?: one! In California alone, there are ,600. This was licensed on a non-exclusive 
basis for a very nominal charge. Such enabling technologies can support entire industries 
if they are widely available; otherwise, they support a very narrow base.
Figure  provides a snapshot of the intellectual-property landscape in agricultural 
biotechnology a few years ago. Pie A shows the landscape across the patent office as a 
whole, with approximately .5 percent assigned to the public sector. Pie B shows a very 
different landscape for ag-biotech, with a few large players with large intellectual-property 
portfolios. It has been speculated that the management of these intellectual-property 
portfolios has played a part in producing an industry that is relatively concentrated in a 
few players. Another different feature is that there is a large public-sector slice in Pie B, 
which is highly fragmented across universities (Pie C).
This gave rise to the formation the Public Intellectual Property Resource for Agriculture 
(PIPRA1) by the Rockefeller Foundation: could it take this public-sector portfolio and 
do something interesting with it—use it in strategic ways to enable not only the public 
sector but enable industries also?
Intellectual Property for Crop Transformation:
A Continuing Saga for Agricultural Innovation 
in the Public Sector
Alan Bennett
University of California
Davis, California
abbennett@ucdavis.edu
1PIPRA enables access to public innovation. PIPRA supports innovation in agriculture, health, water, and energy 
technologies. In collaboration with 50+ universities and research centers and a pro bono attorney network, 
PIPRA provides intellectual property rights and commercialization-strategy services to increase the impact of 
public-sector innovation, particularly for developing countries and specialty markets.
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Figure . Cohen and Boyer’s landmark patent for “producing biologically functional 
molecular chimeras.”
The first thing that the Rockefeller Foundation asked of PIPRA was to look at enabling 
technologies—the vectors, promoters, selectable markers, transformation methods, in-
cluding Agrobacterium, that can link novel traits with good germplasm. The request from 
the Rockefeller Foundation was to examine the public-sector portfolio to see if we could 
create something that has freedom to operate and could be widely used.
We started the process at the Danforth Center in St. Louis. The panel of experts who 
met comprised plant biologists and lawyers. The objective was to define applicable tech-
nical, legal and regulatory design parameters, similar to a standard-setting process that 
would be used in forming a patent pool in the electronics industry. The criteria drawn 
up included:
• Agrobacterium-mediated was preferred
• A wide range of promoters
• Clear of intellectual property (IP) blocks in the United States and elsewhere (the 
most essential feature)
• Plant products should be marker-free
• Desirable to have the possibility of “all plant” integrations.
We went through a process of gathering freedom-to-operate opinions from an attorney 
network who contributed their time on a pro bono basis, and then to define terms of 
technology and corporation into a patent pool. We formed a patent pool around these 
technologies, developed a transformation system, and published it (Chi-Ham et al., 
0). It has been distributed to a number of public-research institutions in the United 
05Bennett
Figure . Recent intellectual property landscape in agricultural biotech.
States and internationally as well as to companies. Currently, it is the basis for seven trait 
incorporations: three that are essentially humanitarian products for Africa funded by 
USAID, and four commercial traits. Furthermore, the system has been used to generate 
a number of commercial events that are now in later-stage field-testing.
As mentioned, the published transformation system is Agrobacterium-based, an aspect 
on which the landscape has changed. Figure 3 shows the timeline of a broad and important 
patent application on Agrobacterium, filed in 983 not only in the United States but in 
many other countries as well. At that particular time, in the rest of the world, patents 
expired 0 years after application. So, in the rest of the world this patent has expired. 
However, in the United States under the pre-995 law, patents have a term of 7 years 
from issuance, and so it will be in force in the United States until 09.
When we developed these vectors, it was during a period when there were no broad 
Agrobacterium patents. The ones that had existed had expired and this particular one had 
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Figure 3. Over 9 years of prosecution. Anticipated expiration date:
September 5, 09.
not yet been issued. And so, this is where the landscape has changed. This very broad, 
well deserved, patent was issued to Monsanto on September 5, 0 (Figure 4): Geneti-
cally Transformed Plants. Filed originally in 985 as a continuation of an application filed 
in983, the patent was issued in 0, and, as discussed above, will stay in force until 
09. University researchers who use Agrobacterium to transform dicots are infringing on 
this patent. On the other hand, Monsanto is offering a free license to academic institu-
tions to use this methodology, which they intend to enforce. Infringing researchers are 
likely to hear from Monsanto. This raises the issue of the terms of that license. In fact, the 
conditions are reasonable and we have been working with Monsanto to improve them.
Figure 5 shows the scope of claims. It talks about genetically-transforming dicots by 
contact with Agrobacterium and incorporating Agrobacterium T-DNA borders; so, it’s 
very broad.
Inventing Around
The broad coverage (Figure 6, arrowed fields) has prompted examination of prospects to 
“invent around” (Figure 6, “X”). There may be opportunities to replace Agrobacterium 
with other bacterial genera. It talks about T-DNA from Agrobacterium. This suggests there 
may be opportunities to invent around utilizing either P-DNA or, potentially, synthetic 
borders. In fact, alternatives to Agrobacterium have been pursued for some time. In 005, 
Richard Jefferson and colleagues published a paper and filed patents on using Rhizobium 
species to harbor a Ti plasmid for delivery of transgenes to plants (Figure 7). This was 
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Figure 4. Recently issued patent.
the basis of what he called BiOS or open-innovation platform. However, efficiency was 
low and the concept failed to gain traction.
In 0, a group in Ireland (led by Ewen Mullins) published on and patented Ensifer 
adhaerens—closely related to the Rhizobium/Agrobacterium group—claiming broad 
 applicability for gene transfer. Figure 8 includes data generated with potato.
Another area to invent around is P-DNA or synthetic DNA borders (Figure 6), which 
has been the topic of important publications (Figure 9). Because we keep a watch on these 
things, we have noticed that one of the seminal papers on this topic has been retracted, 
which may affect the patent. If these move into the public domain, they would probably 
constitute a complete workaround.
Other PIPRA Activities
PIPRA provides intellectual property support to a number of agencies and universities. 
One the reasons that the Rockefeller Foundation became interested in intellectual prop-
erty was the Golden Rice story and the intellectual property audit that identified a large 
number of proprietary technologies that were infringed (Figure 0). Ingo Potrykus agrees 
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Figure 5. Patent No. 873954, Genetically Transformed Plants: Scope of claims.
with Dennis Gonsalves2 that intellectual property was not the main issue preventing the 
advancement of this innovation. In spite of the large number of proprietary technologies 
involved, it was quickly realized that Golden Rice could be “rebuilt” using approximately 
five proprietary technologies instead of seventy. As suggested by Scott Thenell3 regard-
ing planning innovations to address regulatory issues, forethought may also minimize 
intellectual property issues. PIPRA makes a lot of freedom-to-operate assessments for 
public-sector projects to determine if products or processes use third-party proprietary 
technologies and, if so, can the project obtain the rights to those properties? We look at 
intellectual property landscapes and patents, but we also look at materials used and mate-
rial transfer agreements, which, it turns out, are always the more problematic.
Anyone who has used a Gateway vector has agreed to the conditions set out in Figure . 
This license says that the buyer cannot sell or otherwise transfer materials made using this 
product or its components to a third party or for any commercial purposes.
Figure  provides a list of about half of our freedom-to-operate (FTO) assessments, 
many of which were for the Bill and Linda Gates Foundation. Others were for the Depart-
ment of Energy, which is now involved in a number of projects. The common feature of 
these projects is that they are funding research with commercial intentions. The agencies, 
of course, are interested in basic findings but they also want to see products that solve 
real problems. As a result, they’ve gotten quite involved in looking at FTO assessments 
before the research starts, i.e. addressing up-front issues and minimizing downstream 
issues in these particular projects. 
2Pages 37–46.
3Pages 83–94.
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Figure 6. Preliminary analysis: Scope of claims.
Inventing Around
Education and Outreach
Another area of PIPRA involvement is education and outreach. Figure 3 shows a two-
volume set of Best Practices handbooks that we published in 007. We run a licensing 
academy for technology managers from developing countries. The academy currently 
has forty students from twenty countries. There is great interest and significant hunger 
in understanding how to manage intellectual property in developing countries. Accord-
ingly, awareness is increasing. A lot of countries are focusing on increasing their capacity 
so that they can address their own innovations. Not only are they interested in using our 
innovations, but they want to protect and exploit their own.
Bennett
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Figure 8. Transformation of potato with Ensifer adhaerens.
Figure 7. Alternatives to Agrobacterium for gene delivery.

Figure 9. T-DNA replacement with “P-DNA” or synthetic DNA borders.
Figure 0. Intellectual property creates challenges for public research and
missed opportunities for crop development.
Bennett
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Figure . A “shrink wrapped” license.
Gene Patents
PIPRA is involved in a few genome projects and the issues of gene patents. Patent claims 
are appropriating public science at a fast pace. Figure 4 shows a famous patent applica-
tion, sometimes referred to as “the patent from hell.” This is a claim for a transgenic plant 
having an improved trait by expressing any of these genes or any related gene with 65 
percent homology. These are sometimes called “jumbo” patents. 
Figure 5 illustrates the situation for Arabidopsis- and rice-gene patents. Those in blue 
(88) are patents that were issued before the public release of the Arabidopsis genome. Four 
hundred and forty patents were issued on Arabidopsis genes after the public release of the 
genome. The same applies for rice: 84 before and 83 after. This raises the issue of the 
implications of public release of a genome, i.e. putting data on the Internet that provides 
opportunities for appropriating gene ownership.
Genome Projects
PIPRA has been working with the cacao-genome project and will be working with other 
similar projects soon. The cacao genome sequence was completed a few years ago for 
the express purpose of making it publicly available. And so, the sponsors of this genome 
asked PIPRA what it means to be publicly available. We worked with them to develop 
a portal for this genome, which involves an information access agreement with terms 
and conditions:
The user shall not claim legal ownership over the information and data. And the 
user agrees not to claim any sequences in any patent application. On the other 
hand, the foregoing shall not prevent the user from releasing, reproducing, seeking 
intellectual property protection on improved seeds or plants that are developed 
using this information.
The goal is to protect upstream information that can be thought of as research tools and 
enabling technologies to ensure that they remain publicly available and focus on protec-
tion, commercialization and exploitation of downstream products for purposes of making 
such seeds or plants available to farmers for cultivation.
A large multi-sponsored project is on-going to sequence the genomes of some one 
hundred orphan crops in Africa, with the intent of using similar portals. These all may 
become moot points considering that the Supreme Court may disallow patenting of genes 
and other naturally occurring molecules. Patenting of cDNAs and the like, which don’t 
occur in nature, may be allowed. 
3
Figure . Freedom to operate—project assessment/enablement.
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Figure 3. Intellectual Property Management in Health and Agricultural Innovation:
A Handbook of Best Practices.
Figure 5. Number of US patents with word arabidopsis or rice in claims.
5
Figure 4. Patent claims are appropriating public science at a fast pace.
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alan BenneTT is professor of plant sciences at the University 
of California, Davis. He earned BS and PhD degrees in plant 
biology at UC Davis and Cornell University, respectively, and 
has over 60 publications. His research has focused on molecu-
lar biology of tomato-fruit development and ripening; cell-wall 
disassembly; and intellectual property rights in agriculture. He is a fellow of the 
American Association for the Advancement of Science and a senior fellow of the 
California Council for Science and Technology. He has also served in a range of 
leadership positions at the University of California, including department chair, di-
visional associate dean in the College of Agricultural and Environmental Sciences, 
UC system-wide executive director of research administration and technology 
transfer, and associate vice chancellor for research at Davis. In these capacities, 
he has been responsible for research and teaching budgets, for establishing and 
overseeing research policy, and for the management of a portfolio of over 5,000 
patented inventions, 700 active licenses and revenue in excess of $350 million.
 In 004, Dr. Bennett founded the Public Intellectual Property Resource for 
Agriculture (PIPRA) to accelerate the deployment of public-sector technologies 
for specialty and subsistence crops in developing countries. PIPRA has been sup-
ported by the Rockefeller and Bill & Melinda Gates Foundations as well as by 
numerous government agencies and private companies.
In Summary
The intellectual-property landscape for transformation has shifted. Sponsors of transla-
tional research are increasingly interested in clearing IP barriers in advance of making 
grant awards. And plant-gene patents may become moot, if the Supreme Court rules 
similarly to their opinion on human genes. 
Reference
Chi-Ham CL et al. (0) An intellectual property sharing initiative in agricultural bio-
technology: development of broad accessible technologies for plant transformation. 
Plant Biotechnology Journal 0(5) 50–50.
7
Erik Mirkov (Texas A&M University, College Station):  Alan, what is your opinion on 
not only the September 5 Monsanto patent but also the one issued December 8? Do 
you see coexistence with the Syngenta patents?
Alan Bennett:  I think I know the Syngenta patents you are talking about—I thought 
they had expired. They originally came from Washington University, I think. I’m not 
sure about coexistence. Sorry.
Roger Beachy (Global Institute for Food Security, Saskatoon):  What chance is there that 
Monsanto will do a “Cohen and Boyer”?
Bennett:  Little, but I think they should be encouraged to.
Beachy: Absolutely.  That’s the point. This is terribly important. It’s an enabler just like 
the “Cohen and Boyer” patent was. That’s what the industry needs. Are we going to play 
in sandboxes or are we going to play in the big field?
Bennett: Yes, the landscape has changed so much. The intellectual property portfolio—key 
patents that Monsanto had—were really important in establishing them in the industry 
in a very strong position. Clearly, those tools are not valuable in the same way today, and 
enabling an entire industry might be to everyone’s advantage, including Monsanto’s.
Session 3-2: The Regulatory Process and 
Technology Access for Specialty Crops
Q&A
Moderator: David Baltensperger
Texas A&M University
College Station, Texas
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Tom Redick (Global Environmental Ethics Council, Clayton):  Scott, a question mostly 
for you. I’m the guy who started major market approval as a big problem for all the sick 
sisters of biotech and we are starting to talk about whether certain closed-loop1 identity-
preserved production models could work for, say, a specialty crop.  I’m wondering, is there a 
way we could carve out a corner of the world where we could grow it in a confined district 
in a confined production system so that we don’t interfere with the markets overseas?
Scott Thenell:  Tom, you are probably right that it can be done with a considerable amount 
of planning, and reassurance for trading partners that it is robust. Also from a regulatory 
approval standpoint, yes, if you can develop a robust identity-preservation closed-loop 
system, then I think you can.
Tim Hall (Texas A&M University, College Station):  It was mentioned that the Monsanto 
Agrobacterium patent was very strong and very solid for dicot crops. Do you think it is 
equally strong for monocots, considering that it has been found to be extremely good 
in rice, for example?
Bennett:  That particular patent is specific for dicots. Other strong monocot patents exist 
as well, but this is not one of them.
Hall:  For monocots? Agrobacterium-mediated? When you say there are other systems, 
other patents, do you mean including Agrobacterium-mediated?
Bennett:  Yes, Agrobacterium-mediated transformation in monocots—strong patents 
exist.
Peter Schuerman: One of the questions we get a lot within the university is about whether 
or not a patent might be a problem. It’s very easy to think about patents as problems 
rather than as opportunities. Universities got into the patent system about 00 years too 
late. We’ve been innovating the whole time, but better late than never. A patent is an 
opportunity for a conversation. A kind of conversation that universities aren’t used to 
having. If what you want to do infringes on someone else’s rights, you can talk to that 
someone else and say, “Here is how it’s beneficial to both of us,” then it is not a problem, 
it’s an opportunity.
Bennett: That’s a good point. Dennis Gonsalves2 has experienced that. When he had a 
product, it was clear what it was, he went to the patent owners: not a problem. But I’m 
going to refer to one of your slides, Peter, where there was uncertainty for the investiga-
tor— uncertainty as to whether something would work out or not. “Should I even start 
down that path?” That’s the other issue with patent portfolios: they cloud the future.
1Closed loop: see pages 3, 5 and 56.
2Pages 37–46.
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The pipelines for new specialty biotech crops are jammed with new varieties, many of 
which bring long-awaited consumer benefits. While sweet corn, potato, and squash have 
made it to market, barriers await this innovation. These include regulations, export-trade 
objections, a few ill-conceived sustainability standards and continuing consumer or food-
manufacturer resistance. Some new forms of plant breeding may evade some regulations in 
the United States, but face regulatory barriers in wary overseas markets. These markets have 
trade barriers arising from the European Union’s traceability directive, which implements 
the 003 Cartagena Protocol on Biosafety (“Biosafety Protocol”), an international law 
driving “precautionary” laws worldwide. 
In the commodity-crop sector, the innovation pipeline is stacking up in two different 
ways, and the specialty sector will probably fall into the same pattern. First, companies 
stack events by putting two or more genetic events in a biotech crop. Second, regulatory 
approvals are stacking up, as the pace of innovation is straining US and global regulatory 
capacity to regulate in a timely, functional manner. With some nations also requiring 
approvals of stacks, the regulatory approvals of stacked crops will be stacked up like cars 
in line at a freeway on-ramp at rush hour. 
The next ten to twenty years will be key in the transition to a fully functional global 
marketplace that accepts specialty and commodity biotech crops. Depending on the 
level of export-dependency (e.g. corn, soybean, canola, cotton) there will be new stacked 
 specialty crops that are grown in containment without approval in every significant market 
with a functioning approval system. 
The “Stacked” Pipeline of Biotech Specialty Crops
and Regulatory/Market Barriers to Coexistence
Thomas P. Redick
Global Environmental Ethics Council
Clayton, Missouri
tpr@geeclaw.com
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Specialty crops will also benefit from new plant-breeding methods that do not use the 
traditional recombinant-DNA viral vectors, like RNA silencing or interference (RNAi) 
and all the other plant-breeding methods—directed oligonucleotides, zinc fingers, meth-
ylation along an epigenetic chromosome, and others. At the present time, various nations 
are evaluating how these methods will be regulated.
Unfortunately, regardless of scientific reasons to see less risk, some new plant-breed-
ing methods will prove objectionable to anti-GMO activists. In fact, activists are already 
targeting “excessive RNA” in some breeding processes. Unfortunately, new plant-breed-
ing methods will not get a “hall pass” and avoid all regulations, even if scientists show 
they are more precise and even with genes from within the same plant’s genome (i.e. 
“cisgenic”). 
One of the most complex emerging legal issues is the expiration of patents along with 
expiring approvals. Biotech crops go off-patent in 0 years or so, so be sure to consult an 
attorney on actual expiration dates. With that in mind, check approvals in key nations 
where approvals are time-limited (Europe, China, etc.). Roundup-Ready soybean, for ex-
ample, needs renewal of approval for food/feed use every three years in China. Monsanto 
presents new scientific data rebutting environmental concerns and health risks, spending 
millions of dollars annually to maintain such approvals. After patents expire, who will 
renew approval for the “generic” version, if Monsanto or another seed company does not 
help? Fortunately, a new industry stewardship program, the “AgAccord” (04a) offers a 
new agreement on “Data Use and Compensation” (AgAccord, 04b).
Lastly, sustainability is a whole new barrier to entry that everyone is talking about and 
some are trying to define. Unfortunately, when Europe talks about sustainability, it usu-
ally means, “How can we stop American corn and soybeans from being shipped here and 
made into biofuels?” Sustainability will continue to be hard to define. Applying SWOT 
analysis, sustainability is both an opportunity and a threat (Job, 0). Specialty biotech 
crops may be more sustainable. For example, a new specialty soybean—producing high-
oleic oil—offers a more sustainable carbon footprint during its life cycle because you can 
cook twice as many French fries; it lasts longer in the fryer. 
Defining and Supporting Specialty Crops
For purposes of regulation, the term “specialty crops” was defined and litigated 0 
years ago in a Supreme Court case involving the 883 Tariff Act which taxed imported 
vegetables, not fruit. In Nix v. Hedden (893), the US Supreme Court ruled on that still-
debated question: Is the tomato a vegetable or a fruit? The Supreme Court said vegetable; 
the law does not particularly care what a botanist might say on this topic, as they were 
lawyers who became judges appointed for life.
USDA defines specialty in a broad sense. For example, edamame—a soybean grown in 
small identity-preserved amounts and hand-picked—is a specialty crop unlike its cousin, 
the commodity soybean, which is grown in massive amounts. Although USDA actually 
funded edamame to be grown in the United States, 97% is imported, mostly from Asia 
(Roseboro, 0). Amid the commodity sector of corn, soy and canola, biotech crops may 
be grown via a “specialty” production process. Specialized oils, specialized corn, specialized 
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canola and other crops are grown in identity-preserved loops to maintain purity, and are 
produced on smaller scales than the blockbuster commodity crops with input traits that 
over 90% of growers want.
USDA (USDA-NIFA, 03) has a specialty-crop research initiative that probably 
could be used for specialty GM crops and to the extent it continues to be funded under 
the new Farm Bill, this sector should apply to use those funds.
At last count, biotech sweet corn had 40 percent of the market, and biotech papaya 
is firmly established in Hawaii. In some respects, biotech specialty-crop production is, 
therefore, booming, and similar gains may be seen with the Simplot potato1.
Food manufacturers and retailers are the last hurdle, however, and specialty crops face 
high barriers in some corners of the market. McDonalds rejected Bt potatoes ten years 
ago; will they serve Simplot’s low-acrylamide potato, with its health benefit? On the 
positive side, Wal-Mart is stocking biotech sweet corn. But, even Wal-Mart might balk 
at the GMO onion, potato or other specialty crops if there is sufficient consumer back-
lash. It is important to remember that even if a biotech specialty crop can get the food 
manufacturers to accept it, it may not last in the marketplace, because some consumers 
may not want to buy any “GMO.” Even some successful products lose the battle for shelf 
space after a short run of popularity. 
Biotech Benefits and the Upcoming pipeline 
It is now clear that agricultural biotechnology has provided benefits both to human 
health and to the environment. This continues to be clear, despite what activists say, 
since growers are using fewer chemicals such as pesticides. Some of the major US-based 
environmental groups are starting to get behind agricultural biotechnology. In a speech 
to a European audience in 0, the vice president of the Worldwide Fund for Nature 
(WWF-US) in the United States said, “I’m convinced that modern genetic technology 
could help get better yields from local and regional crops in Africa and South-East Asia” 
(McEwan, 0) 
We have improved food safety through use of biotech corn. Iowa State University has 
done excellent research showing that mycotoxin formation is reduced in certain Bt-corn 
varieties. It is unhealthy to eat known carcinogens. If other nations struggling to cope 
with mycotoxin-related effects (cancer, birth defects, etc.), simply by approving planting 
of Bt corn those nations would reduce those effects and bring health benefits through 
biotechnology. (Murillo-Williams and Munkvold, 008).
Moreover, time has trumped the early concerns expressed by Al Gore about biotech 
crops exacerbating over-supply; we know now that the world has become too needy to 
be cavalier in dismissing innovation in agricultural biotechnology. With people around 
the world asking for more and more corn, soy and other foods at reasonable prices, and 
rioting to overthrow their governments, we know that yields actually matter. While many 
factors were contributory, the recent violent protests in North Africa and the Middle East 
coincided with sudden peaks in global food prices. Researchers suggest that a given food-
1Pages 97–09.
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price threshold may exist, above which protests become likely (Lagi et al., 0). With 
such social unrest making the world an increasingly unstable place, we do not have the 
luxury of tinkering with the highly productive US agricultural system that makes food 
for the world without risking serious negative impacts overseas.
The pipeline for biotech crops is becoming more interesting with each innovation in 
plant breeding. Genes are being silenced with no “plant pest” DNA to regulate or test for, 
making regulation more complex. Such new plant-breeding methods involve:
• RNA-interference. 
• Oligo-RNA etc—Cibus, Keygene, etc.
• Public-academic breeding coming on fast?
• USDA does not see a plant pest, EPA sees resistance issues, etc.
The pipeline of biotech commodity crops promises new approaches to food and 
 agriculture, and, finally, direct consumer benefits, not just improved production traits 
(e.g. herbicide and pest resistance) enabling more-efficient production. These include:
• Improved consumer health (high oleic, omega-3 soy, etc.)
• Stress-tolerant cultivars, possibly N-fixing corn
• Environmental impact management—lower GHG emissions
• Feeds to reduce feedlot waste (by manipulating genes for phytase to increase 
 efficiency of consumption of phosphates)
• More crop from a drop—drought-tolerance in time for climate-disrupted 
 agriculture.
Although some proposed innovations may prove to be mere pipedreams, people are 
working on N fixation in corn with symbiotic microorganisms and also making corn pho-
tosynthesis work for soy (i.e. “C4 soy”) (Buchanan et al., 00). There will be more room 
for public and academic breeding tools in the smaller specialized sector of agriculture. 
All of this innovation has environmental and economic benefits. This has led the World 
Wildlife Fund, Environmental Defense Council, and even the Natural Resources Defense 
Council to start talking about technology neutrality vis-à-vis biotech crops. 
Opposition to GMOs keeps coming and coming, however. The recently withdrawn 
French Séralini study, which showed tumors in rats, serves to demonstrate the commit-
ment of certain researchers to bend scientific rules to achieve anti-GMO results. Although 
the study was badly flawed, it has caused governments to say, “Well, that’s peer-reviewed 
science. Let’s ban it and make nations stop exporting it to us.”
While the high cost of regulatory compliance has led to oligopoly power with a “con-
centration” in the biotech-seed marketplace, the coming decade may see more new players 
entering the marketplace (e.g. Okanagan Specialty Crops with its Arctic® Apple2, and J.R. 
Simplot with its “Innate®” potato1).
2Pages 87–94.
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Seed Industry Stewardship Coordinates with Grower Associations
The leading grower associations in US commodity corn, soybean and cotton production 
have established important working relationships with the biotech seed companies to keep 
the potentially adverse impacts of coexistence under better control. Detailed stewardship 
plans are created and the growers associations survey members and communicate to ensure 
compliance at a high level. This helps overseas buyers learn to trust the representations 
made in the United States regarding the “commercial launch” of new biotech crops and 
containment of biotech crops grown in field trials or “closed loop identity preservation” 
(Abramson and Carrato, 00; BIO, 04).
Overseas Approvals and the Biosafety Protocol
The Biosafety Protocol now has 66 parties and the 00 Nagoya-Kuala Lumpur Supple-
mental Protocol on liability remains short of the ratifications needed to enter into force 
(NKLS, 00). This law regulates “living modified organisms” (LMOs) which is their 
unique term for GMO. Under a 006 WTO decision involving the United States, Argen-
tina and Canada against the European Union, the WTO held that the EU and nations 
that have signed that law cannot apply it with its “precautionary approach” to regulatory 
approval against the nonparty grain- and oilseed-exporting nations. The United States is 
not going to sign on to a law that creates trade barriers, although the US seed and grain 
industries support ratification as a tool to give the United States a stronger direct voice 
in implementation decisions.
One area where implementation is troubling is Biosafety Protocol Article 8.(a) with 
its “May contain LMOs” requirement. The EU law implementing this article, the 004 
Traceability Directive, targets that possible presence of “LMOs” and tests for events that are 
not approved, which forces the grain trader to declare all events contained in its shipment 
on the shipping documents. This law enables testing and traceback liability (see below, 
LibertyLink rice nuisance litigation). Such trade disruption between the Americas and 
the European Union has become increasingly common, with Europe’s own economists 
measuring billions of dollars in lost value to US corn and soybean exports (Bernauer, 
003). This has forced food manufacturers in Europe to substitute non-GMO inputs 
and billions of dollars in US trade has been lost. 
Trade is often disrupted when events face regulatory delays, in the United States and 
abroad, and those delays make a stacked-up line of events that wait for approval. In a grow-
ing number of nations, the regulators add another level of regulation for stacks, requiring 
regulatory approval for both the events and the stack. Many nations are regulating (e.g. 
Canada) or considering regulating (European Union, Japan, etc.) biotech events that are 
not “plant pests” nor “plant incorporated protectants” and do not involve recombinant-
DNA methods. These ever-shifting variations in regulatory approach can surprise plant 
breeders, particularly in the United States where stacks and new plant-breeding tools are 
not necessarily regulated. Uncertainty over global regulation is impeding investment in 
new breeding tools; investors really need to know what it will cost to get to market.
Anti-biotech activists are writing papers opposing new plant-breeding methods. Jack 
Heinemann, with an academic appointment in New Zealand, has claimed in a peer-
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 reviewed journal that RNA is overproduced in these crops (Heinemann et al., 03). The 
new plant-breeding technologies will not lack for “anti” attacks.
Depending on the scale of production and importance of the export, some biotech 
specialty crops may be grown without major market approvals. After USDA approval 
(“deregulation”) and perhaps also EPA approval (for any “plant-incorporated protectant”), 
it may be acceptable to the supply chain to have identity-preserved, fully contained pro-
duction without obtaining overseas approval. 
This may be necessary where overseas approval is very difficult to obtain, for example in 
China. Unfortunately, China is borderline functioning in terms of approval (e.g. China’s 
delay of over three years in approving Syngenta’s MIR 6 corn event). They do not let 
companies even file for approval until the applicant has been approved for use in at least 
one exporting nation. This is not like other countries where an applicant can make parallel 
submissions to multiple regulatory agencies. 
Patent and Approval Expiration—the AgAccord
China is also a place where approvals expire. In Argentina, they’ve been thinking about 
approval expiration, in combination with patent approval expiration, for quite some 
time, suggesting that companies should step up and help these generic crops get approval 
renewal (Lema and Lowenstein, 008). 
The AgAccord (04a) is a voluntary industry agreement that sets up a data-com-
pensation system. A generic off-patent biotech crop can have its approval renewed if the 
specialty-crop breeder buys the data, using an arbitrator if value is disputed. With those 
data, specialty crops (blueberries, raspberries, etc.) could contain the Roundup-tolerance 
gene in coming years. 
Monsanto did the right thing on post-patent issues by agreeing to keep Roundup Ready 
traits approved until 0 in China, Europe and elsewhere, unless someone relieves them 
via the AgAccord. While Monsanto offered seven years’ worth of costly voluntary steward-
ship, other biotech seed companies will provide less than half of that commitment under 
AgAccord. This industry agreement would work for specialty crops to allow companies 
to share data and maintain approvals for a few years while the generic industry gets off 
the ground (AgAccord, 04b).
There is a good reason for this stewardship. If Europe and China had approvals that 
expired, the expired Roundup-Ready events could readily disrupt trade. A 008 Uni-
versity of Illinois economic study estimated, after price equilibrium, loss of income of 
$5 billion a year if Europe and China were to go off-approval on a soybean grown in 
America (Paulson et al., 008).
For specialty biotech crops that are paired with generic herbicide resistance, such 
stacks of proprietary-plus-generic traits could create potentially huge opportunities in 
the marketplace after 00. Indeed, all innovation in specialty biotech crops could make 
use of this free genetic event, but researchers have to be aware of any major threats of 
disrupting trade in the particular market where they will be selling their specialty crop. 
As the biotech-plum producers discovered, GM plums may be exported as prunes and 
may upset consumers overseas.
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Stacks involving multiple traits are increasingly seen in the commodity-crop sector, 
and agricultural biotechnology in the specialty-crop sector should also stack, particularly 
in light of royalty-free generic events as older events go off-patent. Roundup-resistant-
crop patents all expire in April 05 in the United States (Monsanto, 0). The patents 
expired already in Canada in 0 and Canadian plant breeders may already be well 
along in breeding generic traits into commodity or specialty crops, getting stacked events 
ready for market. 
Growers have been clamoring for Roundup Ready wheat for years, and specialty-crop 
growers share similar interests in weed control. These resistance genes could add value in 
carrots and some onions, which may enter the market as free “generics.” With the added-
value of a generic royalty-free trait, the stack could give the public benefits. 
Compact for Biodiversity Harm
On the liability issues under the Biosafety Protocol, the Nagoya-Kuala Lumpur Supple-
mental Protocol (00) on LMO environmental liability law had a parallel industry 
compensation plan, the “Compact” that allowed that law to pass. The industry Compact is 
a voluntary contractual compensation mechanism established by industry to compensate 
and remediate any future damage to biological diversity that may be caused by an LMO 
(CropLife International, 04).
In the Compact, companies agreed to have arbitrators determine whether harm to 
biodiversity occurred and to write checks to compensate parties to the treaty. They will 
remediate any harm to biodiversity from biotech crops. They deserve applause for this, 
and, indeed, announcement of the Compact received a standing ovation at a Cartagena, 
Colombia, conference.
As is noted above, the same US seed industry is also leading the way on the voluntary 
post-patent AgAccord. In the Compact and AgAccord, the biotech seed industry has 
stepped up and offered the world voluntary arbitration approaches to two complex threats 
to the environment and industry’s bottom lines. 
Adverse Economic Impacts Lead to NEPA and Nuisance
The National Environmental Policy Act (NEPA) looms over US approval; this goes beyond 
USDA’s narrow “plant pest” authority to require consideration of the economic impacts 
to organic or non-GMO growers or the environmental impacts of glyphosate-resistant 
weeds. The Supreme Court reversed a lower court nationwide injunction, but also held 
that USDA failed to justify adequately its “finding of no significant impact” (FONSI) 
for the commercial launch of Monsanto’s biotech Roundup-Ready alfalfa, citing adverse 
“contamination” impacts including non-GMO contracts for exporters of alfalfa. Since 
then, however, beet sugar fortunately made it past a NEPA lawsuit to take 95 percent of 
US market share. 
In addition to the NEPA litigation noted above, in Canada they have lawsuits called 
“Anticipatory Nuisance” that allows a suit against a threatened nuisance, including one 
involving biotech crops. As a regulation of economic impact, it has parallels to NEPA, 
but uses state common law to compensate growers. Nuisances are entirely economic in 
nature, not in terms of personal injury. 
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Nuisance litigation often follows the economic impact of biotech crops, real or per-
ceived. Monsanto’s isolated rogue field-trial wheat made an appearance in Oregon recently, 
and many lawsuits are pending for negligence and nuisance over lost export markets and 
adverse price impacts, which are consolidated in a Kansas federal court. 
A landmark, still-pending nuisance suit involves Bayer CropScience and LibertyLink 
rice. US rice exports are at most a $00 million market. This is being settled for over a 
billion dollars, which means litigation gives a five-times multiplier over the actual eco-
nomic impact that can reasonably be measured. 
Sustainability
The final barrier to entry could come from sustainability demands. This is also a door to 
be opened if a new stack elicits environmental or health challenges. The sustainability 
standards that I have seen could be technology neutral, or they could eliminate GMOs 
entirely. Some standards ban GMOs in midstream, like the Green Building Council, which 
suddenly came out of the woodwork with “no GMO wood” because the Forest Steward-
ship Council (FSC) was thinking ahead to the day when biotech trees might arrive. 
If producers of specialty-biotech crops do not maintain vigilance, various standard-set-
ting initiatives could encourage entire industries to ban GMOs. This is being attempted in 
the draft national standard on sustainable agriculture by the Leonardo Academy (03) in 
Wisconsin, where a committee with organic advocates published a draft standard for public 
comment through April 6, 04, with what may be interpreted as anti-GMO clauses.
Conclusion
Biotech specialty crops face a number of potential barriers. Regulatory uncertainty over 
new plant-breeding methods and costly overseas approvals could complicate plans for 
commercialization. Stacking a generic crop aids innovators in the marketplace, but generic 
crops may need the regulatory data held by patent holders to achieve regulatory approval. 
Sustainability standards may arbitrarily deny use of biotechnology. Any innovator heading 
into this sector will need to be aware of all the potential threats awaiting these exciting 
opportunities in genetic engineering of biotech crops.
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Four categories present, or have presented, obstacles or limitations to commercializing 
genetically modified (GM) specialty crops: 
• The technology itself. Could we actually identify genes encoding useful traits, 
clone those genes, transfer them into the cells of specialty crop species in vitro, 
and then regenerate whole plants and have them express those traits at commer-
cially viable levels? We know that that’s pretty well overcome. We can transform 
virtually anything with any piece of DNA, or RNA for that matter.
• Intellectual property, including patents on genes and on the fundamental 
enabling technologies that were held largely by big companies or tied up in 
litigation. I know many public scientists who have said, “I can’t use this technol-
ogy because it’s patented.” Some said, “I’m using this technology, although it’s 
patented. So don’t tell anybody.” We continue to have to respect intellectual 
property (IP) rights and I certainly encourage everyone to do that. Furthermore, 
companies that hold the patents are often amenable to negotiation. If you have a 
good idea—a good product in a specialty crop—and a patent holder isn’t actively 
working in that area, they will probably be reasonably receptive to developing a li-
cense or some other freedom to operate. Also, patents for many of these products 
and enabling technologies are expiring. They may not be first-choice state-of-the-
art technologies, but older approaches can be adapted and efficiency improved 
to get the final product that you’re interested in. So, IP is not the obstacle that it 
used to be.
Genetically Engineered Specialty Crops Need 
Regulatory Assistance
Alan McHughen
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• Public acceptance is not the issue that a lot of people think it is. Several different 
groups say, “We speak for the public, and we, the public, don’t like GM organ-
isms, so don’t develop them and don’t release them. If you put them out there, we 
won’t buy them, therefore, let’s ban them so that people don’t have to worry about 
them.” I haven’t done a sociological study on this, but, after dealing with the pub-
lic for 0 years or so, I’d say that about 5 percent of the public definitely will not 
buy a GM fruit or vegetable in the marketplace. Dennis Gonsalves has suggested 
it may be 8 percent. Other people will come up with other figures, But it’s on that 
order 8 to 0 to 5 percent—people who say that they really don’t like GM or-
ganisms (GMOs), and then actually follow through. A lot of people say that they 
don’t like GMOs but buy them anyway, knowing full well what they are. They see 
what the price is, what the quality is, and that other people are buying them and 
are not dropping dead in the street. The best way to measure public acceptance 
is not to listen to activist groups, or any academic for that matter. The best way 
to measure it is to put the products in the market and let the people show you by 
whether they buy them. When people are given that actual real-life opportunity, 
for the most part they buy them. We do have GM papayas, we do have GM sweet 
corn, and other examples here and there. And there’s little problem once people 
are actually allowed to make the choice on their own directly, to buy the product 
today or not.
• The federal regulatory system, which is what I will discuss mostly. 
Specialty Crop Regulatory Assistance Program
The chief obstacle to getting GM fruits and vegetables onto the market, is the regula-
tory system. Several years ago, a group of us, largely from the federal regulatory agencies 
said: 
The genetically modified products on the market now are, in large part, major 
crops: corn, soybean, cotton, and canola, all from large companies. On the other 
hand, hundreds of millions of dollars of taxpayers’ money have supported the 
development of genetically modified specialty crops in our public institutions, in 
USDA, in our universities and other not- for-profit organizations, plus small 
companies. Where are the results of that effort? Did all of those projects fail? Was 
it a waste of money?
A meeting was called in Washington to address whether there was interest in join-
ing forces, either formally or informally, large or small, to promote the use of genetic 
technologies for improvement of specialty crops. It emerged that there was a great deal 
of interest. Passionate about the technology, people wanted to develop products that big 
companies probably wouldn’t be interested in: public-good, high-value items, that don’t 
necessarily have sufficient dollar value to generate industry interest in terms of profit but 
would be good for the environment, for society and for human health. This passionate 
interest existed mostly in small-company and public-sector scientists.
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We discussed ways to facilitate regulatory clearance because of the broadly held view 
that achieving deregulation was a major stumbling block. The Specialty Crop Regulatory 
Assistance (SCRA) program was set up in 004, under the auspices of which we have 
held several meetings, mostly workshops that have included developers of GM specialty 
crops and representatives of the regulatory agencies. With seed money from the secretary 
of agriculture, we hired Kellye Eversole, in DC, who has been involved in this effort 
ever since. We have moved forward with a number of initiatives. Several workshop-type 
meetings have:
• Examined the regulatory system, including the hoops a developer has to jump 
through, and 
• Explored costs, obviously a major issue for everyone.
Cost of Gaining Regulatory Approval
Discussions at this conference have questioned the actual cost of gaining regulatory ap-
proval; is it $50 million to $00 million as some companies have indicated? We have 
learned that it isn’t necessarily that expensive. You have to calculate the cost above and 
beyond the routine R&D involved in producing a new crop variety, which comes down 
to an interesting accounting exercise. When I developed a transgenic flax many years 
ago, I worked at a major plant-breeding institution. We had huge farms and research 
plots, and several teams evaluated the project, supervising seeding, harvesting, quality 
analyses, chemical analyses, amino acid analyses, and performing efficacy and yield tri-
als. All of these functions were part of a large infrastructure within which my lines were 
tested. Tens of thousands of lines of various species underwent tests, all within the same 
infrastructure. It was virtually impossible to determine my segment of the overall bill. 
Furthermore, if this were not a GM product, but a conventionally bred variety of the 
same crop type, how much would that have cost? And then, how much in addition has 
to be spent to generate the additional data required by regulatory agencies for appraisal 
of a GM trait? When you do those calculations, the marginal cost comes down to the 
order of a few tens of thousands of dollars.
When Dennis Gonsalves1 and I compared notes—his papaya and my flax went through 
the regulatory system at approximately the same time—we came up with similar figures. Of 
course, nowadays, it is likely that neither Dennis’s papaya nor my flax would get through 
the regulatory system; it is that much more onerous than it was in the mid-990s. But, 
don’t believe those $50 million price tags that are thrown out. It can be done a lot less 
expensively, and one of the things that we’ve learned during our various workshops is the 
need to talk to the regulators themselves, which is the best way to find out what’s actually 
needed. There are ways to satisfy the requirements without necessarily doing what you 
think you might have to do in terms of additional experimentation or field trials or feed-
ing tests on humans for ten years, etc. You may be surprised to learn that you can achieve 
deregulation without investing a lot of time and/or spending a lot of money.
1Pages 37–46.
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Modeling on IR-4
We wanted to set up a structure similar to that of the IR-4 program or the FDA’s orphan 
drug program, recognizing that many specialty crops are of insufficient value in terms 
of market size to justify full-blown costs of deregulation. We thought that it would be 
useful to propose an institution, modeled particularly after IR-4, within which the SCRA 
program would sponsor a given GM specialty crop event or variety, and actually carry it 
through the regulatory system to obtain approvals. Although IR-4 works through EPA, 
the program is based in USDA. And in our situation with SCRA, it could involve our 
taking this product to all three of the regulatory agencies and navigating the system, 
so that the developer— a university-based person or from a small company—wouldn’t 
bear the total cost. It would be largely subsidized. We’re not looking for shortcuts here 
in terms of exemptions from requirements, but rather rationalizing and organizing the 
dossier so that it meets the requirements, and we have assurance of safety of the product, 
but without “bells and whistles” that may be attached to some of the other dossiers that 
our regulators see.
We decided to focus on the US regulatory system. Many US products are sent overseas; 
we have trading partners in various countries and regions. There was no point in getting 
approval in the United States for a product that served a large export market. Also, we are 
more familiar with the US regulations and majority of our members are in this country. 
There is good coordination between the Canadian and US regulatory systems. Although 
differences exist in legislation and the regulations themselves, the same data package can 
be used, to a great extent, in both Canada and the United States. That certainly was true 
with my flax. We decided that Europe was schizophrenic and paranoid when it came to 
GMOs. They ignore their own laws, so there was no point in going through the European 
Food Safety Authority (EFSA) system and getting an approval only to have some member 
countries initiate a ban anyway. 
At the SCRA, we have our own expertise, provided by plant breeders, molecular ge-
neticists, people who are experienced in the regulatory system, and political people who 
know how the machinery works in Washington. We also have several consultants to help 
individual entities. At our last workshop 8 months ago, we had a session at which we 
provided access to consultants experienced in dealing with our regulatory system and our 
regulators. We also brought in regulators, i.e. not policy people necessarily—they were 
there as well—but agency people who actually work hands-on with dossiers, whose job it 
is to come in every morning and see a stack of papers saying, “Here’s yet another Bt corn 
for you to evaluate.” We conducted this workshop under Chatham House Rules—i.e. 
confidential with no attribution—which lends itself to people saying things that they 
wouldn’t say in a public setting or in a conventional workshop. They didn’t want to be in 
a situation where they could be quoted later: “You told us at that workshop that we could 
provide this data set instead of that data set,” when in actuality they said, “Well, we’re 
thinking about maybe this or maybe that, or here’s a tentative idea. What do you think?’ 
We wanted fresh ideas without necessarily holding the speakers to those ideas.
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It was a great success. Comments received afterwards were enlightening. A number of 
people said that it was the best workshop they had ever attended, having learned more 
than at any other workshop or conferences, and that the information was really useful, 
due to communication between the developers and the consultants, and between the 
developers and the regulators, the people who actually do hands-on work with the dos-
siers. A similar workshop is planned. 
Attempts continue to secure long-term funding to maintain SCRA functions, including 
meetings and direct and indirect assistance to GM specialty-crop developers. Of course, 
in the past five years, no one has obtained the funding they wanted. We don’t have an 
IR-4-like office yet, but we will continue to give varying levels of handholding advice 
and encouragement to people who request it.
Languishing GM Specialty Crops
We know of many GM specialty crops that have not been deregulated. We commissioned 
Kent Bradford and a student at UC Davis to compile a list of GM crops that were devel-
oped at land-grant universities, other universities and smaller companies. He compiled 
a fairly substantial list of different crops with a number of different traits that had gone 
through various stages of development and field evaluation and pre-commercialization 
trials, but then stalled because the developers were unable, for one reason or another, 
to continue. In some cases, the developers were misinformed and didn’t approach the 
regulatory agencies to gain approval for commercialization. Therefore, we know that 
these things exist; it’s not a technical problem and there may be a few IP problems, but 
it’s largely a regulatory issue. Whether misunderstood or not, gaining deregulation is still 
the major stumbling block.
We wanted to contact some of these people, draw them out, and try to help them, 
encourage them, tell them whom they needed to talk to at the federal agencies to help 
them when compiling their dossiers, to tell them that they are not alone, first of all, and 
that successful examples are available. Ralph Scorza finally made it through with his 
virus-resistant plum, as the third public-sector GM specialty crop to be approved. The 
other two were back in the 990s and others are currently in the pipeline, including Neal 
Carter’s non-browning Arctic apple2.
Clearly, achieving deregulation of GM specialty crops is doable. It can be frustrating, 
but we can provide help—admittedly in a limited capacity because we don’t have a lot 
of funds. Hopefully, that will change in the future as the economy turns around, and we 
form an establishment where we can actually take particular products that need some 
additional trials or tests, and either commission those trials on behalf of a developer who 
doesn’t have the in-house capability of doing them, or pair them up with people who do 
have the expertise, to generate essential data. 
We want to encourage the commercialization of these products, because only then can 
we provide consumers with real choice: “Here. If you like it, buy it. And if you don’t, 
don’t.” 
2Pages 87–94.
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Encouraging Acceptance of GM
Overcoming citrus greening is going to be interesting. I am betting that a transgenic, or 
at least a molecular genetic technology, is going to be part of the answer, if not the whole 
answer. And the disease is not confined to Florida. It’s appearing in Texas and California. 
Similarly interesting will be tackling Pierce’s disease of grapevines in California, which 
will also probably involve a molecular genetic technology. There’s a whole range of traits 
that we really need to address, for which genetic technologies are the best tools in the 
toolbox to address them. They are not the only tools, but we have to be able to use those 
tools, which means that we have to overcome what appears to be public resistance. And 
we have to overcome misperceptions about the onerousness of our regulatory system. 
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I am from the North Carolina Research Campus, which is devoted to nutrition, agriculture, 
biotechnology and functional food. Scientists from seven universities on this campus are 
focused on specialty crops that provide bioactive compounds, which, when you ingest 
them or put them on your skin topically, they interface with human therapeutic targets to 
counteract chronic disease or bolster metabolism to increase endurance. These are the crops 
that your grandmother said you should eat, and maybe you didn’t because you didn’t like 
vegetables. We are going beyond what grandma said, going beyond anecdotal evidence to 
try to elucidate biomarkers: what are the mechanisms of action of compounds in specialty 
crops that help them to interact with human therapeutic targets and counteract disease? 
What are these bioactive phytochemicals or “phytoactives” (Figure )?
Not all phytochemicals are important for human health, but phytoactives are those 
that bolster human health in some way, and many are present in specialty crops.
It’s important to note that phytoactives are not necessarily plant nutrients. Of course, 
specialty crops contain nutrients as well: minerals, vitamins, etc., that build strong bones 
and teeth. The phytoactives tend to be secondary compounds, not necessary for the plant to 
grow but which help human metabolism. They include pigments, anthocyanins, betalains, 
chlorophylls and carotenoids, which provides a convenient message for consumers: “Put 
some color on your plate. Don’t just eat foods that are brown and white.” When you do 
put color on your plate, you tend to be consuming phytoactive compounds, which are 
associated with pigments in many specialty crops. Concentrations and profiles of phytoac-
tives vary with species and variety. Some sources are richer than others and some are more 
efficacious against certain disease conditions than others, but they are all there.
Specialty Crops and Human Health Impacts
Mary Ann Lila
Plants for Human Health Institute
North Carolina State University
Raleigh, North Carolina
mlila@ncsu.edu
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Figure . Bioactive phytochemicals—“phytoactives”—are natural compounds in fruits, 
vegetables, nuts and grains that positively affect human health.
At the Plants for Human Health Institute on the North Carolina Research Campus, 
we are investigating the gamut, from whole foods to functional foods to phytopharma-
ceuticals, i.e. removing and purifying an active compound from a plant and putting it 
into a pill, like a pharmaceutical. However, our major focus is on whole foods derived 
from specialty crops. For this presentation, I will address four questions:
• Why the Current Attention?
• How do Phytoactives Modulate Human Health?
• Can Genomics, Metabolomics, etc., Pinpoint How Phytoactives Work?
• What’s the Reaction in the Marketplace?
Why the Current Attention?
You can hardly open a general-interest magazine or the popular section of a newspaper 
without finding something on functional foods. After Oprah Winfrey said that she “pops” 
blueberries like M&Ms during the day, sales of blueberries went through the roof. I talk 
about berries a lot because that’s my area of research, and, inevitably, the talk-show host 
will say, “This is wonderful, but why are we learning about it only now?” In fact, we are 
not just learning about it today. This is ancient stuff. Traditional ecological knowledge 
includes a lot on specialty crops—not named as such, of course—and their impacts on 
health: fruits, vegetables, spices, herbs, etc. The science hasn’t been behind them until now, 
and with the tools we have today, we are able to characterize the compounds involved. 
With animal models and clinical trials, we can determine how phytoactives interact in 
the human body, clearance times and locations of accumulation. We finally have the tools 
to investigate how these things are working.
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To make the jump from traditional ecological knowledge to science now, it’s important 
to realize why plants synthesize these compounds. Usually they are produced in response 
to environmental stress. We like to say “stressed for success” because plants, being sessile, 
need a cornucopia of chemical defenses against disease, insect infestation, nematode at-
tacks, UV light, and so on. They need those defenses to survive, and they are the same 
compounds that, when we ingest them, counteract chronic disease.
How do Phytoactives Modulate Human Health?
How do phytoactives modulate human health, whether it be from a pharmaceutical, 
cosmeceutical or functional food standpoint? It would be advantageous if functional 
foods or wild plants that have phytoactive compounds acted like pharmaceuticals, with 
a nice bridge between using a plant to protect your health and using a pill to protect your 
health. But, plants don’t work like that. They contain complex, interacting mixtures of 
compounds each of which may potentiate effects in the human body. It’s hard to sort out 
the multiplicity of bioactivities. The compounds can do a number of different things. 
They might have activities against cancer and the same little group of compounds may be 
active also against cardiovascular disease. It’s tough for doctors and scientists to understand, 
tending to mitigate against using specialty crops in medical treatments.
Can ’Omics Pinpoint How Phytoactives Work?
With a pharmaceutical, you have a single active compound in a pill, facilitating dose-
response and human efficacy tests. But when it’s a plant extract and you tease out the 
components and pick out an active fraction via some activity in a bioassay, a lot of times 
when you purify the compound, you lose the activity. What’s going on? A lot of times 
with plants, a synergistic effect of a potentiating compound on an active compound results 
in the “big bang” for human health. So there may be a multiplicity of bioactivities; blue-
berry is a good example. Positive effects on urinary tract infections have been attributed 
to blueberries—much like to cranberries—as well as beneficial effects on cardiovascular, 
optic, cancer and brain-function problems.
On the other hand,  skepticism exists on the part of doctors, because they need to 
understand the biomarkers and see the proof. So, “omics” is one way to provide proof. We 
are starting to use genomics, transcriptomics, proteomics and, especially, metabolomics. 
If you have those tools in your hand, you can do a lot to decipher how active compounds 
are working, to pinpoint biomarkers. 
We have a blueberry-genome sequencing effort that will be completed by the end of 
summer 03. It’s a complicated genome that no one else wanted to tackle. The database 
will be open to people looking at cranberry and other plants in the genus Vaccinium. 
Knowing the genomics leads to understanding activities within the human body.
The launch of the Plant Pathways Elucidation Project (“P-Squared EP”) is planned for 
June 03. North Carolina State and the University of North Carolina-Charlotte will be 
academic partners. At NC State we will handle the biology whereas Charlotte will handle 
bioinformatics; the biological data that we generate will go into a knowledge-based cloud 
over the whole project to feed information into what a plant makes, how it makes it, 
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what’s the pathway it takes to get there, and, finally  what good the product is for hu-
man health. In building this knowledge base, Dole and General Mills will be industry 
partners and Castle & Cooke will be a sponsor. Developed technologies will help us to 
understand how specialty crops contribute to human health; can we quantify it so that 
it’s validated in every way?
General Mills and Dole have opened their files on pathways they have elucidated for 
oat, pineapple, and berries, and they are looking to the university researchers to pull 
together teams for complex pathway analyses. We will initiate the effort in two weeks, 
focusing on four crops with input from our industry partners: oat (Avena sativa), broccoli 
(Brassica oleracea), strawberry (Fragaria x ananassa) and blueberry (Vaccinium spp.). Five 
newly recruited PhD students will start on June 0, 03, each of whom will supervise 
six undergraduate summer interns to put together pathways. Almost $ million have been 
provided by the UNC general administration to jumpstart the effort and to ensure that 
the PhD students will have funding for four years. It’s exciting to get this going because 
it involves tools that we already had but we needed manpower to put them to work to 
generate useful data. Several local junior colleges and schools in the UNC system are 
donating interns. We will not donate any, but we will pay the interns to work intensively 
with the PhD students as teams. 
Clinical Trials
Another example of how we get to the bottom of how specialty crops work is with clinical 
trials. These have always been horribly expensive, which is why they have not been used to 
investigate specialty crops or functional foods. We are fortunate to be partnering with the 
Appalachian State University and members of their human performance laboratory where 
they do clinicals, many with athletes—runners, cyclists, NASCAR pit crews, etc.—looking 
at the effects of functional-food components on exercise performance. For example we have 
done some work with runners, supplementing their diets with blueberries and green tea 
to see the effects of polyphenolics on classic markers of inflammation and oxidative stress 
using metabolomics. Classically you don’t see oxidative stress or inflammation changes in 
highly trained athletes, but a nice thing about athletes is that they will cooperate if they 
think that the process will improve their performance and make them stronger. You don’t 
have to pay them as much as for a normal clinical trial and they permit biopsies.
After consuming a supplement of blueberry green tea for 4 days, athletes were ex-
posed to periods of intensive exercise, sufficient to induce oxidative stress (Figure ). 
Only insignificant differences between the placebo and treatment groups were seen in 
the gross markers of oxidative stress like C-reactive protein. But we did see differences in 
bioavailability. The athletes who were supplemented had excellent profiles of gut bacteria 
metabolism of phenolic phytochemicals. We saw, for the first time, that compounds from 
blueberry and green tea were actually getting into the blood of the athletes, intensified 
by kind of a gut leakiness with intensive exercise which persisted during the recovery 
period, so that bioavailability was intensified as revealed by the polyphenolic signature. 
Gut microbial metabolism of the plant polyphenols was clear in the treatment group 
versus the placebo group. Furthermore, runners who were supplemented with blueberry 
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green tea protein continued to utilize fatty acids—they had higher ketogenesis—during 
the recovery period. Athletes show a burst in oxidative stress and fat burning while they 
are exercising, but, whereas the placebo group went down to normal levels during the 
4-hour recovery period, fat burning continued in the treatment group, which was 
quantifiable using metabolomics.
Reaction in the Marketplace 
Wild blueberries have been harvested commercially for many years in Maine and the 
maritime provinces of Canada; it’s backbreaking work (Figure 3). Although it was the 
second largest industry in Maine, it was not highly lucrative for farmers until, in 998, 
the “antioxidant” message emerged (Figure 4).
This wild blueberry antioxidant message was confirmed by researchers in Canada and 
the United States, and later in Europe. A lot of work has been done on wild blueberries 
and diabetes and obesity. Data from clinical trials at the Pennington Biomedical Research 
Center are conclusive for efficacy of blueberries for increasing satiety in their patients and 
cutting triglyceride levels. For hyperglycemia—the hallmark of diabetes—wild blueber-
ries did better than metformin, the drug of choice for diabetes; blood-glucose levels were 
reduced in six hours. These and similar data attracted much media attention.
In 999, colleagues at Tufts University, Barbara Shukett-Hale and James Joseph, showed 
that inclusion of blueberries at  percent of the diet alleviated or prevented the symptoms 
of dementia in artificially aged rats. Furthermore, losses in cognitive and motor function 
were partially replenished by introduction of the blueberry diet. This and similar research, 
reported in the mass media, have taken the humble blueberry from an addition to muf-
Figure . What are the effects of phytoactives on athletic performance?
Lila
4 Biotechnology and North American Specialty Crops
Figure 3. Labor-intensive harvesting of wild blueberries in Maine.
Figure 4. Nature’s # antioxidant fruit.
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Figure 5. Blueberry production trend (×06 pounds/year).
fins to a health icon. These days, it’s hard to pick up a health-related magazine without 
finding something about blueberries in particular. Other functional foods from specialty 
crops have benefitted in the same way, because people are turned on to what they can do 
proactively for their health.
Figure 5 shows increased production of cultivated and wild blueberries since 998 
when news of positive health effects first made the headlines.
We know what we’re supposed to eat and we know how much we’re supposed to eat. 
However, it’s estimated that approximately  percent of the American public—including 
educated people—actually eats the amount of fruits and vegetables they’re supposed to 
eat. There are many reasons why people don’t do what they’re supposed to do. How do 
we take bioactives from fruits and vegetables, from specialty crops, and get them in a 
shelf-stable, convenient form to more people?
We are working with the US Army to develop ways of getting fruits and vegetables to 
soldiers in the field. Figure 6 shows shelf-stable, low-sugar protein-rich flours containing 
extract from muscadine grapes. The same can be done with kale extract. The preparations 
are stable for over three years in some cases. Soldiers in the field will eat it because it tastes 
good, it’s nutty, and they don’t care if it’s GMO or not. 
Lila
44 Biotechnology and North American Specialty Crops
MaRy ann lila is director of the Plants for Human Health 
Institute (PHHI) at North Carolina State University on the 
NC Research Campus. She holds the endowed David H. 
Murdock chair, and is a professor in the Department of Food, 
Bioprocessing, and Nutrition Sciences. Through transdisci-
Figure 6. One-step sorption of the medium polarity polyphenolics in muscadine juice, 
free of unwanted/non-nutritional material.
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In this talk, I will cover a few topics. First, I will describe some of the cutting-edge science 
that’s underway and how we are applying it within Synthetic Genomics, not specifically 
on specialty crops as defined, but on low-acreage or potential crops of the future. Many 
of these concepts will apply to specialty crops.
We can think about progress in synthetic biology, much in the way that children progress 
through school (Figure ). First, in 995, whole-genome sequences were published for 
two simple bacterial species (Haemophilus influenzae and Mycoplasma genitalium), which, 
in the late 990s, were followed by publication of several plant genomes, culminating 
in 00 with the publication of the draft sequence of the human genome. That was 
equivalent to learning to read, as in early grade school, begging the question: “If we can 
read the genetic code, can we begin to write it?” In 003, the synthesis of a small viral 
genome was achieved, at a little over 5,000 base pairs. In 006, effort was initiated to 
chemically synthesize a bacterial cell. The result was published by J. Craig Venter Institute 
researchers in 00: fundamentally, this organism came from nature and we recapitulated 
it with a few additional sequences.
Writing Stories
What’s important now is to take the tools that we have developed in reading and writ-
ing to create our own stories. This is where the design aspect gets interesting in terms 
of developing crops that not only are more robust and higher yielding, but can be more 
beneficial from a health standpoint. Focusing on some of the tools, Figure  shows a 
simplified diagram of the process used to produce the first chemically synthesized cell, 
which has a genome of about . megabases, i.e. over a million base pairs. When this 
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Figure . Approach used to synthesize a Mycoplasma mycoides cell.
Figure . Progress in synthetic biology.
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Figure 3. DNA synthesis/assembly methods: alternatives enabling
combinatorial assembly.
Figure 4. Automation of DNA assembly.
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project was undertaken, the largest DNA assemblies that had been produced were of 
about 30 kilobases—about a thirty-fifth the size. One of the challenges was stitching 
DNA together accurately in these large assemblies. Several methods were developed, but 
constructing these assemblies was only part of the problem; the next question was how 
to activate it and give it life. Methods were developed for handling whole genomes and 
transplanting them into related recipient cells that essentially served as the birthplace 
for the new genome. And again, in this case, much like a virus takes over the host cell, 
the transplanted genome was replicated, transcribed and translated, producing marked 
synthetic cells as in Figure .
Simple Methods for DNA Assembly
Important for future progress was the development of some simple, but powerful, methods 
for assembling DNA. The right-hand side of Figure 3 illustrates the Gibson assembly 
method, now utilized in many laboratories; Dan Gibson’s insight was to use DNA-repair 
mechanisms as the basis for developing an in vitro mix that is isothermal and reliable. This 
method is quite amenable to automation because of its relative simplicity, and Figure 4 
shows a unit we received in December of 0, the prototype of a benchtop instrument 
that will allow all laboratories to synthesize genes or even larger segments of DNA.
The instrument is loaded with the oligonucleotides encoding the gene of interest, a 
button is pushed and overnight the constructs are made. And this has actually been used 
for rapid production of influenza vaccines. SGI has a number of partnerships with leading 
companies, including Novartis Vaccines to develop a faster method to synthesize vaccine 
seeds so that Novartis can get a supply of influenza vaccine to the market more rapidly. 
The importance of this was illustrated in 009, when the HN epidemic was of great 
concern. As Figure 5 shows, the number of cases was growing exponentially before the 
vaccine became available. The reason it took so long to get the vaccine to market was 
both a function of a long process to develop the vaccine seeds as well as low yields with 
the HN virus.
There needed to be a better solution, so the Centers For Disease Control Board/ Bio-
medical Advanced Research and Development Authority (CDC/BARDA) is funding 
Novartis and Synthetic Genomics to develop a better, faster and more reliable method 
for, not only producing vaccines for seasonal flu cases, but also to have a method that can 
be used for responses to pandemics. We have been successful in taking what is typically a 
six-week process using classical genetics to isolate virus-vaccine seeds to a process where, 
now, when the World Health Organization releases information about a strain, we take 
that sequence and, using our assembly methods, can synthesize the DNA constructs in 
about twelve hours, achieve infection of mammalian cells and recover active virus seeds 
in five to six days. This shortens the process by about six weeks. In the long-term, we 
will be able to survey all of the possible materials out there and bank the viral gene seg-
ments for assembly overnight when called for. This was recently reported with the H7N9 
strain in China, which is currently not available in the United States. However, BARDA 
requested it and we were successful in assembling and producing a vaccine seed without 
having those viral strains available.
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Figure 5. Synthetic Genomics case study: Influenza vaccine.
(Data provided by Phil Dormitzer at Novartis Vaccines & Diagnostics.
http://www.cdc.gov/hnlflu/estimates_009_hn.htm)
These improvements in speed are important, but so too is accuracy. We have worked 
hard to develop methods to weed out errors that are inherent with oligonucleotides, the 
60-base-pair segments that are the building blocks for genes and, ultimately, genomes. 
They can be only 60 percent to 70 percent pure, therefore, if large numbers are stitched 
together, assembly errors are almost guaranteed, which can be problematic. To address 
this, we have used bioinformatic capability to develop error-correction methods that we 
now incorporate routinely. This allows us to accurately assemble DNA segments of up 
to seven kilobases without intermediate sequencing to verify accuracy.
Another important factor is cost. At the time, building the genome of Mycoplasma 
mycoides cost about $ million in reagents alone. It was a fascinating project, but not 
something that would be taken on routinely because of the necessary expenditures. This 
field as a whole depends not only on improved accuracy, but on lowering the cost of DNA 
assembly. Figure 6 shows the exponential decrease that has occurred in sequencing costs 
since 990, which has fostered applications of “omics” technologies.
We haven’t seen the same reduction in cost of gene synthesis (Figure 6). We and scientists 
in several other labs are working on methods that involve ultra-low-cost DNA sources 
from microchips as well as next-generation sequencers that allow retrieval of validated 
correct sequences to begin assemblies. If successful, these methods could lower the cost 
by at least an order of magnitude, bringing the assembly cost down to a penny or two per 
base, presenting the possibility of new ways of improving specialty and other crops. 
Flatt
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Figure 6. Cost trends: DNA synthesis and assembly.
(Adapted from R. Carlson, www.synthesis.cc.
Includes SGI Projection.)
Trait Discovery and Pathway Engineering
Over the past six years, we have developed a web-based scalable comprehensive bioin-
formatics platform to allow not only computational biologists, but also novice users, to 
analyze genomic information and to use that information in design and construction 
of DNA assemblies for recombinant cells. And we have done an extensive amount of 
biodiscovery and characterization of fungal, plant and algal genomes, which increases the 
diversity of information available for our work.
Using our proprietary enrichment and isolation methods, we have acquired some 
4,000 microbial isolates—associated with wild grasses—that have been screened for 
various properties. One of the interesting things that came out of this was the idea that, 
with these bioinformatics methods and knowledge of gene structure/function, we could 
then use bioinformatics as an assay in the discovery effort. With a view to discovering 
new Bt-type insecticidal toxins, we took our Bacillus isolates—a subset of about 00 in 
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number—and isolated the plasmid DNA potentially encoding such toxins, pooled those 
plasmids, went through a next-generation sequencing effort and then were able to assemble 
and annotate that information. Within a six-week period, we discovered fifty full-length 
novel Bt genes. This pilot test demonstrated the potential utility of this extensive amount 
of information when analyzed with the new tools.
We now have the ability to efficiently and cost-effectively assemble DNA structures 
from starting-material oligonucleotides. We can now construct digitally designed protein 
variants rather than employ traditional methods that involve either random changes such 
as error-prone PCR or gene shuffling or site-directed mutagenesis, which allows us to 
make base-pair nucleotide changes, but only in specific regions. Being able to design this 
on the computer gives us unlimited flexibility.
We had an enzyme for which we were trying to modify the substrate specificity to induce 
a desired carbon-carbon bond-cleavage reaction. We had an enzyme that performed other 
chemistry on those identical substrates and then we had “enzyme A,” which in fact did not 
work on those substrates but catalyzed the reaction of interest. Through protein modeling, 
we identified a number of changes that would be beneficial within and outside the active 
site and made a set of 88 protein variants, which we screened for function (Figure 7). 
Within one round, we obtained ten mutants that worked on both of the substrates of 
interest. In essence, we had engineered the desired change in substrate specificity.
Molecular Breeding for Specialty Crops
One of the foci of our AgraCast subsidiary is the development of castor-oil plant (Ricinus 
communis) as a source of specialty chemicals. Castor is of interest due to its high content 
Figure 7. Engineered enzyme activity results: the substrate range of the target enzyme 
was modified creating the desired activity.
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of ricinoleic acid, a hydroxylated fatty acid that provides a platform for producing branch-
chain chemicals. It is used by BASF to produce lubricants, for example. However, a 
barrier to broader scale adoption is lack of availability, lack of consistency and high cost. 
Although it grows wild in Texas and in Mexico, commercial production is mainly in 
India by small farmers with relatively low yields, one to two tons per hectare. Typically, 
it is harvested manually because of the plant’s architecture. Several years ago, we began 
both classical and molecular breeding programs to identify plants with larger racemes 
and higher yields (Figure 8). We are up to about four tons per hectare. 
Algae as a Major Crop of the Future
By FAO estimates, we will need to increase the food supply significantly in the foresee-
able future, and we will have to do it without accessing more arable land, usage of which 
has been stagnant for decades. That, coupled with issues associated with climate change, 
increasingly important issues around water availability and the fact that we are seeing 
increases in demand for animal protein that are primarily correlated with increased eco-
nomic development, we see the need not only for increased productivity of our major 
crops, but also of new crops that can be cultivated on non-arable lands with minimal 
inputs of fresh water.
We have had a collaboration with Exxon-Mobil since 009, researching algae for use 
as biofuels, but we may see this commercially utilizable in production of algal-based 
proteins. The potential is shown in Figure 9: algae—even the current forms—are much 
more efficient producers of protein than are terrestrial counterparts. Our characterizations 
show that algal protein provides complete sources of amino acids and are highly digestible. 
Major barriers associated with algae as commercial sources of protein include developing 
domesticated species that will grow robustly in the wild. We see a need to use synthetic 
genomics techniques to combine beneficial traits that have utility under specialized con-
ditions and combine them with photosynthetic efficiency, to allow us to channel carbon 
to target molecules and show improved tolerance of environmental stresses. One of the 
most significant things that we’ll be reporting on towards the end of 03 is research to 
improve photosynthetic efficiency.
Figure 0 shows that when algae grow in dense culture, light becomes limiting and 
overall productivity decreases. In part, this is because, when light is low the algae acclimate 
and build larger antennae that shade their neighbors. We have engineered semisynthetic 
algae that are deregulated in their response to light, allowing significantly more light to 
penetrate the culture without compromising the photosynthetic processes and functional-
ity of the cell. We’ve also taken similar steps to increase lipid productivity in just a matter 
of a few months, again based on bioinformatics and our ability to modify biosynthetic 
pathways. Our algal research is at an early stage, but our synthetic genomics techniques 
give the ability to accelerate the developmental process. Ultimately, I think that we will 
see large-scale algal-production facilities providing a growing share of protein requirement 
in the future.
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Figure 8. Molecular-breeding rationale and targets: the molecular-breeding
approach developed for large-acreage crops will be increasingly applied to
specialty crops like castor bean.
Figure 9. Algae is the best, scalable production system in a land-, water-, and carbon-
constrained world (data based on various literature reports).
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Figure 0. Engineering algae for improved photosynthetic efficiency: increased light 
penetration and improved photosynthetic efficiency.
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Scott Thenell (Thenell & Associates, Walnut Creek):  Tom, earlier you asked about identity 
preservation1 and whether I thought that would work. Obviously, the Soybean Association 
has identity preservation; can you give us an idea about the additional costs?
Thomas Redick:  They have what they call the eleven-point plan for keeping things sepa-
rate in soybeans. Soybeans are self-pollinating, but there are all kinds of opportunities 
to commingle in the chain. The premium for that is a negotiated element, so additional 
costs you incur depend on your own farm, whether you have a guild, and so on. Maybe 
you are growing white corn for FritoLay and are part of a network contributing to a 
dedicated elevator. So, $.40 a bushel is just one example. It could be more, it could be 
less. Definitely, if you are going to go to a specialty preserved chain of commerce, the 
costs of identity preservation mean that the grower is not going to do it unless there is 
something in it for him. It could be a 0-year contract that he’s guaranteed. That could 
do it, if you have a guarantee that every year they are going to buy what you grow. But, 
usually, you need something per bushel to sweeten the pot before you are going to agree 
to a fully identity-preserved production system.
Session 4: Perspectives from Relevant Groups
Q&A
Moderator: Daniel Leskovar
Texas A&M University
College Station, Texas
1Page 8.
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Ralph Hardy (National Agricultural Biotechnology Council, Ithaca):  In the pesticide area 
they have special exceptions for certain crops, called IR-4. It’s also my recollection that 
there is some harmonization between the Canadians and the United States in IR 4. Does 
that concept have any relevance to any of these specialty crops we are talking about?
Redick:  Yes. When we did the Accord, we first talked to folks involved in IR-4 because 
they have their own data-compensation system with USDA oversight. That was designed 
mainly for specialty crops to ensure they get the active ingredients they need when they 
go generic. So, that was driven by a need for chemicals to go into the right places where 
they are needed—whether they are generic or not—without worrying about overseas 
approvals and data and whether issues have been resolved. So, there are plenty of models 
to be followed, and the Accord will be filed this summer. I think the final steps will be 
done and we’ll have a document that folks in the specialty sector may also use for patents 
that have expired.
Roger Beachy (Global Institute for Food Security, Saskatoon):  Are there any opportunities 
for North American identity preservation that would ease some of this? Are there products 
that could be from Mexico, the United States and Canada that that could be called out, 
without need to worry so much about other exports to other countries?
Redick:  I think you could produce a crop in a closed-loop and assure the stakeholders 
who matter that this has been produced in a closed loop, not commingling with the 
export chain of commerce. The trick is going to be to find the place to grow it, where it’s 
not going to just automatically—
Beachy:  But are there products that have enough market to do that?
Redick:  A high-oleic soybean that came out in 999 was grown in a closed-loop but never 
made the market because of the cost. So, there’s no guarantee that the identity-preservation 
cost will justify the new event that you are introducing in a specialty crop. In the soybean 
sector at least, everything has been grown for major market approval. In corn, they only 
have two markets they care about. So their board has voted only Canada and Japan, not 
even Mexico. And Mexico has actually allowed that because they eat so much of our corn 
and feed so much of it to their animals. So, it’s possible that carrots could be more like 
corn than like soybean. Maybe there’s not a big export market for certain crops. Maybe 
there are governing stakeholder groups that say, “We want the innovation.” There are 
models out there for doing it with just a couple of key markets.
Beachy:  Then I have one more. Has there been sufficient validation from the market on 
the heart-healthy oils? Will consumers pay more for them? I just don’t know how that 
consumer research is going. And does that pay for segregation?
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Redick:  That’s the great untested question. There are issues too like glycosylation of 
omega-3s. CAST has actually written a paper on that question. So there’s a lot of tough 
science before you’re going to find on these specialized oils meeting scientific nutritional 
equivalents. I don’t know that every one of those is guaranteed. Actually I’ve heard people 
say that a third of those might actually find the market. Soybean oil economists project 
that you really have to meet certain levels of marketability to get in the niche. But the 
high-oleic soybean that is coming out now—they are looking at 5 percent to 50 per-
cent of the market share because it can fry fast food better and deliver a heart-healthy 
benefit—called Plenish® and other names. They think they are going to get a good market 
share. The soybean check-off is putting a lot of money into making that happen, so we’ll 
see if the market accepts it.
Allan Eaglesham (NABC, Ithaca):  Mary Ann, are wild blueberries more effective than 
cultivated blueberries and, if so, do you know why?
Mary Ann Lila:  Yes, because they are more concentrated they withstanding more stresses. 
In some ways it’s like the organic vs. non-organic argument. But yes, plants in the wild 
accumulate more phytoactives.
Bolormaa Jamiyansuren (University of Minnesota, Minneapolis-St. Paul):  Dr. McHughen, 
you mentioned that people who were against GMOs do purchase GM products after 
seeing the price. I am gathering information on GM products in terms of being cheaper 
or more expensive then conventional or organic products. Can you give a reference to 
that? Or did you do a study on that?
Alan McHughen:  The studies have not been properly done, or at least not for several 
years. In some of the early academic studies prices were equal so consumers making a 
GMO/non-GMO choice didn’t have price as a consideration. We need to do more of 
that and have prices reflect what consumers will see in the marketplace. Presumably, if 
the GMO has a benefit to it, at least agronomically, the price should be lower because of 
the increased efficiency of production. Of course, this will also help to sell more of the 
product. At least for those people who have an open mind, if they see good quality at a 
lower price then they will be inclined to purchase. We did see this early on in the UK 
when GM tomato paste was on sale for a short time. Unfortunately, the cans of tomato 
paste were of different sizes so even though the genetically engineered tomato paste had 
a lower price, consumers couldn’t make a direct comparison. But the GM paste was less 
expensive and, apparently, that is what many consumers chose to purchase. But we will 
be able to answer this only when we have multiple products in multiple markets and 
really see how the consumers treat them. But I’m convinced that the vast majority of 
people don’t particularly care how the product was made as long as the price is good and 
the quality is good.
Leskovar
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Jamiyansuren:  Dr. Lila, you convinced us that blueberries are very good. In terms of the 
blueberries and green tea, your slides indicated statistically significant improvement in 
the treatment group compared to the control group. I wonder about a human factor; if a 
very healthy man happens to be in the treatment group might it produce a better result 
than with the control group?
Lila:  They were all high-performance athletes across the board. I was working with ASU, 
using their standard experimental design—all high-performance athletes.
Bill McCutchen (Texas AgriLife, College Station):  Jim, can you tell us the exact date 
on which we will be able to use the technology you were talking about—homologous 
recombination—to make changes in specialty crops without going through regulatory 
processing? A little joking, but how far away are we from being able to make those types 
of changes?
Jim Flatt:  Most of my insights in this case are gleaned from our work in algae as really 
simple plants and plant models. We have been successful in developing HR homologous 
recombination methods for several of the algae. But, I can say that this is very species-
specific and has required a lot of work to get there. I do think it’s possible, although 
efficiencies vary among the couple of species that we have used to develop the genetic 
tools. One of the things that is beneficial here, though, is in terms of developing some of 
the nucleases to make double-stranded cuts in DNA. We have benefited in our work from 
the ability to make these very specific modifications, in trying to improve the efficiency 
of that process. I wish I could give you the exact date; it’s probably still several years off. 
Certainly, we see some glimmers of hope at least from our work.
McCutchen:  Do you see the possibility, using viral vectors for delivery within the plant for 
homologous recombination? In other words using that as a carrier or other symbionts?
Flatt:  Sure. If we can deliver the DNA or RNA we’re usually able to get good expression. 
Irrespective of the method of delivery, if we have the right sequences we should be able to 
ultimately make the desired changes. But, we’ve not specifically worked with viral vectors 
so I can’t speak any more definitively on that.
McHughen:  This illustrates an important concept that we haven’t really discussed: develop-
ing methodology to circumvent regulations and this is a problem when your regulations 
are triggered by process rather than product. Lots of new technologies have been developed 
since the dawn of recombinant technologies and some of those may be captured by current 
wording in the regulations and some of them may not. But, really, the question is whether 
our environment and our society adequately are protected from real threats to our health 
and to our environment. We can’t achieve that based on a process trigger because we are 
always going to be playing catch up. When harm is caused, it is due to the presence of 
products. So, let’s change our regulation so that they are product-triggered and not have 
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to worry about work-arounds or companies that may be interested in trying to invest in 
a way to avoid regulations. I’m in favor of sensible regulations—not no regulations.
Beachy:  First, I endorse what you just said Alan. I’m curious as to how we take the 
information that you gave us, Mary Ann, about benefit and validation of beneficial at-
tributes of horticultural specialty crops, and then using that to amplify, through synthetic 
biology, metabolic engineering, to enhance specialty crops. A number of us have worked 
in that space. At the end of the day though, the consumer needs to pay more. How far 
off are we before consumers will actually pay for a beneficial attribute? A lot of people 
have spent money in this space, even analyzing consumer attitudes and found out they 
want more but don’t want to pay for it. Jim, how does that affect what you decide to 
do in the company, because it’s all costed by likelihood? Do you delay certain things for 
the next five years until attitudes change? How do you see this moving forward to really 
have good products?
Lila: We’ve been talking through this whole conference about regulation holding things 
back and in the case of specialty crops and health you almost wish there was more regulation 
on what the media say and what they put out there. People who have serious problems with 
health or suspect or are paranoid about that, will pay. They will pay extra for something 
that is validated. Maybe they don’t understand the science, but if they feel it is validated 
and substantiated you will get the extra premium. I can’t put a number on it.
Flatt:  Yes Roger, that is a great question and I’ll address it in a couple of respects. When 
we embarked several years ago on our food efforts, we actually spoke with a number of 
very large multinational, both commodity as well as consumer packaged, food companies 
and a couple of things that those discussions bore out—the first is that the more visionary 
companies definitely saw that there would be growing acceptance of these methodologies 
in particular if they provide benefits that consumers can recognize. I think this is the point 
Mary Ann was making. So, again, to the extent that there is a validated clinically proven 
health benefit or a reduction-of-risk benefit or a performance nutrition benefit, there is 
certainly abundant evidence that consumers will pay for that, and oftentimes it is less 
important how that is produced. Having said that though, companies are very sensitive 
with their image and perception and have asked us to, as we are developing our products, 
to be able to provide them in two forms if you will have it, one that will essentially al-
low them to provide choice to their customers as well as deal with regional worldwide 
sensitivity. So, in some markets it’s acceptable to produce that product through a GMO 
whereas in other markets you are still looking at identity-preserved sources. One of the 
things that we have been working on is how we can do bioinformed sorts of classical 
strain or cell-line improvement. And so we’ve had some progress there but, of course, 
you are still limited in the complexity of problems you undertake. We guide our product 
development making sure we can meet both of those needs. Because, again, you can’t bet 
the whole farm—especially if it’s a smaller development stage company—on producing 
a technical success but a market failure.
Leskovar
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Ralph Hardy (NABC, Ithaca):  At NABC , at the University of California, Davis, there 
was discussion of what was adequate proof of efficacy of some of these entities. One of the 
examples that was used was Activia yogurt. The European scene has required an efficacy 
hoop that is almost impossible, as I understand it, to exceed. That barrier is: it has to be 
proven the same as a drug. What guidance would you give in terms criteria to be used in 
the United States and Canada to be appropriate demonstrations of efficacy?
Lila:  Hard to say, but definitely moving to the clinicals is the important thing, which they 
are doing more and more now. We had such a long drought of just cell-culture studies, 
which—I’m not downing those—certainly get to some answers, but they don’t get to the 
answers that you really need to make a claim. Even when you do have validated repeated 
clinicals, you still have regulatory hurdles to pass through. But I think that clinicals—
 clinical trials—have to be the gold standard to validate a product or a technology.
Flatt:  Mary Ann, in a prior life you were involved in a lot of nutritional research and 
one of the barriers in doing good research was just really the limited amount of money 
and the large base size for a clinical population. One of the trends that we have seen, in 
speaking with various nutritional researchers around the country, is using bioinformatics 
to carefully select and screen the test population so that you can get very meaningful 
data from a much smaller sample set, which helps get you a much more homogeneous 
test population with fewer subjects and allows you to draw definitive, statistically valid 
conclusions. I think that is something that we will see growing and hopefully will help.
Beachy: When you make those selections of population you do it for a variety of reasons; do 
you include microbiome in those populations that eventually would be your test case?
Lila:  Because it’s becoming more and more—
Beachy:  It makes your selection of who that test case is more expensive to evaluate.
Lila:  It does, but individualized nutrition is part of it, and what works on one population 
will not work on another.
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Each year, the North American Agricultural Biotechnology Council (NABC) holds a 
conference as a platform for all stakeholders of biotechnology in North America to discuss 
immediate issues. For 03 (NABC 5), the theme was Biotechnology and North American 
Specialty Crops: Linking Research, Regulation and Stakeholders and bringing smaller-scale 
genetically-modified (GM) crops to market despite challenges of policy and perception. 
The NABC reserves a portion of the conference, the Student Voice, for students to offer 
their insight. 
The Student Voice program was inaugurated at NABC 9 in 007 to promote graduate 
student participation in NABC. A single representative from each member institution 
is sponsored by the NABC with a travel grant of up to $750 to cover travel costs and 
 lodging at the meeting with the conference registration waived. The student representatives 
 attend all of the plenary sessions, the breakout session, and meet separately to develop key 
points of interest that were presented at the conference. The following are the issues and 
concerns deemed important by the NABC-5 Student Voice representatives.
Potential Problems for the Future and Solutions
Our concerns for the future fall into three general categories: Communication, Education 
and Funding. 
1All authors contributed equally.
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Communication
There is a lack of interdisciplinary collaboration and communication outside of the life 
sciences. Life scientists do not consistently collaborate with sociologists, economists, 
or marketing experts, whereas, in industry, such collaboration is standard. Increasing 
interdisciplinary cooperation could lead to improved public perception of genetically 
modified organisms (GMOs).
Also important is communication between scientists and the general public. There is 
a preference on the part of the public to be informed by arbitrary events and opinions of 
celebrities—frequently disseminated as “tweets”—rather than by scientifically substantiated 
discoveries. Although many celebrities do not necessarily speak out against GMOs, they 
may lobby in favor of labeling GM foods/ingredients. An ongoing campaign (justlabelit.
org, 0) is advocating a petition to oblige the FDA to enforce mandatory labeling 
of all GM foods. Interestingly, the Just Label It campaign is organized by a self-titled 
group called the Organic Voices whose major partners are organic producers, and, what 
is more, their petition was written by attorneys representing the Center for Food Safety. 
The Center for Food Safety is a public-interest group that is “working to protect human 
health and the environment by curbing the use of harmful food production technologies 
and by promoting organic and other forms of sustainable agriculture” (Center for Food 
Safety, 03). 
Figure . Nutrition facts table (Health Canada, 008).
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Figure : Nutrition Facts (Health Canada, 008) with a proposed change to include 
crop-production data.
Many groups are fighting to have GM foods labeled, but we have yet to see one fight-
ing to label all cultivar-development methods, or—for example— water-usage rate per 
acre. If mandatory labeling will go beyond specific nutrient composition, there must be 
guidelines for what information beyond nutrient composition must be included, and 
they must be applied to all foods and at the same time. Figure  shows an example of the 
“Nutrition Facts” label required by Health Canada (008) for all foods:
None of this information is of use to a consumer trying to make an informed, ratio-
nal decision with regards to genetics, environment, or the economics of the production 
method. Other labeling options, which are fairly similar between the United States and 
Canada, include health claims that are convoluted for the average consumer. Also “Or-
ganic” or “Irradiated”—as words or symbols—may influence a consumer’s decision based 
on emotion rather than on rationality. 
We propose a change to mandatory labeling of foods to include information on how the 
crop was produced and what, if any, modifications were made (Figure ): It provides con-
text to the consumer—in terms of cultivar-development technology, production method 
and environmental impact—enabling a wiser decision on whether to purchase. However, 
inconsistencies exist within this label. Whereas the “Irradiation” symbol is international, 
the “Organic” symbol is country-dependent, and there is no official international logo 
for GM or GE (genetically engineered), implying that common definitions of “organic” 
Student Voice
66 Biotechnology and North American Specialty Crops
and “GMO” are yet to be reached. It seems imperative that international definitions and 
standards should be determined before discussions about labeling occur.
Another easy improvement to labeling would be quick-response (QR) two-dimensional 
bar-codes (Figure 3), which have been used for nearly twenty years in Japan. Extremely 
versatile, they can impart many types of data, including a website link to in-depth informa-
tion. Although a specific application (“app”) is needed for downloading and a smartphone 
is required for scanning, the readers are available online free of charge (iTunes, 03; 
Mobile-Barcodes.com, 03;). Some 47% and 56% of Canadian and American adults 
now have smartphones (Ipsos, 03; Pew Internet, 03). 
Once linked to a website, an abundance of information may be accessed. For example, 
the first link from the QR code may provide a simple sentence-long definition; at the 
end of that definition there may be an option to view an abstract about the same topic, 
and finally a third linked option may be available with an article or protocol about the 
technology. If the information is from an online unbiased database, such as PubMed2, it 
would help build consumer trust.
Figure 3: A QR code (Kaywa, 03)
2http://www.ncbi.nlm.nih.gov/pubmed.
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Another opportunity for labeling change is serving size. If nutrition calculations were 
based on a consistent portion size, consumers could more readily compare products. 
This would be important in a situation where a GM crop undoubtedly demonstrates 
a nutritional advantage over a non-GM or organic competitor. As serving sizes exist 
now, consumers can easily be misled. Furthermore, certain websites could be more user-
friendly. For example, the Health Canada website3 contains many fragmented, redundant 
labyrinths with a poor internal search engines; even the advanced search options often 
produce countless absurd results unrelated to the inserted keyword.
In mentioning these ideas during NABC 5, typical responses were “no,” and “labeling 
is already established.” This attitude perpetuates a stagnant mindset and accomplishes 
nothing. Obviously it will cost more initially, but there is so much potential to streamline 
the self-education system, that the cost should be examined from a long-term perspective. 
Ability to access information about all types of foods will empower consumers to have 
meaningful discussions with those in industry about legitimate concerns. 
Many opponents of GMOs run stylish, yet simplified, advertising campaigns (Mer-
cola, 0). Of course, no credential pre-requisites are required to create an anti-GM 
website. Superficially, these sites may appear to be neutral, but within a few paragraphs 
of reading, the “anti” message becomes clear. Celebrity names may be mentioned (Afifi, 
0), current events in biology quoted (Latsch, 007), and emotion used (Flores, 03) 
to persuade the lay reader. It is necessary to investigate these sources to comprehend the 
scope of the challenge of properly educating the general public. 
As food-label content and regulatory decisions with regards to food production are 
 typically imposed by food manufacturers and/or the government, there is an urgent need to 
assemble a third-party arbitration group. Ideally, this group would include representatives 
of the government, industry, public-interest groups and lawyers. It could be responsible for 
final decisions on food labeling and on manufacturing and production standards. Primarily, 
it would assure the public of being minimally biased, reaching timely resolutions while 
maintaining the best interests of all stakeholders. Educational outreach programs could 
be facilitated by this group to foster a better-informed public. It would be best if such 
a group could be set up across national borders, as new ideas and perspectives are often 
gained in the absence of geographical constraints; otherwise, arbitration groups set up 
within each country should convene annually, at least, to discuss progress. The NABC-5 
forum is a good example of how insight can be gained from this type of meeting. 
To summarize, “genetic modification” and similar terms have negative connotations. A 
good example of what we can do to overcome this is the tactic being used by the creators of 
non-browning apples4 who are using a trademark to denote genetic modification (Arctic® 
apples; arcticapples.com, 03). They are educating the public on how they made the 
apple, both on their website and in their talks to the public. This goes hand-in-hand with 
3http://www.hc-sc.gc.ca/index-eng.php.
4Pages 87–94.
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our proposal to make labels more educational. Voluntary labeling will bring goodwill and 
separation from the large biotech companies. We also need a unified voice to respond to 
spurious negative claims about the safety of GMOs and we need a social-media presence 
to combat adverse claims in real time. Opponents of GMOs, such as Greenpeace and 
Non-GMO, are pouring large amounts of money into fighting GMOs. We can combat 
this effectively only with calm, reasoned logic. Furthermore, it would not be appropriate 
for the voice of reason to be from industry; perhaps the NABC can be that voice. 
Education
In the United States, there has been a decrease in science- and math-test scores over the 
last few years. This trend applies to students when tested from fourth to twelfth grades 
(National Center for Education Statistics, 03). Furthermore, many students have little 
understanding of where food comes from or what it takes to grow crops and produce 
meat. This problem may be solved as follows:
• The first way is for scientific and mathematical organizations to come together 
and advocate to national, state/provincial, and local governments to stop 
 decreasing spending on STEM5 education; potentially, this is a role that NABC 
can be a part of.
• The second way is for universities and scientific organizations to promote STEM 
and agricultural experiences for primary and secondary students, to educate 
on how food is grown and to show STEM in action. A good example of how 
this can be successfully accomplished is the outreach program administered 
by the Arkansas Center for Plant Powered Production (P3, 03). One of the 
mission goals for P3 is to promote plant sciences in the state of Arkansas. P3 
has developed plant-science kits, which science teachers can borrow, containing 
everything for a plant experiment, such as making biofuel. Additionally, P3 also 
recently sponsored a workshop for middle-school students in Jonesboro, AR, to 
come and transform a plant and extract DNA from strawberries. NABC-member 
institutions could promote similar programs in their respective areas and increase 
exposure of students to science.
• A third way that NABC could help to improve STEM education is to bring 
 students to visit GMO trials so that they can see for themselves what these crops 
can do. By increasing the quality of STEM education and having an outreach to 
the public, we can begin to reverse the negative public perception of GMOs.
Funding
The state of STEM funding in North America is discouraging. Due to budget cuts, 
funding for research has been drastically decreased in the United States. For example, 
the NIH budget for 03 was reduced significantly and is lower than for FY 003 by 
%, or about $4.7 billion (aaas.org, 03). Most other agencies have had minor cuts or 
stayed about the same. Details for FY 04 have not been finalized yet, but more cuts are 
5Science, technology, engineering and mathematics.
6$5.7 billion with adjustment for inflation.
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expected based on the US House of Representatives budget (faseb.org, 03). If the NIH 
budgetary trend is an indication, then funding opportunities will be greatly reduced and 
the number of new projects funded severely cut. As emerging scientists, we feel that this 
trend will negatively impact both innovation and advancement. If the US government had 
not funded the $3.6 billion6 Human Genome Project in 988, we would not be seeing 
the renaissance of genetics and the related “-omic” branches that have led to $ trillion 
worth of biotechnology companies. Given that there is a high return on research-funding 
investment (at least a 30% return and up to 00%), we are not only short-changing 
ourselves but also future generations (Center for American Progress, 0). The NABC 
must stand with other scientific organizations, and concerned citizens, to stop the slashing 
of research funding currently occurring in Washington.
Conclusions
NABC is composed mainly of universities and does not have the “baggage” in promoting 
GMOs so commonly observed in industry. NABC is uniquely positioned to be a voice 
of reason in promoting the benefits of GMOs:
• Increase interdisciplinary and international communication
• Take advantage of media outlets available for either educating or advertising, at 
least to counter the anti-GMO movement that utilizes these tools already
• Find a pro-GMO celebrity with a large following to promote GMO techniques, 
or at least for proper education about GMOs
• Revamp food labeling to present official information about all foods in a 
 comparable manner
• Establish a third-party arbitration group responsible for labeling, educating, and 
dispute resolution
• Get more involved in early education to increase the number of students that are 
interested in STEM
• Advocate for increased funding for STEM research or at the very least no further 
reductions in research funding
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Responses of Selected Garden Roses to 
Cyclic Drought Stress and Four Different 
Soil Moisture Contents
Xiaoya Cai1, Terri Starman1, Genhua Niu2 and Charles Hall1
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Greenhouse studies were conducted to evaluate the response of four garden roses (Rosa 
× hybrid L.), ‘RADrazz’, ‘Belinda’s Dream’, ‘Old Blush’, and ‘Maria Pavie’, to cyclic 
drought stress (Experiment I) and two garden roses, ‘RADrazz’ and ‘Belinda’s Dream,’ 
to four constant soil moisture contents (SMC) (Experiment II). In Experiment I, plants 
grown in containers with a peat-based substrate were subjected to two watering treat-
ments, well watered (30–40% SMC) and cyclic drought stress. The cyclic drought stress 
was induced by watering the plants to container capacity (around 40% SMC) and then 
withholding irrigation until container weight reached a predetermined value and plants 
exhibited incipient wilting (around 0% SMC). In Experiment II, an automatic irriga-
tion system was set up to maintain four constant SMC levels, i.e. 0, 0, 30, and 40%. 
Two cultivars were grown in containers with a peat moss-pine bark based substrate. In 
Experiment I, shoot growth and flower number were reduced in the drought treatment 
compared to the well-watered control in four cultivars. Net photosynthetic rate (Pn), 
stomatal conductance (gs), transpiration rate (E), and mid-day water potential of four 
cultivars decreased as substrate moisture content decreased. In Experiment II, there was 
a 90% reduction in water application at 0% SMC compared to 40% SMC during the 
two-month treatment period. In both cultivars, there were no significant differences in 
growth and physiological responses between 30% and 40% SMC. Photosynthesis was 
highest at 30 and 40% SMC and lowest at 0% SMC in both cultivars. In ‘RADrazz’, 
shoot DW was reduced by 0.7% and 87.3%, root DW was reduced by 34.% and 
8.%, while flower number was reduced by 7.5% and 87.8% at 0 and 0% SMC, 
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respectively, compared to 30% and 40% SMC. In ‘Belinda’s Dream,’ shoot DW was 
reduced by 30.7% and 87.6%, root DW was reduced by 46.8% and 83.5%, while flower 
number was reduced by 4.9% and 77.% at 0 and 0% SMC, respectively, compared 
to 30% and 40% SMC. In summary, ‘RADrazz’ was considered to be more tolerant to 
drought compared to the other three cultivars with its least reduction in shoot and root 
growth, flower number, and gas exchange under drought stress. Plants at 30 and 40% 
SMC maintained the highest shoot and root DW, flower number, midday leaf water 
potential, and photosynthesis. Water applied at 30% and 0% SMC was reduced by 
3% and 70%, compared to 40% SMC, with excellent performance at 30% SMC and 
acceptable growth and quality at 0% SMC. The 0% SMC led to significant growth 
reduction, poor quality, and 5% mortality.
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Characterization of Rosa spp. Breeding 
Populations to Black Spot for QTL 
Identification
Qianni Dong1,2, Dave Byrne2, Kevin Ong3 and Xinwang Wang1,2
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qiannidong@tamu.edu
Black spot disease, caused by the fungus Diplocarpon rosae Wolf, is the most serious disease 
of landscape roses (Rosa hybrid L.) worldwide. Dominant genes for complete resistance to 
specific races of the pathogen were identified in roses as Rdrs. From a breeding perspec-
tive, a rapid screening of potential hybrid materials by molecular markers is beneficial for 
identifying the resistant germplasm efficiently. Although partial resistance has also been 
documented, the responsible QTLs remain unidentified. In this project, responses to D. 
rosae of 6 genotypes of roses that were used as parents in hybrids were characterized with 
two inoculation methods: the detached leaf assay (DLA) and the whole-plant-inocula-
tion (WPI) method. The correlation between the relative resistances among genotypes 
as determined by each method was analyzed. Although DLA is more sensitive than WPI 
in measuring relative resistance, the correlation among the two methods is high (r>0.8), 
which indicates that either can be utilized to characterize D. rosae. Six diploid hybrid 
populations which are segregating for strong partial resistance derived from Rosa wichurana 
have been planted in the field for black-spot evaluations. These plants were also measured 
by DLA for resistance to race 8. The phenotypic data will be combined with the genotyp-
ing data for the populations to identify QTLs for partial resistance to black spot.
Index words: Rosa, Black spot, Disease resistance, Diplocarpon rosae, QTL, 
host-plant resistance
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Understanding Plant Responses to Water Deficit 
Conditions: A Systems Biology Approach
Roel C. Rabara1, Prateek Tripathi1 and Paul J. Rushton2
1Department of Biology and Microbiology
South Dakota State University,
Brookings, South Dakota
2Texas A&M AgriLife Research and Extension Center
Dallas, Texas
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The staggering growth in population, with no expansion for arable land, provides enormous 
pressure to increase food production. However, food production is seriously hampered 
by abiotic stresses such as drought. To address this issue, crop tolerance to drought must 
be improved. In order to develop strategies to improve plant responses to water stress, 
one must understand the regulatory pathways involve in plant responses to water stress. 
Using tobacco as our model, we analyzed the spatial and temporal transcriptome and 
metabolome profiles of plants subjected to water stress at different time points (0, 40, 
60, 0 and 40 min). The transcriptome profile showed major transcription factor 
families such as ERF, WRKY, NAC, bHLH and MYB to be highly induced by water 
stress in both roots and leaves. Downstream genes such as late embryogenesis abundant 
proteins (LEA), dehydrins, aquaporins, raffinose synthase and galactinol synthase were 
also highly induced. The gene-expression profile showed that the gene products from 
the stress-inducible genes can be grouped as regulatory proteins and proteins involved in 
direct protection of the cell from stress.
Metabolome profile showed accumulation of proteinogenic amino acids as well as 
compatible solutes such as proline, trehalose and raffinose. The expression profile of our 
target genes concurred with our metabolome profile.
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The Effect of “Microbial Fermented High 
Protein Soybean Meal” (FSBM), as a Fishmeal 
Replacer, on Functional Properties of Twin-
Screw Extruded Aquadiet
Parisa Fallahi, Kasiviswanathan Muthukumarappan and Kurt A. 
Rosentrater
South Dakota State University
Brookings, South Dakota
Parisa.Fallahi@SDSTATE.EDU
Fast-paced growth in global aquaculture has elevated concerns about the high costs of 
aquafarm production and potential water pollution. Thus, finding eco-friendly and more 
sustainable alternative protein sources for fish diets is of vital importance to the industry. 
A twin-screw extrusion processing study was performed using three ingredient blends 
formulated with graded levels of FSBM (0, 80% and 00% db) as the fishmeal replacer, 
in combination with appropriate amounts of other required ingredients for rainbow trout 
diets. To obtain cohesive extrudates, extrusion processing conditions (conditioner steam, 
extruder water, and screw speed) were varied. The effect of FSBM inclusion on functional 
properties of the extruded diets [moisture content (MC), water activity (aw), thermal 
properties, expansion ratio (ER), unit density (UD), bulk density (BD), water absorption 
(WAI), solubility (WSI), durability (PDI) indices, and color] were extensively evaluated. 
Increasing the FSBM content from 0% to 00% resulted in a substantial increase in 
brightness, greenness, and yellowness, and a decrease in BD, WAI, and UD values of the 
extrudates by .5%, 73%, 30%, 7.3%, 7.5%, and 0%, respectively. Compared to 
the control diet (00% fishmeal-based), extrudate moisture contents increased by 5.% 
and % for the diets containing 80 and 00% FSBM, respectively, although no change 
was observed by increasing FSBM from 80 to 00%. The highest WSI was obtained for 
80% FSBM inclusion; however, further increasing FSBM did not influence the WSI 
significantly. All extrudates represented a low risk of microbial contamination, and high 
mechanical strength due to low aw and high PDI values (<0.5% and >99.5%, respectively). 
The most buoyant extrudates were obtained using total FSBM inclusion, with UD and 
ER values of nearly 660 kg/m3 and .3, respectively. Overall, the results indicated that 
FSBM can be a promising protein alternative in rainbow-trout feed production.
Keywords Aquaculture, Extrusion, Microbial fermented soybean meal, Rainbow trout, 
Twin-screw Extruder
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Effect of Glutamine Synthetase Overexpression 
on the Growth and Biomass Production in 
Sorghum Growing Under Different Nitrogen 
Conditions
Jazmina Urriola1 and Keerti S. Rathore1,2,3
1Molecular and Environmental Plant Sciences
2Department of Soil and Crop Sciences
3Institute for Plant Genomics and Biotechnology
Texas A&M University
College Station, Texas
jazmina.urriola@neo.tamu.edu
Nitrogen is a primary macronutrient for plants and plays a critical role in plant 
growth and crop productivity. However, it is estimated that only between 30% to 
50% of applied nitrogen is taken up by plants, with the remainder contaminating soil, 
water and air. Therefore, from both economic and environmental standpoints, there is 
considerable interest in developing plants that take-up and use nitrogen in a more ef-
ficient manner. In this study, we investigated the effects of glutamine synthetase (GS) 
overexpression on the growth and biomass-production in sorghum (Sorghum bicolor 
L.) under low and optimal nitrogen availability. GS is an enzyme involved in nitrogen 
metabolism and catalyzes the ATP-dependent reaction between ammonia and gluta-
mate to produce glutamine. The ,07 bp long coding sequence of a sorghum cytosolic 
glutamine synthetase gene (gln1) was ligated at the 3’-end of the maize ubiquitin 
promoter, and this construct was introduced into sorghum by Agrobacterium–mediated 
transformation of immature embryos. T generation transgenic plants growing under 
optimal nitrogen conditions showed a reduction in the number of seeds present in the 
primary tiller, but exhibited a significant increase in the shoot vegetative biomass 
due to an accelerated formation of the secondary tillers compared to the wild-type 
counterparts. The number of seeds in these secondary tillers was higher than that in 
the primary tillers of the transformants. Thus, at the termination of the experiment 
(35 days post anthesis in primary tiller), significantly higher number of seeds was 
produced by the transformants. In contrast, no differences in growth or developmental 
parameters were observed between the transformants and wild-type grown under low 
nitrogen conditions. Our findings suggest that overexpression of gln1 in sorghum affects 
the physiological response of the plant to nitrogen availability, leading to enhanced 
grain yield and biomass accumulation under optimal nitrogen levels.
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Microarray Analysis of Soybean Cultivars Under
Salt Stress to Identify Differentially Expressed 
Genes
Alma G. Laney and Kenneth L. Korth
University of Arkansas
Fayetteville, Arkansas
alaney@email.uark.edu
With a worldwide increase in irrigation and agricultural expansion into marginal lands, 
saline soils are increasingly problematic for farmers. Soybean, Glycine max (L.) Merr., 
cultivars can react differently to salt stress; soybean lines that accumulate chloride in the 
leaves are typically salt sensitive and those that exclude chloride from the leaves are generally 
more salt tolerant . Current efforts in developing salt tolerance focuses on breeding and 
screening for chloride sensitivity. A cisgenic approach would be much faster without the 
yield drag that can accompany conventional breeding. However, the genetic basis and the 
exact mechanism for salt tolerance are currently unknown. The first step in developing a 
salt-tolerant cisgenic soybean is to identify the genes involved in salt tolerance. To identify 
genes differentially expressed in response to salt stress, the chloride-sensitive cultivar Clark, 
and the chloride-tolerant cultivar Manokin were compared in whole transcriptome studies. 
Plants were flooded daily with 00 mM NaCl or HO for six days. On the sixth day, leaf 
tissue was collected, total RNA was extracted and subjected to transcriptome analysis on 
a whole soybean transcriptome Affymetrix GeneChip®. The resulting data were analyzed 
in a Multiple Experiment Viewer and JMP®. In total, 9 genes in Clark and 54 genes 
in Manokin were differentially expressed in response to salt stress. A two-way ANOVA 
identified 387 genes that were differentially regulated between Clark and Manokin either 
treated with HO or NaCl. Select genes that were differentially regulated in response to 
salt stress in Clark and Manokin were verified with reverse transcription (RT)-PCR and 
RT-qPCR. Identification of the genes involved in salt tolerance in soybean excluders is 
the first step in generating a stable, salt-tolerant cisgenic soybean. Candidate genes were 
identified and future work will focus on their roles in soybean salt tolerance.
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Molecular Analysis and Characterization of the 
Gene(s) Involved in the Biosynthesis of 15-OH 
18:2-9,12 Hydroxy Fatty Acid in avena (Oat)
Matthew Bernard
University of Saskatchewan
Saskatoon, Saskatchewan
matthew.bernard@usask.ca
Oat is the only known source of 5(R)-hydroxy-(9Z),(Z)-octadecadienoic acid (5-
OH 8:-9,) which is believed to be enzymatically derived from linoleic acid (LA) 
in developing seed tissue. The properties of a hydroxy fatty acid (HFA) have negative 
gastrointestinal effects once consumed, and thus minimal HFA levels are desirable. For 
non-food purposes, HFAs have properties ideal for replacing petroleum-based products, 
so high levels are ideal. The ability to increase the levels of HFAs to economically 
significant amounts, or to eliminate them for food purposes, may require the genetic 
optimization of crops. Determining the genetic sequence of the gene(s) involved in 
producing the Δ5-linoleate hydroxylase (FAH5) that results in this unusual fatty 
acid (UFA) may lead to a new crop with the capacity for a customized fatty acid (FA) 
profile at industrial-scale production levels and making economic sense. Novel genetic 
information will also enhance marker-assisted breeding.
The putative FA hydroxylase is believed to share high similarity to a fatty acid desaturase 
(FAD) that acts upon the same position of the LA substrate as that of the putative FAH. 
Using bioinformatic software, previously-characterized FAD3 sequences from other species 
were queried against oat developing seed expressed sequence tags (ESTs), to determine 
putative oat fah contigs on which to base the subsequent experiments.
After synthesizing mRNA-derived cDNA, the gene was amplified with PCR and 
selected for after transforming Escherichia coli (E. coli) with a recombinant intermediate 
vector and gene of interest; this was followed by ligation into a eukaryotic expression 
vector. Currently, expression in Saccharomyces cerevisiae is being performed to observe 
hydroxylase functionality. Expression will be confirmed via presence of the gene’s product, 
5-OH 8:-9,, using gas chromatography/mass spectrometry (GC/MS) analysis.
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Early Breeding and Genetic Work for 
Developing vigna unguiculata (L.) Walp. 
(Cowpea) Lines Tolerant of the Phosphorus-Poor 
Soils of Sub-Saharan West Africa
Julie Rothe
Texas A&M University
College Station, Texas
jrothe@ag.tamu.edu
In the United States, two types of Vigna unguiculata (L.) Walp. (cowpea) are consumed as 
seed: black-eyed peas and purple hull peas. In Sub-Saharan Africa, cowpea is a widespread 
staple crop consumed for all components—leaves, pods, and seed—both by people and by 
livestock. However, soils of West Africa are poor in phosphorus (P), a soil macronutrient 
all crops need for growth. The cost of using P reserves to produce fertilizer with P is too 
high for developing countries in Africa, and thus fertilizer with P is not readily available. 
The purpose of this research is to start breeding and genetic work for the development of 
cowpea lines that grow well in low-P soils. At least three cowpea varieties have been success-
fully identified with measurable tolerance as estimated by shoot biomass in a hydroponic 
screening method. Both tolerant and susceptible varieties have been further analyzed for 
seed P, root biomass, internal shoot-P content, and internal root-P content to gain basic 
physiological insight into cowpea varieties’ tolerance of P deficiency. This research lays 
the foundation for determining genes or quantitative trait loci (QTL) responsible for 
cowpea’s tolerance of low-P soils. F, BC and recombinant inbred line (RIL) populations 
have been developed from ‘high × low’ crosses of lines for their tolerance of low-P soils. 
Fs and BCs have been screened for tolerance to understand the genetic control of the 
trait. The RILs will be used to begin QTL mapping using simple sequence repeat (SSR) 
and single nucleotide polymorphism (SNP) markers. QTL mapping will give a potential 
foundation for future marker-assisted selection (MAS) of the low-P-tolerance trait in 
cowpea and other crops.
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Graphic Mapping of Molecular Markers Related 
to Fiber Production in Sugarcane
Karine Kettener
São Paulo State University
São Paulo, Brazil
karinekettener@gmail.com
Sugarcane is a complex polyploid and aneuploid species, which makes genomic studies 
a huge challenge. This crop is economically important because it is the main source of 
both sugar and ethanol production. In sugarcane-breeding programs, functional markers 
can be used to accelerate the process and select important agronomic traits. Besides 
this practical application, molecular markers are also suitable to study the genetic 
architecture of complex agronomic traits (quantitative traits) that can be resolved into 
single Mendelian components. The advent of next-generation DNA- sequencing (NGS) 
technologies has led to the development of rapid genome-wide single nucleotide poly-
morphism (SNP) detection, which can be applied to mapping and characterization 
of traits of interest in larger populations. Such an approach, where sequences are 
used simultaneously to detect and score SNPs, is known as genotyping-by- sequencing 
(GBS). One of its main advantages is the ability to use the genetic maps generated 
using GBS-based sequencing information subsequently for identifying loci of interest 
from different sets of individuals, including segregating populations or mutant pools.
The aim of this work is to identify microsatellite markers and SNPs associated 
with lignin and cellulose in sugarcane. The mapping population is composed of 50 
individuals derived from a bi-parental cross between two elite clones from CTC’s 
(Center of Sugarcane Technology) breeding program in Brazil. We already tested 8 
microsatellites developed from a Sugarcane EST database (SUCEST), which generated 
4 potential markers to be mapped. The results that will be generated in this study 
will increase the probability of development of functional SNPs and microsatellites 
associated with important agronomic traits for sugarcane-breeding programs.
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The Influence of Leaf Epicuticular Wax on 
Stomatal Conductance, Light Reflectance, 
Canopy Temperature, and Chlorophyll Content 
in Long-Term High-Temperature-Stressed 
Spring Wheat (triticum aestivum) 
Suheb Mohammed, T. Huggins and D.B. Hays
Texas A&M University
College Station, Texas
dbhays@tamu.edu
Leaf epicuticular wax (EW) acts as a barrier between leaf tissue and the surrounding 
environment. EW protects the leaf from fungal attack, moisture loss from stomates, as 
well as excess heat, and radiation. Preliminary tests have identified the influence of EW in 
decreasing the heat-susceptible index (HSI), leaf-canopy temperature (CT), and improving 
total yields of wheat (Triticum aestivum). Most cultivars show the presence of leaf EW, but 
its role in improving high-temperature-stress tolerance during reproductive stages has yet 
to be defined. This study seeks to provide insight to the behavior of flag-leaf EW during 
different reproductive stages of wheat cultivars. Different glaucous wheat cultivars were 
studied in the greenhouse, exposed to a high-temperature treatment (°C-night and 
38°C-day) during 03. Leaf EW discs and physiological data (transpiration, chlorophyll 
fluorescence (CF), reflectance, leaf CT) were collected every 3rd day after head initiation 
to the 5th day after pollination (DAP). The marked results were a significant increase in 
EW load on the flag leaf from head initiation to 5 DAP. CF remained constant from 0 
DAP to 5 DAP, conferring chlorophyll content was not much significantly decreased. 
Transpiration was significantly lower at 0 DAP compared to 3 DAFE (days after head 
emergence) and 5 DAP. Presence of EW statistically influences percent reflectance 
between 700 nm to 0 nm wavelength. The cultivars ‘Seri M8’ ‘Len’ and ‘Halberd’ 
exhibited high levels of leaf EW and low adaxial transpiration under high temperature. 
Leaf adaxial surface had significantly higher transpiration compared to abaxial surface. 
Leaf epicuticular wax of ‘Seri M8’ showed a strong correlation with CT, leaf temperature 
depression, abaxial transpiration, and CF. 
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Abscisic Acid: A New Management Tool for 
Vegetable Transplants
Shinsuke Agehara and Daniel I. Leskovar
Texas AgriLife Research
Texas A&M University
Uvalde, Texas
shinsuke.agehara@gmail.com
Abscisic acid (ABA) is a plant hormone that triggers adaptive responses to water stress, 
including stomatal closure, inhibition of leaf expansion, and promotion of primary-root 
elongation. Using these growth modulations, our goal is to produce high-quality, more-
stress-tolerant vegetable transplants. First, we examined the stress control effect of ABA. In 
muskmelon (Cucumis melo L.) seedlings subjected to water withholding, pre-stress treat-
ment of ABA (0. to 7.6 mM) improved the maintenance of leaf relative water content 
by limiting transpirational water loss. Upon rewatering, the ABA-treated seedlings showed 
faster photosynthetic recovery and greater dry-matter accumulation than the control. 
Second, we examined ABA as a growth-holding agent to extend the marketable period 
of transplants. When jalapeno (Capsicum annuum L.) seedlings were treated with ABA 
(3.8 mM) at marketable size and extendedly grown in a greenhouse, excess stem elonga-
tion and leaf expansion were reduced by up to 7 and 3 days, respectively. The relatively 
rapid recovery of leaf area is important to avoid long-term growth inhibition, and thus 
its cellular basis was studied in arabidopsis (Arabidopsis thaliana). Whereas ABA ( mM) 
inhibited leaf expansion of young developing leaves, it had no effect on epidermal cell 
division, suggesting that ABA inhibits leaf expansion solely by limiting cell expansion. 
More importantly, the maintenance of cell division may enable transient leaf-area adjust-
ment without limiting plant-growth capacity. Finally, we examined the role of ABA in root 
growth using ABA-deficient mutants (aba2-1 and nced3-2) of arabidopsis. Although ABA 
( µM) promoted primary root elongation both of the wild type and mutants, its effect 
was more pronounced in nced3-2 than in the wild type under moderate water stress (– 
MPa). These results suggest that ABA can be used as a new growth regulator for improved 
stress control and extended marketability in vegetable transplants.
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Does Ethylene Alter the Regulation of Health-
Promoting Compounds in Grapefruit?
Priyanka R. Chaudhary, Haejeen Bang, G.K. Jayaprakasha and
Bhimanagouda S. Patil 
Vegetable and Fruit Improvement Center
Texas A&M University
College Station, Texas
hbang@tamu.edu
Grapefruit (Citrus paradisi Macf.) is a rich source of bioactive compounds including fla-
vonoids and furocoumarins that have demonstrated various health-promoting properties 
such as anti-inflammatory, anti-proliferative, and anti-carcinogenic as well as affecting 
absorption of certain medications. These bioactive compounds are influenced by various 
pre-harvest and post-harvest treatments. Early-season grapefruits are degreened using 
ethylene to promote peel color change from green to reddish orange. It is critical to 
study the effect of ethylene on biosynthesis of flavonoids and furocoumarins. In our 
preliminary study, ethylene treatment appeared to change the levels of flavonoids and 
furocoumarins in the Rio Red grapefruit pulp. Flavonoids namely narirutin, naringin, 
neohesperidin, didymin and poncirin significantly increased (P < 0.05) in degreened 
fruits at 7 days of storage. Non-degreened (control) fruits had significantly higher content 
of furocoumarins including 6’,7’-dihydroxybergamottin (DHB) and bergamottin at 7 
days; however, at 4 and  days, furocoumarins were significantly higher in degreened 
fruits. To further understand how ethylene affects the regulation of flavonoid and furo-
coumarin biosynthesis, three major genes namely phenylalanine ammonia lyase (PAL), 
chalcone synthase (CHS) and S-adenosyl-L-methionine:bergaptol O-methyltransfersase 
(SAM-BMT) were selected. Using a rapid amplification of cDNA ends approach, the full-
length cDNAs of PAL and CHS were isolated and cloned from Rio Red grapefruit, and 
the SAM-BMT gene will be cloned. The alignment of amino acid sequence of grapefruit 
CHS showed 99.% similarity with CHS and 98.% with CHS3 of Citrus sinensis. The 
transcriptional activities of these genes after ethylene treatment will be investigated using 
quantitative real-time PCR. This project is based upon work supported by the USDA-
NIFA # 00-3440-0875 “Designing Foods for Health” through the Vegetable and 
Fruit Improvement Center.
86 Biotechnology and North American Specialty Crops
Impact of Undergraduate Students on 
Biotechnology Research at the Vegetable and 
Fruit Improvement Center, Texas A&M AgriLife 
Research: Gene Discovery, Molecular Marker 
Development and Genetic Transformation 
Associated with Bioactive Compounds
Dennis Vandenberge, Natacha Villegas, Brianne Schnettler, Leia 
Lozano, Heather McMillan, Sandra Michael, Caroline Eppler, 
Megan Culp, Christine Oh, Daniel Kim, Neelou Shekarabi, Rock 
Demarais, Yan Ren, Kevin Crosby, Daniel I. Leskovar, Haejeen 
Bang and Bhimanagouda S. Patil
Vegetable and Fruit Improvement Center
Texas A&M University
College Station, Texas
k-crosby@tamu.edu
Melons rank among the top five most frequently purchased fruits in the United States. 
Because of consumers’ increased interest in enhanced nutrition and chemopreven-
tive properties, breeders have focused on developing fruit and vegetable cultivars with 
enhanced health-promoting compounds. The research at the Vegetable and Fruit Im-
provement Center-Plant Biotechnology Core Unit mainly focuses on gene discovery, 
molecular-marker development and genetic transformation, in order to help breeders 
rapidly and effectively introduce key traits into elite varieties. The objectives are to identify 
candidate genes and develop molecular markers associated with bioactive compounds. 
This study examined the mechanisms of carotenoid regulation and found that lycopene 
beta-cyclase (LCYB) may be crucial for conditioning flesh color differences between red 
and canary-yellow watermelons. Polymorphic sequences were identified in the promot-
ers and developed into a PCR-based marker for selection of LCYB alleles. In addition, a 
single nucleotide polymorphism (SNP) was identified in the coding region of carotenoid 
isomerase (CRT) of red and salmon-yellow watermelon; this SNP results in substitution 
of a conserved leucine to proline. The CRT SNP co-segregated with salmon-yellow flesh 
color, suggesting that CRT may be essential for lycopene accumulation in watermelon. 
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In addition, watermelon phytoene synthase C was introduced into an elite honeydew to 
elevate beta-carotene. Altered phenotypes were observed in rinds of transgenic lines, and 
biochemical assays showed that beta-carotene and phytoene were elevated. Elucidating 
carotenoid regulation mechanism and developing molecular markers will provide useful 
tools to enable rapid breeding of novel watermelon varieties with enhanced profiles of 
health-promoting bioactive compounds. Importantly, undergraduate students participated 
fully in all aspects of this research, gaining research experience and hands-on training 
in molecular techniques, biochemical analyses, and genetic transformation. The present 
report is based on work supported by “Designing Foods for Health,” USDA CSREES 
Grant # 00-3440-0875.
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Bitter Melon (Momoridica charantia):
A Potential New Vegetable in Texas and its 
Antidiabetic Properties
Jose L. Perez, G.K. Jayaprakasha and Bhimanagouda S. Patil
Vegetable and Fruit Improvement Center
Texas A&M University
College Station, Texas
b-patil@tamu.edu
Several studies have reported bitter melon to possess various health-promoting properties 
such as anti-oxidant, anti-bacterial, anti-cancer and anti-diabetic activities. Relatively 
few studies have attempted to evaluate the positive health effects of individual purified 
compounds isolated from bitter melon. The goal of this multi-faceted study is to identify 
the phytochemical constituents of bitter melon fruit and seeds responsible for anti-dia-
betic and anticancer properties. Data presented here illustrate the ability of bitter melon 
methanolic extract to inhibit α-amylase (8–99% inhibition), an enzyme present in the 
intestine responsible for breaking down polysaccharides into absorbable glucose units. 
The amount of inhibition was comparable to the current type- diabetes-management 
synthetic drug, acarbose. Furthermore, higher total phenolics were found in bitter melon 
fruit that was dried under refrigerated conditions versus higher temperature-drying tech-
niques. Currently, two compounds have been isolated from bitter melon fruits by flash 
chromatography. The future directions of this study involve the quantification of these 
health-promoting compounds in several varieties, the fluctuation of these compounds 
due to various pre- and post-harvest treatments, vegetative propagation strategy for the 
production of phytochemical-dense plants and optimal growing strategies for Texas. 
Lastly, gene expression will be explored for the possibility of production of anti-diabetic 
triterpenoids in tissue culture. This project is based upon work supported by the USDA-
NIFA # 00-3440-0875 “Designing Foods for Health” through the Vegetable and 
Fruit Improvement Center.
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Microplate Reader: A Rapid Tool in an Onion-
Breeding Program to Determine Quality
Akshata Kulkarni, Ram M. Uckoo, G.K. Jayaprakasha and 
Bhimanagouda S. Patil
Vegetable and Fruit Improvement Center
Texas A&M University
College Station, Texas
b-patil@tamu.edu
Onions are the second highest-valued horticultural crop produced in the United States. 
They are valued for their distinctive flavor and recognized for their potential health ben-
efits. Pungency of onions is a major criterion for economic remuneration and it can be 
quantified by measuring enzymatically produced pyruvic acid. Conventional methods of 
pyruvate measurement have certain limitations in terms of stability of the colorimetric 
reaction leading to inaccurate quantification. The pyruvic acid content is significantly 
influenced by variety, location, and interaction with the environment. Approximately 80% 
of the total variation is genetic, which is a major problem to the producers in maintaining 
uniform quality in mild onions. Therefore, accurate measurement of pyruvic acid is criti-
cal. In the present study, a rapid colorimetric method was developed to determine pyruvic 
acid in onions by reacting the onion sample with , 4-dinitrophenylhydrazine (DNPH). 
The absorbance of the colored complex was measured at λ485 nm using a microplate 
reader. The developed method was used to determine the levels of pyruvic acid in differ-
ent onion cultivars. The observed pungency for red onion is .0 ± .89 mM, yellow 
onions being less pungent with 0.34 ± 0.93 mM, white onions having lesser pungency 
with 6.05 mM ± .53 and honey sweet onions with the least pungency of 4.37 ± . 
mM. The use of a strong base enhanced the stability of the colored complex for up to two 
hours. The developed method is simple, robust, economical and reproducible for analysis 
of pungency in onion breeding programs within a short duration of time. This project 
is based upon work supported by the USDA-NIFA # 00-3440-0875 “Designing 
Foods for Health” through the Vegetable and Fruit Improvement Center. 
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Flash Chromatographic Separation of 
Limonoids from Dancy Tangerine 
Michael A. Harris, G.K. Jayaprakasha and Bhimanagouda S. Patil
Vegetable and Fruit Improvement Center
Texas A&M University
College Station, Texas
b-patil@tamu.edu
Dancy tangerine (Citrus tangerina) is a popular citrus variety that produces a bright-orange, 
easy-to-peel fruit. In recent years, due to their taste and quality characteristics, a rapidly 
increasing trend in their production is noticed. Apart from their sensory attributes, they 
also contain a wide array of biologically beneficial health-promoting compounds such 
as limonoids, flavonoids, amines, carotenoids, and organic acids. Specifically, limonoids 
have been further investigated for their health benefits and pharmacological uses such 
as: antibacterial, antifungal, antiviral, and anticarcinogenic activities. In order to pro-
vide proof-of-concept, limonoids need to be tested in animal- and human-intervention 
trials, which require an isolation and purification method that is cost-effective, rapid, 
and repeatable. The seeds and carpel membranes—waste byproducts of the citrus juice 
industry—are among several sources commonly used to isolate and characterize bioactive 
compounds. Utilizing these byproducts provides an economical resource for purification of 
health-promoting compounds. Furthermore, flash chromatography can be used to isolate 
compounds of high purity in a short time in comparison to the traditional method of open 
column chromatography. Limonoids were extracted from Dancy tangerine seeds using 
ethyl acetate resulting in a condensed, crude product. Silica gel was used to impregnate 
the samples which were then subjected to flash separation. Fractions were pooled based on 
retention times from individual fractions of high-pressure liquid chromatography (HPLC) 
analysis which led to three compounds: obacunone, limonin, and deacetyl nomilin. To 
the best of our knowledge, this is the first study on flash chromatography separation of 
limonoids from Dancy tangerines in multi-gram quantities. 
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High Tunnel for a Specialty Crop: Strawberry 
Production in Texas 
Sabrina A. Myers, Ram M. Uckoo, G.K. Jayaprakasha, Russell W. 
Wallace and Bhimanagouda S. Patil 
Vegetable and Fruit Improvement Center
Texas A&M University
College Station, Texas
b-patil@tamu.edu
Six commercial cultivars of strawberry (Albion, Chandler, Festival, Radiance, San Andrea’s, 
Seascape) were grown in high tunnels and in the open field at Lubbock, TX. At maturity, 
fruits with similar size and shape were harvested and analyzed for quality (sugars and 
titratable acidity), total phenolic content (Folin Ciocalteu assay) and radical scavenging 
activity (DPPH assay). Strawberries grown in high tunnels showed higher levels of sucrose 
and fructose. No major effect of the production system was noticed on the level of glucose 
or titratable acidity. Chandler, Festival and San Andreas varieties had significantly higher 
levels of total phenolic in comparison to other varieties. Chandler, Festival, San Andreas 
and Seascape had significantly higher levels of radical-scavenging activity as compared 
to Albion and Radiance varieties. However, no clear trend on the effect of high-tunnel 
cultivation as compared to field cultivation was noticed in the total phenolic content or 
radical-scavenging activity. These results suggest that high-tunnel cultivation could be an 
effective strategy for cultivating specialty strawberry with better quality and maintenance 
of phenolic content and radical-scavenging activity. 
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Taxpayers in the United States have invested heavily in public-sector research in agri-
cultural biotechnology to provide more-sustainable and productive crops and safe and 
nutritious foods. Since the mid-1980s, scientists at the USDA and in university and small 
private laboratories have developed a broad range of genetically engineered (gE) varieties 
of specialty crops with useful traits including enhanced tolerances of biotic and abiotic 
stresses and improved nutrition1. Almost a thousand different gE lines of small-market 
and specialty crops1 were among the almost 17,000 regulated field trials approved by 
USDA since 19872. 
 In spite of this large public investment—as well as early technical successes and promis-
ing results in field trials—only a few gE specialty crops developed in public institutions 
have been released to date:
• Virus-resistant papaya
• A now defunct flax intended to be used for bioremediation
• Virus-resistant plum
These are very sparse returns considering substantial public investment over a quarter 
century. In fact, the majority of scientists at public institutions do not even consider fur-
ther development of gE crops for commercial utility, even for traits that could advance 
agricultural systems, improve human health and help feed the increasing global population. 
On the other hand, there are signs that this trend is changing. Several transgenic events 
in specialty crops, are now moving towards commercialization as a result of collaborative 
efforts involving universities, industry, and regulatory agencies.
 Furthermore, the Farm Bill—passed in February 2014—has restored the Specialty 
Crop Research Initiative funding, to about $80 million per year3. We are pleased with 
this reemphasis of the fundamental importance of research in specialty crops, consistent 
with the focus of NABC’s twenty-fifth annual conference.
 NABC 25—held at Texas A&M University, College Station, June 4–6, 2013—brought 
together academic researchers, industry leaders, and government officials to discuss the 
roles of genomic sciences, regulatory policy and related topics in an attempt to catalyze 
increased agricultural progress, especially as it relates to specialty crops.
1Miller J Bradford K (2010) The regulatory bottleneck for biotech specialty crops. Nature Biotechnology 
28(10) 1012–1014.
2Anonymous (2014) Information Systems for Biotechnology: A National Resource in Agbiotech Informa-
tion–USDA Field Tests of gM Crops. http://gophisb.biochem.vt.edu/search-release-data.aspx
3http://www.thepacker.com/fruit-vegetable-news/Senate-passes-farm-bill-243553121.html#sthash.I9Xbcib1.
dpuf.
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 To foster discussion, NABC 25 was organized under five topics:
• Opportunities and Challenges for Specialty Crops
• genetic Engineering and Specialty-Crop Improvement
• Case Studies
• The Regulatory Process and Technology Access
• Perspectives from Relevant groups
 The final session on the morning of the third day focused on “Next Steps.” Speakers 
Tony Shelton (Cornell), Thomas Redick (global Environmental Ethics Counsel) and 
Neal Carter (Okanagan Specialty Fruits) formed a panel along with conference host Bill 
McCutchen (Texas A&M). The discussion, which involved audience contributions, was 
moderated by Steve Pueppke (Michigan State). Salient points emerging from the “Next 
Steps” exchanges are included in a “conference overview” chapter.
 A poster session was held on the evening of the first day. Prizes totaling $5,000 were 
awarded to the five best poster presentations ($1,500–$500).
 Participants in the Student Voice at NABC program4 attended the keynote and plenary 
sessions and met as a group on the second evening to discuss issues that emerged from 
the conference subject matter.
 This volume contains the conference overview, manuscripts generated from transcripts 
of the verbal presentations by the speakers (see Contents on pages ix–x for the full speaker 
list), transcripts of Q&A sessions, which included audience participation, the Student 
Voice report, and abstracts from the posters.
 NABC’s twenty-sixth conference—New DNA-Editing Approaches: Methods, Applica-
tions and Policy for Agriculture—will be held October 8–9, 2014, in Ithaca, NY, hosted 
by Cornell University and the Boyce Thompson Institute.
Allan Eaglesham      Ralph W.F. Hardy
Executive Director      President
NABC       NABC
Figures are printed in grayscale, hence information may have been lost from graphics
lifted from colored PowerPoint slides. Color versions of the figures are available at 
http://nabc.cals.cornell.edu/Publications/Reports/pubs_reports_25.htm.
4The Student Voice at NABC program provides grants of up to $750 to graduate students at NABC-member 
institutions (one student per institution) to offset travel and lodging expenses. Also, registration fees are 
waived for grant winners. Information on the Student Voice at NABC 26 will be available at http://nabc.cals.
cornell.edu/StudentVoice.htm.
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